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ABSTRACT OF DISSERTATION

TOWARDS THE RATIONAL DESIGN AND APPLICATION OF POLYMERS FOR
GENE THERAPY: INTERNALIZATION AND INTRACELLULAR FATE
Gene therapy is an approach for the treatment of acquired cancers, infectious
disease, degenerative disease, and inherited genetic indications. Developments in the fields
of immunotherapies and CRISPR/Cas9 genome editing are revitalizing the efforts to move
gene therapy to the forefront of modern medicine. However, slow progress and poor
clinical outcomes have plagued the field due to regulatory and safety concerns associated
with the flagship delivery vector, the recombinant virus. Immunogenicity and poor
transduction in certain cell types severely limits the utility of viruses as a delivery agent of
nucleic acids. As a result, significant efforts are being made to develop non-viral delivery
systems that perform mechanistically similarly to viral delivery but lack immunogenic
factors. Though safer, existing agents lack the efficacy inherent in the natural design of
viral vectors. Clinical relevance of non-viral vectors will therefore depend on the ability to
engineer optimized systems for cellular delivery in physiological environments.
Progress in non-viral vector design for gene delivery requires a deep understanding
of the various barriers associated with nucleic acid delivery, including cell surface
interaction, internalization, endosomal escape, cytosolic transport, nuclear localization,
unpackaging, etc. Further, it requires a knowledge of vector design properties (surface
chemistry, charge, size, shape, etc.) and how these physical parameters affect interactions
with the cellular environment. Of these interactions, charge is shown to govern how
particles are internalized and subsequently processed, thereby affecting the intracellular
fate and efficacy of delivery. Charge also affects the in-serum stability where negative zeta
potential improves stability and circulation time. Therefore, it is important to understand
the effects of polyplex charge and other parameters on the internalization and intracellular
fate of polyplexes for gene therapy.
In chapter 2, studies are performed to delineate the effects of polyplex charge on
the cellular internalization and intracellular processing of polymer-mediated gene delivery.
Charge is shown to affect the endocytic pathway involved in internalization, and the
caveolin-dependent and macropinocytosis pathways lead to higher gene delivery efficacy,
likely due to avoidance of acidified compartments such as late endosomes and lysosomes.
In chapters 3-4, novel nanoparticles carrying DNA, RNA, and antioxidants are assessed
for therapeutic effect with an emphasis on studying the internalization mechanisms and
resulting effect on efficacy. Novel RNA delivery agents are shown to benefit from EGFRtargeting aptamer and nanoceria/PEI hybrids are demonstrated to provide simultaneous
antioxidant and gene therapy. Finally, chapter 5 demonstrates the use of silencing RNA
and CRISPR/Cas9 genome editing to study the prevalence of gene targets in vivo.
The overall goal of this work is to contribute to the design and application of novel
nanoparticles for gene delivery and offer insight into the engineering of novel polyplexes.
It remains clear that route of internalization is key to successful gene delivery, and

designing polyplexes to enter through non-acidified endocytic pathways is highly
beneficial to transgene expression. This can be achieved through incorporation of surface
chemistries that trigger internalization through targeted pathways and is the source of
further work in the lab.

KEYWORDS: Polymer Gene Delivery, Endocytosis, Polyplex, Gene Therapy, Cancer

Landon Alexander Mott
(Name of Student)
4/22/2019
Date

TOWARDS THE RATIONAL DESIGN AND APPLICATION OF POLYMERS
FOR GENE THERAPY: INTERNALIZATION AND INTRACELLULAR FATE

By
Landon Alexander Mott

Dr. Daniel Pack
Director of Dissertation
Dr. Stephen Rankin
Director of Graduate Studies
4/22/2019
Date

DEDICATION
To my friends and family

ACKNOWLEDGMENTS

For the successful preparation of this dissertation and constant guidance through
my graduate career, I would first like to acknowledge my Dissertation Chair, Dr. Daniel
Pack. His guidance and willingness to allow me to pursue my own ideas has given me
freedom to exercise innovation and creativity in the lab. In conjunction, I would extend
gratitude to the remainder of my dissertation committee and external examiner for their
effort in reviewing my work and providing guidance through the years: Dr. Tom Dziubla,
Dr. Zachary Hilt, Dr. Subba Palli, and external examiner Dr. Renee Fatemi. The academic
excellence and poise of this group of individuals is a source of admiration and example to
many others and myself.
No one succeeds alone and I am no exception. I owe many thanks to my group
of peers, not only for technical assistance, but also for their encouragement and
perspective. To my lab mates: Robert Wensing, Jason Absher, Logan Warriner, Caleb
Akers, and Levi Lampe. To my supportive peers: Andrew Colburn, Matthew Hancock,
Xiaobo Dong, and Conor Sprick.
Finally, I am indebted to my family, whose constant support and encouragement
has been a source of refreshment and rejuvenation. Thanks to my parents for preparing
me for this journey, to my siblings for inspiration, and especially to my fiancée for her
persevering support and character. Of course, many thanks to all my supportive friends
for their contribution to my morale and impetus in achieving my academic goals.

iii

TABLE OF CONTENTS

ACKNOWLEDGMENTS ............................................................................................... iii
TABLE OF CONTENTS ................................................................................................ iv
LIST OF TABLES ......................................................................................................... viii
LIST OF FIGURES ......................................................................................................... ix
CHAPTER 1. Intracellular and Limiting Steps to Gene Therapy .............................. 1
1.1 Introduction ............................................................................................... 1
1.1.1 A Brief History ................................................................................... 1
1.1.2 The Ethical Dilemma .......................................................................... 2
1.2 Gene Delivery Strategies ........................................................................... 4
1.2.1 Naked DNA ........................................................................................ 4
1.2.2 Viral Gene Therapy............................................................................. 5
1.2.2.1 Retrovirus ..................................................................................... 6
1.2.2.2 HIV-1 Lentivirus .......................................................................... 7
1.2.2.3 Adenovirus ................................................................................... 7
1.2.2.4 Adeno-Associated Virus (AAV) .................................................. 8
1.2.2.5 Other Viruses................................................................................ 9
1.2.3 Non-viral Gene Therapy ................................................................... 10
1.2.3.1 Lipid Assemblies ........................................................................ 10
1.2.3.2 Cationic Polymers ...................................................................... 12
1.2.3.3 Cell Penetrating Peptides ........................................................... 15
1.3 Barriers to Non-Viral Gene Delivery ...................................................... 15
1.3.1 Serum Stability and Extracellular Transport..................................... 16
1.3.2 Cellular Membrane Interactions ....................................................... 18
1.3.3 Internalization and Endosomal Escape ............................................. 19
1.3.4 Cytosolic Transport and Nuclear Localization ................................. 23
1.3.5 Intracellular Dissociation .................................................................. 24
1.4 Rational Design of Non-Viral Vectors .................................................... 25
1.4.1 Size and Shape .................................................................................. 25
1.4.2 Surface Chemistry............................................................................. 27
1.4.3 Charge Density and Zeta Potential ................................................... 30
1.5

Concluding Remarks ............................................................................... 32

CHAPTER 2. Effect of Surface Charge on Polyplex Internalization and
Intracellular Trafficking ....................................................................... 34
2.1

Introduction ............................................................................................. 34
iv

2.2 Materials and Methods ............................................................................ 37
2.2.1 Cell Culture ....................................................................................... 37
2.2.2 Materials ........................................................................................... 37
2.2.3 Polyplex Formation........................................................................... 37
2.2.4 Size and Zeta Potential...................................................................... 38
2.2.5 Agarose Gel Electrophoresis............................................................. 38
2.2.6 Measurement of Non-Specific Protein Binding................................ 39
2.2.7 In Vitro Transfection......................................................................... 39
2.2.8 Flow Cytometry ................................................................................ 40
2.2.9 Cytotoxicity....................................................................................... 41
2.2.10 Confocal Fluorescence Microscopy.................................................. 41
2.2.11 Scanning Transmission Electron Microscopy .................................. 42
2.2.12 Intracellular Trafficking .................................................................... 43
2.3 Results and Discussion ............................................................................ 43
2.3.1 Polyplex Characterization ................................................................. 43
2.3.2 Ghost Particle Effect on Transfection and Viability ......................... 51
2.3.3 Transfection and Cellular Internalization of Ternary Polyplexes ..... 47
2.3.4 Inhibitor Toxicity and Specificity ..................................................... 53
2.3.5 Effect of Polyplex Charge on Endocytic Pathway............................ 57
2.3.6 Intracellular Trafficking .................................................................... 63
2.4

Conclusions ............................................................................................. 68

CHAPTER 3. Delivery and Intracellular Processing of Polymer and Nanoceria
Hybrid Polyplexes for Gene and Antioxidant Therapy ..................... 70
3.1

Introduction ............................................................................................. 70

3.2 Materials and Methods ............................................................................ 73
3.2.1 Materials ........................................................................................... 73
3.2.2 Cell Culture ....................................................................................... 74
3.2.3 Standard Transfection Protocol......................................................... 74
3.2.4 Size and Zeta Potential...................................................................... 75
3.2.5 Scanning Transmission Electron Microscopy .................................. 76
3.2.6 Generation of Nanoceria ................................................................... 76
3.2.7 Antioxidant Potential ........................................................................ 77
3.2.8 Polyplex and Inhibitor Toxicity ........................................................ 77
3.2.9 Polyplex Transfections Optimizations .............................................. 78
3.2.10 Flow Cytometry ................................................................................ 79
3.2.11 Co-Localization Imaging .................................................................. 79
3.2.12 Intracellular Trafficking .................................................................... 80
3.3 Results ..................................................................................................... 81
3.3.1 Nanoceria Synthesis .......................................................................... 81
3.3.2 Formation and Characterization Ternary Polyplexes ....................... 82
3.3.3 Transfection with NC/PEI/DNA and PGA/PEI/DNA Polyplexes.... 85
3.3.4 Antioxidant Activity of NC/PEI/DNA Polyplexes ........................... 87
3.3.5 Mechanism of Internalization of NC/PEI/DNA Polyplexes ............. 89
v

3.3.6

Intracellular Trafficking .................................................................... 91

3.4

Discussion ............................................................................................... 93

3.5

Conclusions ............................................................................................. 98

CHAPTER 4. EGFR-Targeted RNA Aptamer Potentiates 3WJ Internalization
Through Clathrin-Mediated Endocytosis and Induced
Macropinocytosis ................................................................................. 100
4.1

Introduction ........................................................................................... 100

4.2 Materials and Methods .......................................................................... 101
4.2.1 Materials ......................................................................................... 101
4.2.2 Cell Culture ..................................................................................... 102
4.2.3 Cell Transfections ........................................................................... 102
4.2.4 Inhibitor Toxicity and Validation ................................................... 103
4.2.5 Flow Cytometry .............................................................................. 104
4.2.6 EGFR Inhibition.............................................................................. 104
4.2.7 Confocal Microscopy ...................................................................... 104
4.2.8 Intracellular Trafficking .................................................................. 105
4.3 Results ................................................................................................... 106
4.3.1 Validation of EGFR Expression ..................................................... 106
4.3.2 Transfection with 3WJ Nanoparticles ............................................. 106
4.3.3 EGFR Dimerization ........................................................................ 108
4.3.4 Investigation of EGFR-Specific Internalization of 3WJ Nanoparticles
109
4.3.5 Investigation of Internalization Pathway of 3WJ Nanoparticles .... 110
4.3.6 Intracellular Trafficking of 3WJ Nanoparticles .............................. 113
4.4

Discussion ............................................................................................. 115

4.5

Conclusions ........................................................................................... 121

CHAPTER 5. Evaluation of FOXC1 as a Therapeutic Target for Basal-Like Breast
Cancer................................................................................................... 123
5.1

Introduction ........................................................................................... 123

5.2 Materials and Methods .......................................................................... 125
5.2.1 Materials and Cell Lines ................................................................. 125
5.2.2 In vitro siRNA Transfection ........................................................... 125
5.2.3 Western Blot ................................................................................... 126
5.2.4 Silencing of FOXC1 Expression in 4T1 Cells by CRISPR/Cas9 ... 127
5.2.5 Cellular Proliferation ...................................................................... 127
5.2.6 Migration and Invasion ................................................................... 128
5.2.7 Orthotopic BLBC Model ................................................................ 129
5.3 Results ................................................................................................... 129
5.3.1 Optimization of FOXC1 Knockdown ............................................. 129
5.3.2 Generation of 4T1-∆FOXC1 by CRISPR/Cas9 .............................. 131
vi

5.3.3
5.3.4
5.3.5

Effect of FOXC1 Knockdown on 4T1 Proliferation....................... 132
Effect of FOXC1 Knockdown on 4T1 Mobility ............................. 133
Effect of FOXC1 on 4T1 Tumor Growth and Metastasis In Vivo . 135

5.4

Discussion ............................................................................................. 137

5.5

Conclusions ........................................................................................... 139

LIST OF REFERENCES ............................................................................................. 140
LANDON MOTT VITA ............................................................................................... 165

vii

LIST OF TABLES
Table 1: Endocytic inhibitors, their mechanisms of action, and concentrations producing
80% viability in HeLa, U-87 MG, and HEK 293 cell lines. ............................................. 57

LIST OF FIGURES
viii

LIST OF FIGURES
Figure 1.1: Common polymer vectors for gene delivery. ................................................. 13
Figure 1.2: Barriers to non-viral gene delivery. A) Extracellular transport/stability. B)
Extravasation from vasculature endothelium or diffusion by enhanced permeation and
retention effect. C) Surface interaction and internalization by endocytosis. D) Early
endosome maturation into late endosome. E) Transport and fusion of late endosome with
lysosome. F) Endosomal escape through osmotic selling. G) Transport through cytosol to
nuclear envelope. H) Nuclear localization. I) Vector dissociation into DNA and cation. 16
Figure 2.1: Polyplex complexation process according to bulk mixing protocol. PEI is added
in excess to DNA to form binary polyplexes. PGA is then added to binary polyplexes to
form ternary polyplexes. Some free PEI binds PGA to form polyelectrolyte ghost particles.
........................................................................................................................................... 44
Figure 2.2: (A) Polyplex zeta potential at various PGA/PEI/DNA weight ratios. (B) Gel
electrophoresis of polyplexes at PEI:DNA weight ratios 0.5:1, 1:1, 2:1, and 3:1. Ladder
indicates standard DNA ladder. (C) Polyplex sizes at various PGA/PEI/DNA weight ratios.
(D) Scanning transmission electron micrographs of polyplexes at PGA/PEI/DNA weight
ratios of 0:3:1 (zeta potential +16 mV), 1.5:3:1 (+11 mV), 4:3:1 (0 mV), and 5.2:3:1 (-11
mV). (E) BSA aggregation with free PEI and polyplexes at 3:1 PEI/DNA of varying PGA
weight. (n=4, error bars represent standard deviation; *p=0.0008, **p=0.004)............... 45
Figure 2.3: (A) Transfection of HeLa cells with binary PEI/DNA polyplexes at 1:1 (w:w)
in the presence of PGA/PEI ghost particles of 1:1 (w:w) or free PEI. All samples were
normalized to binary polyplex controls transfected in the absence of ghost particles or free
PEI. (B) HeLa cell viability after transfection with binary polyplexes in the presence of
ghost particles or free PEI as in A. (n=4, error bars represent standard deviation). ......... 53
Figure 2.4: Transfection (A,D,G), cellular uptake (B,E,H), and cytotoxicity (C,F,I) of
PGA/PEI/DNA polyplexes at various PGA:PEI:DNA weight ratios in HeLa (A-C), U-87
MG (D-F), and HEK 293 (G-I) cell lines. PGA/PEI ghost particles (GHOST) were formed
at ratios corresponding to the PGA:PEI weight ratios that provided maximum transfection
efficiency (0.5:1:1, 1.5:3:1, and 2:5:1). ............................................................................ 49
Figure 2.5: (A-C) Cytotoxicity of GST, mBCD, CPZ, AMN, and AML in (A,D) HeLa,
(B,E) U-87 MG, and (C,F) HEK 293 cell lines. Metabolic activity was normalized to cells
in the absence of inhibitors. (D-F) GST, mBCD, CPZ, AMN, and AML effect on uptake
of markers of caveosomes (CTxB), clathrin-coated vesicles (Tf), and macropinosome
(DEX). (n=3, error bars represent standard deviation; *p<0.05, †p<0.01, ‡p<0.001
compared to control groups). ............................................................................................ 56

ix

Figure 2.6: (Top) Fluorescence confocal micrographs of HeLa, U-87 MG, and HEK 293
cells transfected with positive (1.5:3:1 w:w:w:, +11 mV) and negative (5.2:3:1 w:w:w:, 11 mV) polyplexes and immuno-stained for caveolin-1 or clathrin heavy chain, or exposed
to dextran Texas Red to label caveosomes, clathrin-coated vesicles, or macropinosomes.
Mander’s coefficients are listed for green overlap with red under each image (M2). Blue
indicates cell cytoskeleton, green indicates polyplexes, and red indicates endosomes.
(Bottom) Co-localization maps highlighting only overlap regions. ................................. 60
Figure 2.7: Co-localization of positively and negatively charged polyplexes to caveosomes,
clathrin-coated vesicles (CCV), and macropinosomes. Mander’s coefficients were
normalized for co-localization to each of the three pathways. ......................................... 60
Figure 2.8: Luciferase gene expression (A-C) and polyplex uptake (D-F) of positive
(1.5:3:1 w:w:w, +11 mV) and negative (5.2:3:1 w:w:w, -11 mV) polyplexes in the presence
of endocytic inhibitors of caveolin-dependent endocytosis (GST and mBCD), clathrindependent endocytosis (CPZ and AMN), or macropinocytosis (AML) in HeLa (A,D), U87 MG (B,E), and HEK 293 (C,F). All inhibited samples were normalized to a noninhibited control of equivalent polyplex charge to determine effect on gene expression or
uptake. (n=6 for gene expression, n=3 for uptake, error bars represent standard deviation;
*p<0.05, †p<0.01, ‡p<0.001 compared to control groups). ............................................. 62
Figure 2.9: (A) HeLa, U-87 MG, and HEK 293 transfections of positive (1.5:3:1 w:w:w,
+11 mV) and negative (5.2:3:1 w:w:w, -11 mV) polyplexes in presence of ATPase inhibitor
bafilomycin A1 (BAF) and/or endosomal buffering agent chloroquine (CQ). All samples
treated with BAF and/or CQ were normalized to untreated controls. (B) Co-localization of
negative (top) and positive (bottom) polyplexes with acidified endosomes marked by
Lysotracker in HeLa cells. Green indicates polyplexes, red indicates endosomes, and blue
indicates cell cytoskeleton. (n=4, error bars represent standard deviation; *p<0.02,
**p<0.004). ....................................................................................................................... 66
Figure 2.10: Summary of internalization pathways associated with positive and negative
charged polyplexes. CME designates clathrin-dependent endocytosis, CAV designates
caveolin-dependent endocytosis, and MP designates macropinocytosis. ......................... 68
Figure 3.1: (A) Surface-area-weighted distribution of hydrodynamic diameters of
nanoceria suspended in water. (B) TEM image of polyhedral, crystalline nanoceria. (C)
FTIR spectrum of citrate-coated nanoceria. Peak at 3300 cm-1 represents a hydroxyl group.
Peaks at 1375 and 1540 cm-1 represents a carboxylic group. ........................................... 82
Figure 3.2: (A) Complexation of NC with PEI and DNA to form a polyplex. (B-D)
Transmission electron microscope imaging of binary (B) PEI/DNA (23:1 N/P), (C)
PGA/PEI/DNA (10:23:1 O/N/P), and (D) NC/PEI/DNA (1.7:23:1 O/N/P) polyplexes. (E)
EDS spectrum of imaged NC/PEI/DNA polyplex. N peak indicates the presence of PEI
and DNA, P peak indicates presence of DNA, and Ce peak indicates presence of nanoceria.
........................................................................................................................................... 84

x

Figure 3.3: (A) NC/PEI/DNA zeta potential curves at various O/N/P ratios. (B)
PGA/PEI/DNA zeta potential curves at various O/N/P ratios. (C) NC/PEI/DNA and (D)
PGA/PEI/DNA size curves at various O/N/P ratios determined by DLS. (n=3, error bars
represent standard deviation). ........................................................................................... 85
Figure 3.4: (A) Expression of luciferase reporter gene delivered by NC/PEI/DNA or
PGA/PEI/DNA polyplexes (dashed lines). (B) Uptake of NC/PEI/DNA and
PGA/PEI/DNA polyplexes at various O/N/P ratios. (C) NC/PEI/DNA polyplex toxicity
profiles for varying O/N/P ratios of NC/PEI/DNA. White bars indicate samples treated
with only NC. (n=4, error bars represent standard deviation). ......................................... 87
Figure 3.5: (A) Anti-oxidant dose curves for Trolox standard and NC/PEI/DNA polyplexes
at 23:1 N/P. All samples were damaged with menadione except for “Cells” control. NC
indicates nanoceria incubated with cells in absence of PEI or DNA. Trolox samples were
normalized to a 0 nM Trolox control and NC/PEI/PGA were normalized to NC-free
(binary) control. Free NC samples were normalized to non-treated controls. (B) Nondamaged control HeLa cells and (C) menadione-damaged control cells. (D-E) Trolox
antioxidant activity in HeLa cells at 12.5 nM and 200 nM concentrations. (F-G)
NC/PEI/DNA antioxidant activity in HeLa cells at O/N/P ratios of 1.7:23:1 and 27:23:1.
Red represents CellRox indicating presence of ROS and blue is phalloidin cell cytoskeleton
stain. (n=3, error bars represent standard deviation)......................................................... 89
Figure 3.6: (A) Endocytic inhibitor (GST, mBCD, CPZ, AMN, and AML) effects on gene
expression and uptake of NC/PEI/DNA at optimum O/N/P ratio (1.7:23:1) in HeLa cells.
All inhibited samples were normalized to controls in the absence of inhibitors. (B) Colocalization of NC/PEI/DNA polyplexes to cholera toxin subunit B (caveosomes, CAV),
transferrin protein (clathrin-coated vesicles, CCV), and 70-kDa dextran (macropinosomes,
MP). Particles are in green, endosomal compartments in red, and cell cytoskeleton is in
blue. Images were captured with a 60x objective. (n=4, error bars represent standard
deviation; *p<0.05, †p<0.01, ‡p<0.001 compared to control groups). ............................ 91
Figure 3.7: (A) Effects of bafilomycin A1 (BafA1, 10 nM) and chloroquine (CQ, 20 µM)
on gene expression of optimum ternary NC/PEI/DNA (1.7:23:1, O/N/P) and binary
PEI/DNA polyplexes (23:1, N/P). Samples treated with BafA1and/or CQ were normalized
to controls treated with neither. (B) Co-localization at 1 h of NC/PEI/DNA polyplexes or
(C) binary PEI/DNA polyplexes to lysosomes using Lysotracker. Polyplexes are in green,
lysosomes (Lysotracker) in red, and cell cytoskeleton in blue. (n=4, error bars represent
standard deviation; *p<0.05, †p<0.01 compared to control groups). ............................... 92
Figure 3.8: Transfection and cellular processing of NC/PEI/DNA polyplexes for combined
gene and antioxidant therapy in cancer cells. ................................................................... 94
Figure 4.1: (A) Uptake of EGF at various concentrations in MDA-MB-231-Luc and MDAMB-231 cell lines. (B) 6 h uptake of 3WJ, 3WJ-EGFapt, and EGF at various concentrations
in MDA-MB-231-Luc cells. (C) Receptor-bound 3WJ, 3WJ-EGFapt, or EGF (red) 15 min
after transfection. Red represents nanoparticles or EGF. Blue represents cell cytoskeleton
stain. (n=3, error bars represent standard deviation)....................................................... 107
xi

Figure 4.2: Knockdown of luciferase expression mediated by 3WJ and 3WJ-EGFapt in
MDA-MB-231-Luc cells. All samples were normalized to non-treated controls. (n=3, error
bars represent standard deviation; *p<0.05, †p<0.01, ‡p<0.001 compared to control
groups). ........................................................................................................................... 108
Figure 4.3: Internalization of 3WJ-EGFapt in MDA-MB-231-Luc cells in the presence of
varying concentrations of EGF. LIPO represents a positive control of 3WJ or 3WJ-EGFapt
delivered using Lipofectamine2000 transfection agent. Data by (A) cytometry and (B) plate
reader yielded the similar results. (n=3, error bars represent standard deviation). ......... 109
Figure 4.4: (A) Uptake and (B) luciferase expression of 3WJ and 3WJ-EGFapt following
EGFR inhibition using EGFR-targeting siRNA (siEGFR) compared to non-targeted siRNA
negative controls (siNEG) transfected with 3WJ or 3WJ-EGFapt. (n=3, error bars represent
standard deviation; *p<0.05, †p<0.01, ‡p<0.001 compared to control groups). ........... 110
Figure 4.5: Endosomal co-localization of 3WJ-EGFapt to caveosomes (CAV), clathrincoated vesicles (CCV), or macropinosomes (MP) in MDA-MB-231-Luc cells. Green
represents tagged endosomes, red represents 3WJ-EGFapt nanoparticles, and blue
represents cell cytoskeleton. Images were captured using a 60x objective. ................... 111
Figure 4.6: (A) Cytotoxicity of GST (10 mg/L), mBCD (3.75 g/L), CPZ (6 mg/L), AMN
(75 mg/L), and AML (80 mg/L) in MDA-MB-231-Luc cells. Inhibited samples were
normalized to controls in the absence of inhibitors. (B) Inhibitor effect on uptake of control
compounds marking caveosomes (CTxB), clathrin-coated vesicles (transferrin, Tf), and
macropinosomes (dextran, DEX). Uptake of all inhibited samples was normalized to
controls in the absence of inhibitors. (C) Uptake and (D) Luciferase expression of 3WJ,
3WJ-EGFapt, or EGF following transfections in the presence of GST, mBCD, CPZ, AMN,
or AML. All inhibited samples were normalized to controls transfected with 3WJ or 3WJEGFapt in the absence of inhibitors. (n=3, error bars represent standard deviation; *p<0.05,
†p<0.01, ‡p<0.001 compared to control groups). .......................................................... 113
Figure 4.7: (A) Relative uptake of 3WJ or 3WJ-EGFapt in MDA-MB-231-Luc when
transfected in the presence of bafilomycin A1 (BAF) and/or chloroquine (CQ).
(B)Transfections of 3WJ or 3WJ-EGFapt in the presence of BAF and/or CQ. All inhibited
samples were normalized to controls transfected with 3WJ or 3WJ-EGFapt in the absence
of inhibitors. Further, all inhibited samples were corrected for metabolic shift associated
with BAF or CQ by normalization to BAF- or CQ-only controls. (n=3, error bars represent
standard deviation; *p<0.05, compared to control groups). ........................................... 115
Figure 5.1: (A) Western blot of FOXC1 expression in 4T1 cells transfected with 0.1 nmol
siFOX or siNEG and the indicated volume of Lipofectamine RNAiMAX. (B)
Quantification of FOXC1 knockdown expressed as [1-(intensity of siFOX band)/(intensity
of siNEG band)]x100%................................................................................................... 130

xii

Figure 5.2: (A) Western blot of FOXC1 expression in 4T1 cells transfected with the
indicated siRNA concentration at lipid:siRNA 8:10 (v:v). (B) Quantification of FOXC1
knockdown expressed as [1-(intensity of siFOX band)/(intensity of siNEG band)]x100%.
......................................................................................................................................... 131
Figure 5.3: Western blot of FOXC1 expression in 4T1 cells transfected with the indicated
CRISPR/Cas9 plasmid(s). (*, clones with successful FOXC1 knockout) ...................... 132
Figure 5.4: (A) Proliferation of 4T1 non-transfected controls (NTC), 4T1 cells transfected
with negative control siRNA (siNEG), and 4T1 cells transfected with FOXC1 siRNA
(siFOXC1). Cell counts were normalized by the initial cell number (n=3, ± standard
deviation). (B) Proliferation of 4T1 and 4T1-∆FOXC1 cell lines. ................................. 133
Figure 5.5: Migration and invasion of 4T1 cells transfected with siFOXC1 or siNEG, and
4T1-∆FOXC1 cells in Boyden chamber assays. (n=3, ± standard deviation) ................ 134
Figure 5.6: 2D migration of 4T1 cells transfected with FOXC1 siRNA (A-C) or negative
control siRNA (D-F) before transfection (A, D) and at 21 (B, E) and 29 h (C, F) posttransfection. ..................................................................................................................... 135
Figure 5.7: (A) Body weight of animals receiving 4T1 or 4T1-∆FOXC1 cells. (n=6, ±
standard deviation) (B) Tumor volume (measured by calipers) after implantation with 4T1
or 4T1-∆FOXC1 cells. (n=6, ± standard deviation) (C) Mass of 4T1 and 4T1-∆FOXC1
excised after 24 days. (n=6, ± standard deviation) (D) Excised 4T1 and 4T1-∆FOXC1
tumors after 24 days. (E) Excised organs 24 days after injection of 4T1-∆FOXC1 cells
showing tumor colonies as indicated by arrows. ............................................................ 136
Figure 5.8: Western blots of 4T1 cell culture lysates (4T1) and excised wild-type 4T1 (WT)
and 4T1-∆FOXC1 (KO1 and KO2) tumor lysates for protein expression of FOXC1 and βActin loading control. ..................................................................................................... 137

xiii

CHAPTER 1. INTRACELLULAR AND LIMITING STEPS TO GENE THERAPY
1.1

Introduction
This chapter will focus on the fundamental concepts of gene therapy and the

current strategies for gene delivery. Non-viral vectors that do not stimulate immunogenic
response are discussed that offer alternative options to viruses. Next, the characteristic
barriers to delivery are presented to establish the process by which non-viral agents must
chaperone their cargo into the cell. These steps and their implications on efficacy are
demonstrated through years of research by the lab and other groups. Finally, the
importance of rational design is discussed for the engineering of new polymeric vectors
for gene delivery. Various properties are outlined and their effects on delivery delineated.
The understanding of how these design properties affect vector-cell interactions is
extremely important to the development of polymer vectors for gene delivery and is the
subject of this dissertation.
1.1.1

A Brief History
Over three decades ago, scientist begun exploring the hypothesis that inherited

genetic indications could be cured through genetic modification using delivered exogenous
DNA. The underlying hope was that the manipulation of the genome offered a robust, onetime treatment capable of permanent curative effects. Inspired by nature, viral delivery
vectors became the choice delivery agents as their natural evolution promotes highly
efficient delivery and expression. In 1985, proof of concept was established when
collaborative efforts of national agencies showed that ADA, an immunodeficiency disease,
could be corrected through integration of a compensatory gene into patient cells in tissue
culture. In the early 90’s reports began to demonstrate that ex vivo T-cell therapies were
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capable of safe and efficient administration in human patients, but clinical trials in the late
90’s demonstrated the primary weakness of the golden viral vector, immunogenicity. The
field experienced a slow-down at the turn of the century as a patient experienced extreme
immunogenic shock from a viral therapy and died shortly thereafter. This elucidated a need
for alternative vectors for gene delivery that do not produce immune system response in
the patient.
Despite the safety concerns associated with the virus, successful clinical trials
resulted in the first approved gene therapy in 2012. The EMA approved Glybera in Europe
for treatment of rare forms of pancreatic cancer. However, the target population was so
small that the drug was forced to sell for unrealistic prices, resulting in discontinuation.
Several more overly expensive orphan drugs were approved in Europe over the years but
all have faced the tribulation of unaffordability and small patient bases. In 2017, the United
States approved two CAR-T therapies (Kymriah and Yescarta) for ex vivo treatment of
ALL and B-cell lymphoma. Shortly thereafter, Luxturna was approved as the first in vivo
gene therapy in the US for the treatment of retinal dystrophy. While still expensive, these
drugs are at the pioneers of modern gene therapy. While only a few approved therapies
exist, dozens of gene therapies continue to enter the developmental pipeline as over 250
companies pursue the field. This is a prime indication that gene therapy is on the brink of
a golden era that will disrupt modern medicine.
1.1.2

The Ethical Dilemma
Because many of the uses of gene therapy involve the permanent alteration to the

body’s basic set of instructions, several scientific, economic, and social concerns arise.
These questions are primarily centric on the poor understanding of the human genome and
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the effects of anthropogenic modification on healthy function. These concerns are
particularly focused on the technology of heritable modifications of germ cells (sperm and
egg cells). Germline modifications involve the permanent genetic manipulation of
reproductive cells, affecting individuals who have not yet been born and have no
governance in the treatment. Due to our poor understanding of genetics in development,
these alterations have the potential to cause detrimental effects to normal development and
lifelong handicap. For these reasons, the US government and many governments of the
world do not allow federal funding of these controversial germline therapies in humans.
Despite these restraints, a Chinese scientist secretly genetically modified an egg to resist
HIV and implanted it in a woman, producing healthy twins. Though no disfigurement
resulted, the scientist’s actions were ruled illegal and unethical and he was fired from his
institution. This is an indication that, while the world condemns this unethical behavior, it
is incapable of restraining unscrupulous individuals with the technical capacity for
controversial gene therapies.
The concept of gene therapy is somewhat foreign to healthcare in that it produces
curative effects instead of symptom relief. This means that, similar to an organ transplant,
a single treatment is required to permanently correct for the indication. Since most modern
medicines offer treatments and not cures, modern healthcare doesn’t have much experience
in establishing the economic value of a cure. Due to unregulated drug economics, the price
tag associated with gene therapies ranges from $425k (per eye) for Luxturna (ocular
dystrophy) to >$1M for Glybera (pancreatitis) with new gene therapies expected to exceed
$4M. Clearly, this introduces the dilemma of access. People with potentially life
threatening disease untreatable by alternatives are faced with a price tag that the average
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consumer cannot afford. Whether these astronomical costs will be covered by healthcare
is yet to be determined.
1.2

Gene Delivery Strategies
In order to effectively provide therapeutic utility to a cell, nucleic acid (DNA or

RNA) must be delivered to its target in a manner that retains its functionality and integrity.
DNA delivered directly into the bloodstream or ingested through enteral routes is easily
digested by the stomach or degraded by circulating nuclease enzymes. While certain
modifications to the structure can provide resistance to degradation or immune activation,
efficient circulation and uptake in most tissue must be facilitated by a delivery vector. This
vector is responsible for the protection of the nucleic acid from serum factors (nucleases
and protein) and transfer across the cell membrane. Further, mammalian immune response
can be incited by recombinant plasmid DNA produced by prokaryotic sources. The
immune system can recognize specific methylation patterns in CpG islands characteristic
of prokaryotic-synthesized DNA [1, 2]. Therefore, a delivery vector simultaneously shields
the DNA from the body and the body from the DNA. Currently there are three delivery
options available: naked nucleic acid, viral vectors, and non-viral vectors.
1.2.1

Naked DNA
Naked nucleic acid refers to DNA or RNA that is not associated with any protective

agent (delivery agent). While DNA tends to be localized to the intracellular environment,
its presence in the bloodstream is not uncommon due to cell lysis and invading pathogens.
To combat the presence of genetic information in circulation, blood is rich in serum
nucleases (DNase and RNase). These factors make it difficult for extended circulation of
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nucleic acids and help minimize infection. As a result, unprotected DNA circulation is
severely limited. Furthermore, cellular permeability of naked DNA is inhibited by size,
shape, and anionic charge. Despite these challenges, naked DNA delivery has become quite
common in the arena of DNA vaccines.
DNA vaccines are injections of naked DNA that codes for the production of a
specific antigen that triggers immune response [3]. Upon tissue internalization, the antigen
is expressed and stimulates immunogenic response. This approach is safer and more stable
than conventional vaccines since DNA is non-live and non-replicating. Further, the risk of
genome integration of a simple plasmid is lower than that associated with naturally
occurring mutations [4]. Interestingly, the type of cell that most readily uptakes naked
plasmid DNA is muscle cells that do not typically contribute to immune signaling [5]. This
technique has moved rapidly into its second generation where secondary and/or adjuvant
molecules are delivered co-currently with DNA in order to increase uptake or direct
immunogenic response. Mixed modality treatments of traditional vaccines with naked
DNA encoding equivalent immune responses are even being used to produce synergistic
effects on vaccine efficacy [6-8]. Though simplistic and fragile, these advancements in
DNA vaccines make naked DNA delivery an exciting prospect for gene therapy.
1.2.2

Viral Gene Therapy
As previously mentioned, the traditional modality for gene delivery is the virus. A

virus is an intracellular parasite evolved as an efficient vehicle for nucleic acid to cells. As
there is a broad spectrum of viral vectors capable of gene delivery, they are categorized
according to several phenotypic characteristics such as transient vs. stable expression, type
of nucleic acid carried (DNA vs. RNA), and the single- vs. double-stranded nature of that
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nucleic acid [9]. Each virus possesses certain advantages or disadvantages associated with
its subset. However, all viruses contain two components 1) a nucleic acid genome and 2) a
protective protein capsid that contains the genome. Some subsets of viruses also contain a
lipid envelope that envelopes the capsid, aids in binding the host cell, and facilitates entry
[10]. Due to the presence of the protein capsid or lipid envelope, all natural-occurring
viruses produce immune stimulation. The most common viral subsets used for gene
therapy, as will be discussed here, are retroviruses, lentiviruses, adenoviruses, and adenoassociated viruses.
1.2.2.1 Retrovirus
Retroviruses are RNA viruses that deposit their RNA payload into the cell to be
reverse-transcribed into double stranded DNA, which is subsequently integrated at random
into the host genome [11]. This permanent incorporation is highly advantageous as it
provides permanent therapeutic effect. However, these viruses require cell division for
infection and are primarily used ex vivo due to powerful immune response. Though initially
the most preferred viral subset for gene delivery, safety concerns have shifted focus away
from the retroviral system for several reasons. First, the random incorporation of the viral
genome into the host presents the possibility of insertional mutagenesis. Disruption of vital
genes in the host can result in deleterious expression profiles, which manifest themselves
in phenotypic changes or cellular functional losses. For example, a retrovirus was used to
treat severe combined immunodeficiency-X1 (SCID)-X1 in children with success [12].
However, after a one-year checkup, a patient had developed lymphoblastic leukemia
attributed to retroviral insertional mutagenesis [13]. Second, and more severe, retroviruses
carry the possibility to generate replication competent retroviruses (RCR). These RCRs
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essentially recover their ability to self-replicate and produce viral side effects like standard
viruses [14]. Despite these safety concerns, retroviruses remain strong contenders for
clinical trials due to advances in directed insertion and reduction in RCR generation [15].
However, safer categories of retroviruses (such as the lentivirus) have been engineered to
avoid many safety concerns associated with retroviruses and may one day render them
obsolete.
1.2.2.2 HIV-1 Lentivirus
The lentivirus is a special group within retroviruses with the capacity to infect
dividing and non-dividing cells. Unlike the retrovirus, lentiviruses do not possess viral
proteins or contain replication competent genomes [16]. Like their counterparts, however,
they retain the ability to stably integrate their genome into the host. Unfortunately, this
integration remains random, which retains the possibility of insertional mutagenesis.
Lentiviruses were developed to solve some of the safety concerns with retroviruses and
have largely replaced them. In fact, one of the US-approved CAR-T therapies employs the
lentivirus for ex vivo T-cell transduction [17]. While the lentivirus is by no means perfect,
it does demonstrate the advancements in virology to solve safety and immunogenic
concerns.
1.2.2.3 Adenovirus
The adenovirus is a DNA virus that does not integrate into the host genome but
localizes to the nucleus as an episomal element. Therefore, it is limited by transient
expression of days to weeks and usually requires multiple administrations [11]. With the
capacity to infect dividing and quiescent cells, the adenovirus is an attractive candidate for
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in vivo studies and is the most used virus in gene therapy. However, 90% of humans have
been exposed to the common adenovirus through natural means and have thus already
acquired antibodies against the virus [11]. Due to the extreme immunogenic nature of the
virus, repeat administration becomes less effective, even after a single exposure. Further,
the efficient uptake of the virus make it non-specific in vivo, which is a problem when
targeting specific cells, such as cancer [18]. The virus can be engineered to be replicationdefective for treatments involving foreign gene expression or replication-competent to seek
out and destroy cancer cells through the natural lytic nature of viral infection [19]. As such,
the replication-defective adenovirus is commonly used in gene therapy vaccines while
replication-competent vectors are being used heavily for cancer treatment.
1.2.2.4 Adeno-Associated Virus (AAV)
The adeno-associated virus (AAV) is one of the most investigated vehicles for gene
delivery. It was initially thought to be a contaminant of adenovirus preparation but was
discovered to be a separate, single-stranded DNA virus [20]. A primary advantage of this
virus is that its evolution mediates cellular entry through very specific receptors or surface
biomarker, which can be tuned by the engineer. This allows selective targeting with the
virus and certain variants might even be able to traverse the blood-brain barrier to infect
neurons in the central nervous system [21, 22]. Another advantage is that genome
integration always occurs at a defined location in chromosome 19, thereby minimizing
insertional mutagenesis because no vital genes are disrupted [23]. Further, the immune
response associated with AAV is less severe than previously discussed viruses, which make
it safer in terms of immunogenicity. However, like the adenovirus, many people have preexisting antibodies to AAV from natural exposure to the virus. This diminishes the effects
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of treatment, potentially even the first time. A viable solution to this problem is to apply
different AAV serotypes to each re-administration to avoid immune clearance.
1.2.2.5 Other Viruses
Though the retrovirus, lentivirus, adenovirus, and AAV make up a large portion of
viruses in clinical trials, there is a host of exotic viruses being studied for their unique
properties. Herpes simplex virus (HSV) is an efficient neuronal-infecting virus with
excellent packaging capacity and ease of production of replication-defective titre. Genome
integration and broad tropism make HSV an extremely advantageous, especially for
neurological disease [24]. A similar large-capacity virus is the poxvirus, the same virus
used to eradicate smallpox. This vector has been studied for decades due to its nonintegrating and low immunogenicity and is used extensively in veterinarian medicine.
Attenuated sub-strains Ankara and Copenhagen NYVAC are of human clinical interest and
are promising gene delivery vectors [25]. Further, self-amplifying ssRNA alphaviruses
offer a rich arena of low-packaging capacity viruses that produce transient, high-expression
profiles. These vectors are highly promising for their oncolytic capacity [26]. For example,
the Newcastle disease virus (NDV) has been shown to replicate only in cancer cells,
making it a focus for cancer gene therapy [27]. These lesser-studied viruses often offer
advantages to the more-popular standard vectors but often possess a fatal flaw that makes
them difficult to tame. However, as they become better understood by the scientific body,
they may one day be engineered to be among the most efficient and safe gene delivery viral
vectors.
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1.2.3

Non-viral Gene Therapy
Safety and production concerns associated with the recombinant virus stunted

funding and momentum of the gene therapy field around the turn of the millennium due to
adverse clinical trials. This caused a split in the direction of gene delivery as scientists
begun to delve into potential alternative vectors for delivery of nucleic acids. These
alternative vectors include biomaterials such as liposomal assemblies of lipids, cationic
polymers, and cell penetrating peptides [28]. Though synthetic vectors are generally
considered less efficient, they do not possess the inherent immunogenic nature or
complexity of the virus. Despite this simplicity, they retain the problematic issues of
formulation and storage inherent in most biological drugs. These vectors work by
condensation and encapsulation of plasmid DNA such that they sterically hinder DNA
access to serum nucleases, preventing degradation. Though efficient at carrying DNA and
entering cells in vitro, synthetic vectors do tend to have poor toxicological profiles and
circulatory clearance problems [29]. These issues are being addressed through rational
design of next-generation synthetic vectors that overcome these issues while retaining the
ability to transport nucleic acids.
1.2.3.1 Lipid Assemblies
Cationic lipids are attractive biomaterials for gene delivery due to their ease of
preparation, ability to modify individual structural elements, and ease of characterization.
All lipid delivery systems are comprised of three components 1) polar head group 2)
hydrophobic moiety and 3) linker [30]. The polar head group is a positive charged,
hydrophilic structure usually produced from protonation of amine groups [31]. Multivalent
head groups have been shown to be more effective than more simple univalent head groups,
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making lipids with multivalent head groups used more often [32]. The hydrophobic section
is comprised of saturated or unsaturated steroid or alkyl chains [30]. Finally, the linker is
the bond between groups and determines chemical stability and biodegradability of the
lipid [33]. These three components form individual lipids that make up the greater
liposomal structure for gene encapsulation. However, formations of ionizable lipids are
coming of interest. These advanced lipids increase gene delivery efficacy through
modulated pKa. At mild basic formulation pH, nucleic acid loading is maximized due to
the positive charge of the lipids. At circulatory physiological pH, the particles take on
neutral charge that helps to avoid clearance. However, once in the cellular endolysosomal
environment, where pH is continuously lowered, the amines of the lipid head group become
protonated and associate with the endosome lipid bilayer. This “charge pairing” causes
DNA release and membrane disruption, resulting in leaky endosomal compartments
susceptible to DNA escape [34].
Lipid nanoparticles are efficient at electrostatically condensing nucleic acid
(lipoplexes) on the scale of just a few base pairs (therapeutic RNA) to millions of base
pairs (chromosomes). Further, these structures are easily functionalized with stealth and
targeting ligands that allow cellular specificity and circulatory longevity [34]. However,
lipids are not without their shortcoming. Physiochemical properties such as charge and size
are shown to be limiting factors in uptake of lipoplexes into cells and transfection
efficiency [35, 36]. These properties further induce severe cytotoxicity which limits clinical
application of lipids [37].
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1.2.3.2 Cationic Polymers
Cationic polymers were discovered to have the ability to electrostatically condense
nucleic acid (polyplex) and traverse the cell membrane [38]. As a result, these biomaterials
have established a prominence in the non-viral gene delivery arena. The primary
differences in cationic polymers and lipids is that polymers lack a hydrophobic moiety and
are soluble in water [39]. Multiple properties such as molecular weight, surface charge,
charge density, hydrophilicity, and structure effect the delivery and transfection efficiency
of polyplexes, making their optimization a focus of the scientific field [40]. Like lipids,
polymers offer the ability to be chemically modified, allowing engineering of structural
motifs and conjugation of molecules that enhance functionality [41]. Common polymers
for gene delivery include PEI, PAMAM, PLL, and Chitosan [42], each with their own
advantages (Figure 1.1). Though promising advances have been made in polyplex design,
the mechanisms of cellular interaction, internalization, and intracellular trafficking are not
well understood. Since these processes are believed to pose limitations on gene delivery
efficiency, there is a push to better understand these mechanisms for the improved rational
design of polyplexes. This is a necessary step if polymer-based gene delivery is to rival the
efficacy of the virus.
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Figure 1.1: Common polymer vectors for gene delivery.
Polyethylene imine (PEI) is the gold standard of polymers for gene delivery due to
high transfection capability resulting from the ability to buffer endosomal influx of protons
[43]. This causes chlorine influx that results in osmotic swelling and subsequent escape of
polyplexes into the cytoplasm. PEI is available in branched or linear format at various
molecular weights. Increasing molecular weight was found to improve transfection but
increase cytotoxicity, limiting the in vivo applications [44]. To offset this toxicity,
modifications are commonly made to the PEI structure to chemically modify or shield the
structure from the biological environment to mitigate toxicity while preserving transfection
quality [45-48]. Despite these improvements, clinical application of PEI is limited to lower
molecular weights to avoid toxicity.
Dendrimers are highly branched spherical polymers of controlled surface charge
and diameter. As a popular dendrimer, PAMAM has been used to mediate efficient, albeit
nonspecific gene transfer in vitro [49]. Abundance of amine surface groups allows facile
chemistries and endosomal escape via similar mechanisms as PEI. Toxicity of PAMAM is
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a prevalent problem though less severe to that of PEI. The characteristics of the dendrimer
(size, surface charge, surface density) are controlled by the number of synthetic steps [50].
While primarily generations 3-6 are used for efficient gene delivery, strides must be made
to reduce the cytotoxicity of these vectors. Attempts to shield the surface amine groups
using hyaluronic acid, PEG chains, arginine, cyclodextrin, and Tat peptide have been
successful in mitigating this toxicity [51].
Polylysine (PLL) was one of the earliest polymers discovered for non-viral gene
delivery. This polymer is biodegradable and, upon modification with dextran or PEG,
exhibits essentially no cytotoxicity as a condensed polyplex [52]. However, PLL is often
associated with poor transfection quality due to the lack of endosomal buffering capacity.
Therefore, the polymer is often delivered accompanied by endosomal buffering agents to
facilitate escape and efficient gene expression. Though improvements have been made,
PLL is primarily used as a reference for other vector’s transfection quality.
Chitosan is an attractive, natural polymer for gene delivery due to its low toxicity,
biocompatibility, and biodegradability [53]. The cationic polysaccharide contains ample
amines for DNA condensation and chemical modification to enhance delivery. However,
use of chitosan can be challenging due to poor solubility, poor cellular specificity, and low
transfection efficiency [42]. However, manipulation of surface amine groups is beginning
to rectify these shortcomings. Interestingly, chitosan is a mucoadhesive polymer, making
it a powerful transfecting agent of gastrointestinal epithelia in gut-associated lymphoid
tissue [54].
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1.2.3.3 Cell Penetrating Peptides
Cell penetrating peptides (CPP) are small amino acid sequences (10-30 residues)
that have the ability to cross the cell membrane independent of endocytosis [55]. CPPs
were discovered in the 1980s when it was demonstrated that the tat gene encoded by the
HIV-1 virus could be taken up by cells in vitro and translocate to the nucleus [56]. Further
studies showed that its biological conjugation with impermeable compounds resulted in
cellular uptake of these compounds without loss of therapeutic activity [57]. Furthermore,
immunogenicity associated with CPP is minimal [58] and there remains astonishingly low
cytotoxicity since CPPs do not cause cellular membrane disruptions [59]. Early studies
showed high competency of CPP for the delivery of siRNA into cancer cells, representing
promising potential for gene therapy vectors. While there seems to be no disadvantage of
CPP-based delivery, cell specificity seems lacking. However, reports indicate that specific
cancer targeting are possible [60]. Though poorly understood and early in development,
CPPs offer exciting potential for delivery not just of nucleic acids but many
macromolecules.
1.3

Barriers to Non-Viral Gene Delivery
Successful gene delivery is contingent on vector ability to effectively navigate

through various physiological environments while protecting its cargo and avoiding
clearance. The simplest environment for gene delivery is the controlled in vitro setting
where cellular delivery is achieved with minimal extracellular resistance. In the body,
however, polyplexes and lipoplexes are subject to lytic enzymes and electrostatic exposure
to serum elements that destabilize and degrade the vector and cargo [61]. Delivery in vivo,
therefore, is subject to a number of environmental interactions that act as barriers to
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delivery. Further, vectors that localize to the target tissue are faced with the additional
barriers of internalization and intracellular processing. These extra- and intra- cellular
barriers are inherently detrimental to efficacy and involve extracellular transport, serum
stability, cellular membrane interaction, internalization, endosomal escape, intracellular
trafficking, cytosolic transport, and nuclear localization (Figure 1.2).

Figure 1.2: Barriers to non-viral gene delivery. A) Extracellular transport/stability. B)
Extravasation from vasculature endothelium or diffusion by enhanced permeation and
retention effect. C) Surface interaction and internalization by endocytosis. D) Early
endosome maturation into late endosome. E) Transport and fusion of late endosome with
lysosome. F) Endosomal escape through osmotic selling. G) Transport through cytosol to
nuclear envelope. H) Nuclear localization. I) Vector dissociation into DNA and cation.
1.3.1

Serum Stability and Extracellular Transport
Condensation of DNA is often performed by electrostatic binding with excess

cation, resulting in a vector of positive charge. Naked DNA alone is capable of stimulating
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inflammatory response by toll-like receptors [62]. Therefore, this electrostatic
incorporation into a nanoparticle results in shielded DNA that avoids immune activation
and protects the cargo from enzymatic degradation. The positive charge mediates cell
uptake but causes non-specific interactions in circulation. Interaction with serum
components in the blood results in electrostatic disruptions between the nucleic acid and
vector, which can lead to premature dissociation or deteriorated shielding [63]. Since the
presence of nucleic acids in the blood stream is discouraged by high concentration of
nucleases, lack of shielding directly corresponds to nuclease degradation and poor delivery.
Binding serum proteins also expedites aggregation of vectors, leading to condensation and
renal clearance. Further still, electrostatic interaction with non-target cells and extracellular
matrix diminish delivery efficiency. Binding plasma proteins leads to recognition by the
reticuloendothelial system (RES) which localizes delivery to RES organs such as the liver,
spleen, and bone marrow [64]. These interactions within the blood stream are major
barriers to successful gene delivery and their mitigation or avoidance are a subject of
critical study.
Perhaps the first barrier to gene delivery is introduction to the blood stream
followed by effective shielding of non-specific interactions in circulation. However, to
reach non-vascular targets, non-viral vectors must extravasate through the vasculature wall
to gain access to the desired tissue. Of the common vesicular wall structures, the
discontinuous structure contains gaps of 30-500 nm capable of mediating random diffusion
of vectors through the wall [65]. Nanoparticles or aggregates of particles beyond this size
will remain in circulation until encountering vascular beds in the liver where they
accumulate and become cleared [66]. Non-viral vectors must be capable of condensing
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their cargo into nanoparticles within this size range for non-vascular delivery. Diffusion
through these gaps, therefore, is a tremendous barrier to intravascular delivery in the
absence of vasodilators that temporarily increase the size of fenestrations in the vessel
lumen. However, gene delivery to cancer tumors is much more trivial due to the enhanced
permeation and retention effect (EPR) associated with the tumor endothelium. Tumors
undergoing angiogenesis tend to possess a leaky, discontinuous structure that allows
permeation of macromolecules and most nanoparticles [67]. This in conjunction with poor
lymphatic drainage results in accumulation of nanoparticles within the tumor vasculature,
making the EPR effect an effective means for passively targeting established tumors [6870].
1.3.2

Cellular Membrane Interactions
Once the administered non-viral vector has navigated its way through the biological

extracellular barriers, it must interact with the target cell membrane such that
internalization occurs through endocytosis. This process of internalization is energy
dependent and in most cases requires activation through interaction with intermembrane
protein domains [71]. Though cationic amphiphile-DNA complexes were originally
believed to undergo fusion with the cell membrane, studies have proven that most all nonviral vectors internalize through endocytosis, even the vectors considered non-specific
[72]. These vectors bind to the cell through either receptor interactions or non-receptor
binding. Receptor binding is mediated by cognate recognition of a ligand by a surface
biomarker. Multiple ligands such as transferrin, insulin, EGFR, and folate [73-76] have
been conjugated to non-viral vectors in order to provide specificity in targeting. Nonreceptor binding, on the other hand, is primarily driven by electrophilic interactions of
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vectors with charged intermembrane proteins. For example, the cell surface comprises a
large concentration of proteoglycans, one of the most negatively charged components of
the cell [77]. Cationic vectors likely bind these protein complexes through electrostatic
interactions and trigger subsequent internalization as shown by inhibited transfection upon
proteoglycan inhibition [78]. Negative zeta potential vectors are repulsed by these
proteoglycans and are forced to localize to regimes of positive cell surface charge to
interact with protein groups of positive charge. It is highly likely that the internalization
mechanism associated with these positive and negative particles are different [79], leading
to disparities in intracellular processing and gene expression as discussed in chapter 2.
1.3.3

Internalization and Endosomal Escape
As previously discussed, internalization of non-viral vectors is preceded by

interaction with the cell membrane, which governs the endocytic mechanism of uptake.
Internalization through receptor-mediated endocytosis involves concentration of receptors
in special membrane regimes of clathrin-coated pits followed by invagination of the cell
membrane around the vector-receptor complex and transport through the membrane [80].
At the inner side of the cell membrane, the particle becomes encased by structural actins
and coated with clathrin to form clathrin-coated vesicles (CCV). These vesicles are
acidified as they are trafficked to late endosomes and then to lysosomes [81]. This clathrindependent endocytic pathway is well characterized and by far the most studied endocytic
mechanism. However, alternate mechanisms involving membrane transport independent
of clathrin are known to be involved in the intermembrane transport of many
macromolecules. Perhaps the most studied clathrin-independent mechanism involves
flask-like membrane invaginations that bud off the membrane in caveolin-structured
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vesicles called caveolae [82]. Unlike clathrin-dependent internalization mechanisms that
are solely purposed for endocytosis, caveolae are implicated in a host of cellular functions
such as calcium signaling, homeostasis, and cholesterol transport [83, 84]. A further
differentiation from clathrin-dependent uptake is that caveosomes are suspected to avoid
harsh acidification and trafficking to lysosomes [85, 86]. Interestingly, cells also possess
non-specific internalization pathways for the fluid phase uptake of solutes and extracellular
constituents from the immediate surroundings. Phagocytosis is one such pathway uniquely
utilized by macrophages and other immune cells to engulf large components even on the
cellular level. However, this is a pathway used only by specialized cells. The common cell
approach to non-specific fluid phase internalization occurs through macropinocytosis, a
process that involves the formation of membrane ruffles that eventually engulf large
portions of extracellular fluid. The resulting vesicle is called a macropinosome and can
measure up to 5 microns in size [87]. Though this mechanism is non-specific, it is generally
activated through stimulation of growth factor receptors on the cell membrane [88]. Cancer
cells overexpressing growth factors, therefore, are particularly active in terms of uptake
through macropinocytosis. Though other unique, clathrin-independent pathways do exist
[89-92],

clathrin-dependent

endocytosis,

caveolin-dependent

endocytosis,

and

macropinocytosis are believed to be responsible for the internalization of most
macromolecules.
Following internalization and the formation of an early endosomal vesicle (CCV,
caveosomes, macropinosome, etc.) the cell must sort the endosomal contents for secretion,
digestion, or recycle to the cell surface. Though this sorting process is poorly understood
[80], the current model involves the procession from early endosomes to acidified
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endosomes to lysosomes [93]. This endosomal classification defines the compartments
based on pulse or pulse-chase protocols and presence of unique marker proteins. Generally,
the early endosome is sorted into a maturing endosome that is acidified from physiological
conditions to a pH of 5-6 when fully matured as a late endosome. This late endosome is
characterized by the presence of degradative enzymes and the highest concentration of the
cation-independent mannose 6-phosphate receptor (M6PR) which is localized to the
internal wall of the vesicle [94]. This late endosome undergoes fusion with lysosomal
cellular compartments to form a hybrid vesicle containing high concentrations of
degradative enzymes and a pH of ~4.5 [81]. Any nucleic acid that survives sorting to the
lysosome will surely be degraded by the compartment acidity and host of nucleases.
Therefore, efficient gene delivery requires vector escape from the endosome before
conditions destroy its cargo.
The process, or lack thereof, of endosomal escape is a major limiting step to
efficient gene delivery [95]. As such, early vectors showed high levels of uptake but low
subsequent gene expression due to lack of ability to escape the endosome [96]. Therefore,
three main mechanisms have been developed to promote endosomal escape of non-viral
vectors for gene delivery. First, the pore formation model involves conjugation of pHactivated peptides that undergo conformational changes at the pH of the maturing
endosome. These changes result in peptide insertion into the endosomal membrane,
creating ion channels allowing vector escape [97]. Since this mechanism is common in
viruses, fusogenic peptides were isolated and conjugated to vectors and showed increases
in delivery [98]. The second model is termed flip-flop and involves endosomal escape by
the fusion of the vector with the endosomal membrane. This is a popular technique for
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lipoplexes since they require a phospholipid for lipid bilayer stabilization.
Dioleoylphosphatidylethanolamine (DOPE) is particularly successful at providing
fusogenic activity of the lipoplex with the endosomal wall [97]. The final model, the proton
sponge, is a system inherent in several cationic polymers such as PEI and PAMAM. These
vectors possess high densities of amine groups capable of protonation at endosomal pH.
Influx of protons during endosomal acidification are buffered by the amine groups,
resulting in excessive accumulation. This invokes chloride ion influx, causing the
endosome to swell and become increasingly permeable, allowing escape [99]. Since many
cationic lipids and polymers do not possess this buffering ability, conjugation of
endosomolytic agents such as glycerol or chloroquine can provide this endosomal buffering
capacity for improved efficacy.
The process of internalization is known to affect the resulting endosomal sorting
[100-106]. While clathrin-mediated endocytosis leads to rapid internalization, the pathway
is known to sort its contents to late endosomes and lysosomes [81]. While this may seem
to be of benefit since most endosomal escape mechanisms require acidification, efficient
internalization of cationic polymer PEI shows higher efficacy upon internalization through
caveolin-dependent endocytosis, a route hypothesized to avoid endosomal acidification
and lysosomal trafficking [100]. Therefore, avoidance of the endolysosomal pathway by
caveolin-mediated uptake may be more efficient than endosomal escape by the
hypothesized proton sponge effect mediating escape after clathrin-mediated uptake. This
is indicative that internalization pathway is closely linked to subsequent intracellular
trafficking and transfection efficiency of non-viral vectors.
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1.3.4

Cytosolic Transport and Nuclear Localization
Upon micro-injection into the cytosol, naked DNA becomes rapidly degraded by

cytosolic nucleases, producing little gene expression [107]. Therefore, it is highly likely
that at least a portion of the vector-DNA complexes escape the endosome intact such that
nucleic acid shielding continues to occur in the cytosol. However, smaller segments of 21
bp DNA were shown to be more successful at traversing the cytosol and entering the
nucleus where double stranded DNA sequences up to 500 base pairs were shown to localize
to the nuclear envelope and 6 kb DNA was immobilized, likely due to cytosolic crowding
[108, 109]. Cationic lipid lipoplexes directly injected into the cytosol showed decreases in
expression compared to naked DNA, indicating their dissociation in the endosome is
critical [110], whereas PEI or PLL polyplex microinjection resulted in boosted expression
[111]. Therefore, efficiency in polycation-based vectors is most likely dependent on
continued condensation and shielding of DNA after endosomal escape. As an alternative
hypothesis to cytosolic diffusion, models of active transport have been suggested that
involve the transport of complexes or naked DNA along cytoplasmic spanning structures
such as actin filaments or microtubules [112]. Interestingly, the inhibition of tubulin
transport using nocodazole was shown to improve gene expression in lipoplexes [113].
Though this was expected to be from the avoidance of trafficking along microtubules to
lysosomes, it indicated that microtubule transport was indeed a mode of cytosolic transport
for lipoplexes. For PEI-DNA polyplexes, depolymerization of microtubules or inhibition
of dynein motors decreased expression while microtubule stabilization increased
expression 20-fold [114]. This indicates that lipoplexes and polyplexes are dissimilar not
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only in their mechanism of dissociation, but also in their mechanism of active or passive
cytosolic transport.
Nuclear accession is achieved either by transport through nuclear pore complexes
or by entrainment during nuclear formation. Nuclear pores are the exclusive method of
chaperoned entry to the nucleus, excluding compounds of >45 kDa without explicit nuclear
localization signals [115, 116]. This would seem to indicate that dissociation of DNA from
the vector would be a prerequisite of nuclear internalization. However, PEI-DNA
complexes were shown in the nucleus after delivery, indicating that dissociation is not
required for nuclear localization [111, 117]. A proposed mechanism for entrance is that
exposed DNA is bound by transcription factors in the cytosol. Since these transcription
factors localize to the nucleus, they possess the import signals needed to enter through
nuclear pore complexes, thereby ushering the bound vector-DNA complex into the nucleus
[118]. Alternative theories of nuclear localization of dividing cells involves the breakdown
and formation of the nucleus during mitosis. The formation of the newly formed nucleus
simply entrains the vector-DNA or naked DNA, which is then trapped in the new nuclear
environment. A third, less-likely hypothesis is that the membrane disruptive nature of the
cationic vector facilitates membrane disruption of the nuclear wall in a similar fashion to
endosomal membrane disruption. This forms a temporary avenue by which the vectorDNA and other compounds can pass through the membrane [95, 119].
1.3.5

Intracellular Dissociation
Though it is unclear as to when the vector-DNA complex dissociates within the

cell, intact polyplexes were observed within the nucleus after transfection, indicating that
dissociation is not required for nuclear delivery [111]. However, it is likely that exposure
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to acidifying factors in the endosome as well as cytosolic proteins caused decreased
electrostatic interaction between the vector and DNA, allowing access of the genetic cargo
to transcriptional factors required for expression. Further, it is possible that dissociation
does not occur universally. Dissociation location might vary depending on a variety of
factors and interactions within the cell, resulting in polyplexes and lipoplexes of varying
stability in all cellular compartments.
1.4

Rational Design of Non-Viral Vectors
Many structural, chemical, and physical properties of non-viral vectors influence

the stability of the vector-DNA complex and ability to overcome the many barriers to
delivery. Though advancements have been made in vitro leading to increased gene
delivery, the efficacy of in vivo vectors is wanting. Therefore, a deep understanding is
required for the manipulation of particle properties to optimize the stability and robustness
of non-viral vectors. These properties as they apply to nanoparticles are well studied [41,
120-122]. However, much less attention has been devoted to their effects on non-viral gene
delivery vectors. Here, a brief review of several of these properties will be explored in the
context of polymer-mediated gene delivery.
1.4.1

Size and Shape
The effect of particle size on internalization is somewhat confounding. Intuitively,

larger particles should internalize slower and to lesser extent than smaller particles due to
the extra energy required for their internalization. However, this is not the case for PEIDNA polyplexes where polyplexes of hundreds of nm exhibited more transfection than
particles <100 nm [123, 124]. A proposed explanation for this in vitro phenomenon
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suggested that smaller polyplexes remain in suspension while larger polyplexes sediment
onto the surface of the adherent cells, forcing more cellular interaction than the suspended
smaller polyplexes. This was supported by an increase in transfection upon centrifugation
of smaller particles to promote sedimentation [125]. However, this was not a generalized
statement for all polymers since PLL and pDMAEMA exhibited differing results. An
alternative explanation is that the size of the polyplex governs the endocytic pathway of
internalization [126]. Large polyplexes might therefore internalize through pathways
alternate to their smaller counterparts. Since clathrin-mediated endocytosis is the suspected
uptake mechanism of the smaller PEI-DNA polyplexes [73], larger ones might avoid the
endolysosomal demise of the smaller. This phenomenon is not surprising since endocytic
uptake mechanisms possess upper size limits that cause a shift in uptake pathway from
smaller to larger particle, as demonstrated by polystyrene internalization [127]. Large
polyplex design is also though to benefit endosomal escape by the proton sponge effect as
higher weights of polymer capable of protonation allows higher endosomal buffering
capacity. This was supported by increased transfection of smaller PEI-DNA polyplexes but
not larger polyplexes when transfected in the presence of lysosomotropic agent chloroquine
[128]. Though this is true for protonable polymers, the same might not be said for those
unable to buffer the endosome. A further advantage of large polyplexes is the direct
relationship between DNA protection from degradation by nucleases, where large
polyplexes were shown to be more effective at DNase shielding than smaller, exposed
polyplexes [129]. Though it may seem that larger polyplexes are advantageous in many
concepts, they are not without their shortcomings. Polymeric vectors are shown to pose
significant and sometimes excessive cytotoxity [29]. However, this toxicity is heavily
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dependent on the molecular weight and chemical makeup of the cationic polymer [130].
Further, large polyplex mobility was shown to be greatly impeded in the cytosol, as
previously discussed. Therefore, design of polyplex size should optimize the transfection
capacity while maintaining cytosolic mobility and low cytotoxicity.
Shape of nanoparticles is an important property since larger surface area mediates
maximum membrane interaction. Polyplexes, however, lack the ability to control the
electrostatically bound complex form. Condensation of DNA with cationic polymer results
in a globular shape or a rod shape when functionalized with PEG [131]. However, toroidal
polyplexes micelles were formed by PEG-DNA-polymer condensation in the presence of
600 mM NaCl and exhibited superior transfection over standard rod shaped polyplexes
[132]. This process involved the spooling of DNA into a polymer micelle, a process similar
to viral packaging [133]. Though of interest in forming artificial viruses, this technique
requires highly controlled complexation and is likely too complicated to consider for most
applications. Therefore, the rational design of polyplex shape is limited.
1.4.2

Surface Chemistry
Though great strides have been made in the field of biomaterials, the need exists

for a deeper understanding of their interactivity at the cellular interface. This is true for
non-viral vectors where these interactions govern the physiochemical response of the cell
and subsequent vector efficacy. Therefore, extensive work has been performed to
characterize the chemical and structural properties of polymer vectors as they relate to
biological interactions [134]. Modification of these surface properties is key to optimizing
desirable biological interactions (DNA condensation, cellular internalization, protection
against nucleases, cell targeting, etc.) while minimizing the undesirable (non-specific
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binding, aggregation, toxicity, etc.). Though the term “surface chemistry” encompasses
many different aspects of the vector surface design such a hydrophobicity, elemental
composition, morphology, charge, and end-functionalization, only design strategies
involving moiety substitutions and molecular conjugations are discussed here with surface
charge/density addressed in the following section.
Oftentimes, surface moiety modifications that disrupt the homogeneity or
hydrophobicity of the vector surface are beneficial to vector functionality [135]. These
modifications help to reduce the original properties while promoting new interactions
through replacement of chemical functional groups. For example, acetylation of up to 57%
of the primary amines of PEI was shown to enhance gene expression up to 58-fold in
HEK293 cells [48, 136]. The source of this enhancement was determined to be the decrease
in interaction with DNA, allowing easier dissociation within the cell. Further, succinylation
of PEI was shown to produce a similar effect, improving gene expression through reduced
serum interaction and intracellular dissociation [137]. Substitution of amines on 2-kDa PEI
with various aliphatic lipids also exhibited positive effects on gene delivery by boosting
the inferior expression associated with low molecular weight PEI to rival that of 25-kDa
PEI without increasing toxicity [138]. A particularly interesting modification for the
generation of degradable PEI was the appending of low molecular weight PEI with linear
biodegradable polyesters with carbon-carbon double bonds [139]. The resulting, crosslinked polymers retained the ability to effectively condense DNA while providing
transfection similar to 25-kDa with little toxicity. These modifications are used to alter the
surface chemistry in a way that enhances or shields the effects of functional groups by
substitution.
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One of the advantages of polymer and lipid vectors is the ease of functionalization
due to accessible surface groups. Therefore, conjugation of ligands, small molecules,
proteins/peptides, stealth agents, and antibodies has become mainstream. Perhaps the most
common conjugation is that of the stealth agent polyethylene glycol (PEG). This
modification results in a PEGylated particle with a hydroxyl-rich shell that reduces surface
charge, resulting in decreased non-specific serum interactions and clearance by phagocytic
systems, thereby extending circulation in vivo [140]. While this hydrophilic shell helps to
shield undesirable interaction, it hampers desirable interactions such as cellular uptake,
controlled intracellular trafficking, and endosomal escape too, reducing gene delivery
efficiency [141, 142]. Other beneficial conjugation techniques involve the installation of
ligands that compliment specific biomarkers on a targeted cell population. This is a
particularly effective method to specifically targeting cancer cells with known
overexpressed surface receptors. Ligand selection often involves the selection of a preexisting endogenous molecule that couples to well-studied receptors [143]. Perhaps the
most widely studied ligand is transferrin, whose receptor is expressed on the surface of
many proliferating cells and overexpressed on many cancers [144]. Transferrin has been
extensively used in polymer delivery systems for the purpose of targeting cancer [100,
123]. Another effective targeting ligand is folic acid, a vitamin heavily sought out by ovary,
kidney, uterus, testis, brain, colon, lung, and myelocytic blood cancers [145]. It has also
been used extensively in the therapeutics arena, including cancer-targeted polymer gene
delivery [100, 146-148]. Another type of receptor common to cancers are growth factors.
In particular, the epidermal growth factor (EGFR) has shown promise as a cancer-targeting
agent, being overexpressed in approximately 30% of solid tumors [149, 150]. This growth
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factor has been used in polymer systems to increase specific transfection in lung cancers
[75], colon cancers [151], liver cancers [152], and several others. Other ligands being
utilized for cancer targeting of polymer vectors include but are not limited to the RGD
peptide [153, 154], hyaluronic acid [155, 156], and DNA/RNA aptamers. These aptamers
are an exciting new field that involves the sequencing of DNA or RNA to fold into complex
tertiary structures that compliment cell receptors, offering targeting capacity for many
therapeutic systems [157]. Though these aptamers have been used in polymer systems for
drug delivery [158, 159], their use for polymer gene delivery is essentially unexplored
[160].
1.4.3

Charge Density and Zeta Potential
A particularly impactful trait of the non-viral vector surface is charge group density

and the subsequent effect on DNA condensation and cell cytotoxicity. The DNA-binding
mechanism (electrostatics) is the same for all cationic polymers. Therefore, the defining
differences from vector to vector are the functionality and length of the polymer backbone
[161]. Even the same cationic polymer can exhibit significantly different toxicity and
delivery efficiency at varying lengths as exemplified by higher molecular weights of PEI
producing higher transfection efficiency and toxicity while lower weights are less toxic but
also less efficient [130]. However, when comparing different vectors of equivalent
molecular weight, the density of positive charge groups becomes the source of performance
disparities. In general, higher charge group density results in higher localized charge and
greater local electrostatic interaction with opposite-charged surfaces. This greatly aids in
the condensation of DNA into smaller polyplexes as increased charge pairing neutralizes
the DNA backbone repulsion of itself to allow higher angles of folding [162]. This charge
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group density also affects the polyplex surface interactions after complexation through
strong interactions with negative surface groups on the cell membrane as discussed
previously. This leads to higher binding and internalization potential, but tighter DNA
compaction requires more dissociative effort in order to expose the DNA for transcription.
Stronger binding of the cell membrane is beneficial for internalization but can also results
in irreparable membrane disruptions that induce cytotoxic effects on the cell [163]. Further,
high cationic surface density can also lead to increased in vivo interaction with non-specific
blood factors, resulting in aggregate formation, clearance, and off-site targeting. Therefore,
polymers of high cationic charge group density tend to have strong performance in vitro
but are rapidly cleared when administered in vivo. As such, several strategies are in place
to prevent the undesirable interactivity of the polyplex surface with the in vivo environment
while preserving the transfection potency of these polymers. As discussed in the previous
section, substitution of a portion of the charge groups is an effective means to reduce the
number of cationic functional groups at the polyplex surface, decreasing interactivity. This
method is successful at improving serum stability and reducing cytotoxicity, but it fails to
vastly mitigate non-specific interactions as required by in vivo application, which requires
polyplexes of neutral or negative charge for extended circulation through prevention of
non-specific interactions with negative serum proteins. An alternative strategy is to involve
a further layer of electrostatic interactions to coat the polyplex surface in a layer of anionic
polymer to form a ternary system. This coating serves to partially or fully neutralize the
cationic groups of the polycation, resulting in reduced surface charge and lessened DNA
interaction [164]. Several different polyanion coatings such as hyaluronic acid [165] and
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poly (glutamic acid) [166, 167] have been used to produce ternary polyplexes for gene
delivery.
The major benefit to ternary polyplexes is the ability to control zeta potential
through varying the weight ratio of polycation, polyanion, and DNA. Excess weights of
polyanion can even result in negative surface charge. This surface charge plays a pivotal
role in non-specific in vivo interactions, cellular internalization, and intracellular fate of
polyplexes [164]. Therefore, investigation of the effects of charge on each of these
mechanisms is important for the rational design of polyplexes for in vivo application.
Though physiological implications are somewhat explored [164], there is little
investigation of the effect of negative polyplex charge on the cellular barriers to gene
delivery. Cell surface interactions, internalization, and intracellular processing are all areas
that lack characterization in terms of negative charged polyplexes and are therefore a focus
of chapter 2. Here, it was demonstrated that charge is an important factor in the process of
internalization where positive ternary polyplexes emphasized different endocytic pathways
than negative polyplexes. Therefore, there is much work to be done in the development
and understanding of ternary polyplex systems before clinical relevance can be established.
1.5

Concluding Remarks
The onset of the Human Genome Project has brought gene therapy into great

relevance in modern medicine. The juxtaposition of healthy genetics against disease states
allows for the identification of genetic etiology and subsequent curative therapies. The
applications have therefore become endless, including but not limited to acquired cancers,
infectious disease, cardiovascular disease, degenerative disease, and heritable genetic
indications. Though viral vectors exhibit exceptional gene delivery capacity, their poor
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safety profiles, while ever improving, remain largely restrictive of their in vivo application
as exemplified by poor clinical success. Therefore, considerable efforts are being made to
develop non-viral alternatives that lack the immunogenic hallmark of viral counterparts.
These vectors, while safer and easier to functionalize, fall short of the efficacy achieved by
the virus and are therefore the center of intense design efforts. While some non-viral
vectors have been established as high performers, it is critical that a deep understanding of
vector interactions with the physiological and cellular environments be characterized. This
knowledge will help to improve the efficiency of non-viral gene delivery through the
rational design of new systems or modification to current ones.

Copyright © Landon Mott 2019
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CHAPTER 2. EFFECT OF SURFACE CHARGE ON POLYPLEX INTERNALIZATION AND
INTRACELLULAR TRAFFICKING
2.1

Introduction
Transport of biomolecules across the plasma membrane is required for cell-to-cell

communication, immune surveillance, uptake of nutrients, and recycling of surface
markers that interface with the surroundings. Such transport often occurs by endocytosis,
which encompasses several distinct energy-dependent processes. Various nanoparticle
drug and gene delivery vehicles, including polymer-DNA complexes (polyplexes), also
utilize endocytosis to enter cells. As understanding of endocytic processes has advanced,
it has become apparent that the endocytic pathway involved in polyplex internalization
plays a prominent role in the intracellular fate of the genetic cargo and efficiency of
transgene expression.
The primary mechanisms for nanoparticle internalization are clathrin-dependent
endocytosis, caveolin-dependent endocytosis, and macropinocytosis. Clathrin-dependent
endocytosis results from invaginations of the plasma membrane known as clathrin-coated
pits (CCPs), which form clathrin-coated vesicles (CCVs) following dynamin-mediated
scission [168]. During the subsequent endocytic trafficking, the vesicles are acidified by
the influx of protons and counter ions to pH 5-6 before being trafficked to lysosomes for
further acidification to pH ~4.5 [81, 169]. Caveolin-dependent endocytosis begins in cuplike invaginations in the cell membrane called caveolae, which are released from the
membrane by dynamin, similar to CCVs, but have a very slow turnover at steady state.
Unlike CCVs, caveosomes are believed to avoid extreme acidification and trafficking to
lysosomes [86, 170]. Finally, macropinocytosis is a fluid-phase mechanism for rapid, non-
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specific uptake of solutes and large components near the plasma membrane. Stimulation
of surface growth factors triggers Arf6-induced ruffle formations, which propagate into
macropinosomes. These vesicles range in size up to 5 µm, encapsulate large volumes of
extracellular fluid and any other species in solution adjacent to the cell membrane, and are
inherently leaky [87, 168]. Though macropinosomes are mildly acidified, trafficking to
lysosomes is only apparent in macrophages, while in most other cell types macropinosomes
are believed to avoid fusion with lysosomal compartments [171, 172]. Multiple
nanoparticle properties (size, shape, charge, surface chemistry, etc.) influence the cellular
mechanisms through which nanoparticles are internalized and their subsequent
intracellular processing [41]. Therefore, understanding the effect of such design properties
on cellular processing is critical for rational design of nanoparticle drug and gene delivery
systems.
Polyethylenimine (PEI) is a cationic polymer composed of repeating amine groups
and an ethylene spacer, and studies using PEI as a gene delivery vector are abundant [173175]. The high density of ionizable amines allows the polymer to effectively condense
DNA and, in polyplexes with excess PEI, provides electrostatic binding to the cellular
membrane and internalization through endocytosis [176]. It has been hypothesized that,
within acidified endocytic vesicles, protonation of the amine groups results in influx of
counter ions, osmotic swelling, and vesicle rupture, releasing the polyplexes into the
cytosol [99, 177]. However, the highly cationic nature of the polymer also results in
cytotoxicity due to disruption of cell and mitochondrial membranes in many cell types
[163]. Furthermore, high cationic charge density leads to agglomeration with negatively
charged serum proteins, which promotes rapid clearance and inhibits cellular
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internalization of PEI/DNA polyplexes [178, 179]. These disadvantages may be alleviated
by inclusion in the polyplexes of an anionic material that decreases the overall surface
charge and the severity of the electrostatic disruption of the cell membrane. Inclusion of an
anion also results in competition with DNA for binding of PEI, which facilitates
dissociation of the polyplexes within the cell and reduces aggregation with serum proteins
en route to the cell through charge shielding [164].
Here we show that poly(α-glutamic acid) (PGA) is a suitable anionic polymer for
the formation of ternary polyplexes (PGA/PEI/DNA). By addition of varying amounts of
PGA to PEI/DNA polyplexes, the zeta potential could be controlled to investigate the
effects of polyplex charge on cellular internalization in HeLa (cervical adenocarcinoma),
U-87 MG (glioblastoma), and HEK 293 (embryonic kidney) cell lines. We and others have
shown that the endocytic pathway through which polyplexes are internalized governs
intracellular processing and efficiency of gene delivery [100-106]. That some endocytic
pathways result in transport to acidified endosomes while others do not offers a partial
explanation for the differences in effectiveness of various gene delivery polymers [170].
Therefore, it is important to understand the mechanisms of internalization for rational
design of polymeric gene delivery vectors. Transfection with PGA/PEI/DNA polyplexes
exhibiting varying zeta potential, in the absence and presence of pharmacological inhibitors
of specific endocytic pathways, were employed to investigate the effect of polyplex charge
on uptake pathway, the resulting intracellular trafficking, and subsequent reporter gene
expression.
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2.2
2.2.1

Materials and Methods
Cell Culture
HeLa (CCL-2), U-87 MG (HTB-14), and HEK 293 (CRL-1573) cell lines and

EMEM cell culture media were purchased from ATCC. Cell culture was performed
according to the ATCC protocols in EMEM supplemented with 10% fetal bovine serum
(FBS) at 37ºC and 5% CO2. Phosphate buffered saline (GE Life Sciences,10 mM Na2HPO4,
1.8 mM KH2PO4, 137 mM NaCl, pH 7.2) was used to wash cells while Trypsin comprising
0.53 mM EDTA (Corning) was used to dissociate cells. Cells were lysed with cell culture
lysis reagent at pH 7.8 composed of 25 mM Tris-Phosphate buffer, 0.7 g/L 1,2diaminocyclohexane, 10% glycerol, 1% Triton X-100, and 1% protease inhibitor cocktail
(Millipore).
2.2.2

Materials
pGL3-control vector, encoding a modified firefly luciferase optimized for

transcription in mammalian cells under control of the SV40 promoter-enhancer, was
purchased from Elim BioPharm. Polymers (branched, 25-kDa polyethylenimine and 15kDa poly-L-α-glutamic acid sodium salt) and pharmacological endocytosis inhibitors
(genistein,

methyl-β-cyclodextrin,

chlorpromazine

hydrochloride,

amantadine

hydrochloride, and amiloride hydrochloride) were all purchased from Sigma-Aldrich.
2.2.3

Polyplex Formation
PGA, PEI, and pGL3 stocks were produced by dissolution in PBS at 0.1 mg/mL.

Subsequently, desired weight of pGL3 was further diluted 1:5 v:v in PBS. Differing
amounts of PEI or PGA were diluted in PBS to the same volume to produce solutions of
37

varying PEI or PGA concentrations. The diluted PEI solution was added to the pGL3
solution, gently mixed, and incubated for 10 min at room temperature in order to form
binary polyplexes. Ternary polyplexes were then formed by adding the dilution of PGA to
the binary polyplex solution and incubating at the same conditions for 10 min. These
polyplexes were then diluted to the desired well volume by addition of EMEM and
supplementation to 5% FBS. All transfections were performed in 5% FBS unless stated
otherwise.
2.2.4

Size and Zeta Potential
Particle size analysis was performed on a Brookhaven 90Plus Particle Size

Analyzer. Polyplexes were formed according to the protocol described above at various
PEI/DNA and PGA/PEI/DNA ratios containing 2 µg pGL3 plasmid and then diluted to 1
mL in 0.1X PBS. Particles were transferred to a disposable cuvette and analyzed over three
reads at 5 min per read. Zeta potential was determined using a Malvern Zetasizer.
Polyplexes containing 800 ng pGL3 were formed at various PEI/DNA and PGA/PEI/DNA
ratios by the standard protocol and then diluted to 750 µL in 0.1X PBS. The polyplex
suspension was transferred to a Malvern Nano Series disposable folded capillary cell and
analyzed for three reads, each consisting of 20 measurements. All samples were run in
triplicate and averaged.
2.2.5

Agarose Gel Electrophoresis
Ternary polyplexes of varying weight ratios were prepared in 10uL 1X TAE buffer

by adding desired weights of 0.1 mg/mL PEI to 200 ng DNA tagged with YOYO-1 at 1
dye molecule per 50 bp, incubation for 10 min, and then the addition of desired weight
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ratio of 0.1 mg/mL PGA. After a further 10 min incubation, polyplexes were diluted in 1X
TAE buffer to a total volume of 20 µL and then 4 µL 6X loading buffer added (Enzo Life
Sciences). A 250 - 10,000 bp DNA ladder (Ampigene) and polyplexes were loaded in a
0.8% agarose gel and electrophoresed at 100 V for 2 h before washing and visualizing by
a BioRad ChemiDoc MP Imaging System.
2.2.6

Measurement of Non-Specific Protein Binding
Polyplexes at 0:3:1, 1.5:3:1, 4:3:1, 5.2:3:1, and 5.6:3:1 (w:w:w) PGA:PEI:DNA

were formed according to the protocol above, producing zeta potentials of 16, 11, 0, -11,
and -16 mV, respecitively (w:w:w). An equal volume of 2 mg/mL bovine serum albumin
(BSA) was added to polyplex suspensions containing 800 ng DNA or free PEI at equivalent
weights and incubated at 37ºC for 1 h. The samples were centrifuged at 10,000 rpm for 10
min to precipitate aggregates of polyplex/protein. The supernatant was then assayed for
total protein using a BCA assay and protein concentration was determined by comparison
to a standard curve of known BSA concentrations. The fraction of BSA aggregated with
polyplexes or free PEI was calculated by the equation below where CS is the protein
concentration in the supernatant, VS is the total sample volume, C0 is the initial BSA
concentration (2 mg/mL), and V0 is the initial BSA volume (0.5VS).
𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 𝐵𝐵𝐵𝐵𝐵𝐵 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 = 1 −
2.2.7

𝐶𝐶𝑆𝑆 𝑉𝑉𝑆𝑆
𝐶𝐶0 𝑉𝑉0

In Vitro Transfection
Cells were cultured in standard growth media and seeded at 2x104 cells per well in

96-well tissue-culture plates 24 h prior to transfection. Polyplexes at various
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PGA/PEI/DNA weight ratios were formed by the standard protocol with 200 ng DNA at
100 µL well volume. Wells were aspirated and polyplex solution added for 3 h. For
transfections in the presence of endocytosis inhibitors, growth media was removed and
replaced with 50 µL EMEM with 5% FBS and concentrations of either genistein, methylβ-cyclodextrin, chlorpromazine HCl, amantadine HCl, or amiloride HCl producing 80%
cell viability (Error! Reference source not found. in appendix). After 1 h, 50 µL of
polyplex suspension containing 200 ng DNA was added to each well to a final well volume
of 100 µL and incubated for 3 h. Subsequently, the transfection medium was replaced with
100 µL fresh growth media. Luciferase expression was assessed on cell lysate 24 h after
transfection using a luciferase assay system (Promega) according to manufacturer’s
protocol. Luciferase activity was measured in RLU using Synergy 2 microplate reader.
Luminescence results were normalized to total lysate protein using a BCA protein assay
system (G-Biosciences).
2.2.8

Flow Cytometry
Cells were seeded into 24-well plates at 2x105 cells per well with growth media and

allowed to grow for 24 h before transfection. pGL3 plasmid was fluorescently labeled with
YOYO-1 iodide (Invitrogen) at 1 YOYO/50 bp, and polyplexes were prepared following
the protocol described above. Transfections were performed in the absence or presence of
endocytosis inhibitors as described above. After 3 h, the polyplexes were removed, and the
cells were washed once with 0.001% SDS in PBS, twice with 300 µL PBS, and dissociated
with 200 µL trypsin. After approximately 10 min, the trypsin was neutralized by addition
of 50 µL FBS, and 750 µL PBS was added to bring the total volume in each well to 1 mL.
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Collected cell samples were analyzed on an Attune Acoustic Focusing Cytometer
(ThermoFisher). Cytometry data was analyzed with FlowJo data analysis software
(FlowJo). Standard gating techniques were used to remove cell debris and calculate mean
fluorescence.
2.2.9

Cytotoxicity
Cytotoxicity of polyplexes and endocytosis inhibitors was assessed using the

CellTiter Blue cell viability assay (Promega). Cells were seeded in a 96-well plate at 2x104
cells per well and incubated for 24 h in growth media. Growth media was replaced with 50
µL of each inhibitor diluted to desired concentrations (Error! Reference source not
found. in appendix) using EMEM supplemented with 5% FBS. Cells were incubated with
the inhibitors for 1 h and then 50 µL growth media added to the well to simulate addition
of polyplex. After 3 h, wells were aspirated, washed with 50 µL PBS, and 100 µL growth
media added. Approximately 20 h later, growth media was removed and replaced with 120
µL of 1:5 (v:v) CellTiter Blue in growth media and incubated for 2 h at 37ºC and 5% CO2.
One hundred µL was transferred from each well to an opaque 96-well plate and the
fluorescence (530/25 ex, 590/35 em) was quantified using a Synergy 2 microplate reader
(BioTek). Fluorescence was converted to cell count using a standard curve of non-treated
cells.
2.2.10 Confocal Fluorescence Microscopy
Cells were seeded at 2x104 cells/well of an eight-chamber Lab-Tek 2 Chamber
Slide (ThermoFisher) and incubated for 24 h. Ternary polyplexes were prepared according
to the standard protocol, and polyplexes containing 200 ng DNA were added to each well
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of the chamber slide for 30 min. During this time, 0.5 mg/mL 70 kDa dextran Texas red
(Invitrogen) was added to some of the wells as a macropinosome marker. Following
transfection, the transfection media was aspirated, and the cells were washed with 0.001%
SDS in PBS to remove any surface bound particles and washed twice with PBS. Cells were
then fixed with 4% formaldehyde for 10 min, washed three times with PBS, permeabilized
with 0.1% Triton X100 in PBS for 15 min, and again washed three times with PBS. After
permeabilization, cells were blocked with 1% BSA in PBS for 45 min, then exposed to
primary antibodies for caveolin-1 (CAV-1) or clathrin heavy chain (CLTC, Invitrogen)
diluted to 1:125 and 1:200, respectively, in blocking solution for 2 h at room temperature
or overnight at 4°C. The wells were aspirated and cells washed four times with PBS before
incubating 1 h with Alexa Fluor 405 Phalloidin (Invitrogen) at 165 nM and Alexa Fluor
594 goat anti-mouse IgG secondary antibody (Invitrogen) diluted in PBS to 2 µg/mL.
Finally, cells were washed four times with PBS before adding Prolong Diamond Antifade
mountant (Invitrogen) and mounting with a No.1.5H precision coverslip (Thor Labs).
Slides were imaged using the 60X objective in a Leica SP8 confocal fluorescence
microscope.
2.2.11 Scanning Transmission Electron Microscopy
Polyplexes were formed at varying stoichiometries according to the standard
protocol with the exception that all polymers and DNA were dissolved in water to avoid
the presence of salt. Once polyplexes were formed, Lacey Carbon 300 mesh copper grids
(Ted Pella Inc.) were dipped into polyplex solution for 10 seconds and allowed to dry
overnight. Scanning transmission microscopy was performed on a Talos F200X
microscope.
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2.2.12 Intracellular Trafficking
To assess whether particles of positive and negative charge are trafficked to the
lysosome, LysoTracker Deep Red (Thermo Fisher) was used to fluorescently label the
lysosome. Cells were seeded at 2x104 cells per well of an 8-chamber slide. After 24 h, cells
were transfected as described above. After 30 min, Lysotracker was added to each well to
a concentration of 1.6 µM. After an additional 30 min, cells were washed and mounted as
described above and imaged for co-localization of polyplexes with Lysotracker dye.
To study the effect of acidification on endosomal processing of polyplexes, cells
were seeded in 96-well plate at 2x104 cells per well and incubated 24 h. Cells were then
exposed to 10 nM Bafilomycin A1, 20 µM Chloroquine, or both for 1 h. Polyplexes were
then prepared according to the standard protocol, and 50 µL of polyplex suspension
containing 200 ng DNA was added to each well. After 3 h, the transfection media was
replaced with growth media, and the cells were incubated for an additional 21 h before
assessing reporter gene expression and total protein, as described above.
2.3
2.3.1

Results and Discussion
Polyplex Characterization
PGA/PEI/DNA polyplexes were prepared in two steps (Figure 2.1). First, PEI was

added to a DNA solution to form binary polyplexes. To these binary polyplexes, PGA was
added to form ternary polyplexes. By varying the PEI and PGA weight ratios at fixed
amount of DNA, the polyplex zeta potential could be controlled (Figure 2.2A). At
PEI/DNA ratios from 0.5:1 to 5:1 (w:w), the zeta potential of the binary polyplexes was
+10-16 mV and tended to increase with increasing PEI/DNA ratio. The zeta potential of
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the polyplexes decreased with addition of PGA. The zeta potentials of the ternary
polyplexes with PEI/DNA ratios of 0.5:1, 1:1, and 1.5:1 (w:w) reached a minimum of -32
to -35 mV, and the amount of PGA present at the minimum increased with increasing
PEI/DNA ratio. With further addition of PGA, the zeta potential increased. This increase
may be due to competition between PGA and DNA for PEI binding resulting in the
formation of PGA/PEI “ghost particles” and disruption of the polyplexes. In fact, gel
electrophoresis of ternary polyplexes revealed DNA dissociation from the polyplex at
PGA/PEI/DNA ratios corresponding to the minimum zeta potential (Figure 2.2B). These
ghost particles are suspected to be smaller than the polyplex and form up to 97.5% of the
overall particle composition at PGA/PEI/DNA ratios of 1.2:1.8:1 [180]. Their presence
may aid endosomal disruption, similar to the effect of free PEI [181], though to a lesser
degree.

Figure 2.1: Polyplex complexation process according to bulk mixing protocol. PEI is added
in excess to DNA to form binary polyplexes. PGA is then added to binary polyplexes to
form ternary polyplexes. Some free PEI binds PGA to form polyelectrolyte ghost particles.
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Figure 2.2: (A) Polyplex zeta potential at various PGA/PEI/DNA weight ratios. (B) Gel
electrophoresis of polyplexes at PEI:DNA weight ratios 0.5:1, 1:1, 2:1, and 3:1. Ladder
indicates standard DNA ladder. (C) Polyplex sizes at various PGA/PEI/DNA weight ratios.
(D) Scanning transmission electron micrographs of polyplexes at PGA/PEI/DNA weight
ratios of 0:3:1 (zeta potential +16 mV), 1.5:3:1 (+11 mV), 4:3:1 (0 mV), and 5.2:3:1 (-11
mV). (E) BSA aggregation with free PEI and polyplexes at 3:1 PEI/DNA of varying PGA
weight. (n=4, error bars represent standard deviation; *p=0.0008, **p=0.004)
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The size of binary PEI/DNA polyplexes decreased with increasing PEI/DNA ratios.
Weight ratios of 1:1, 2:1, 3:1, and 5:1 exhibited sizes of 232, 162, 143, and 111 nm,
respectively, suggesting that the higher PEI/DNA ratios result in more condensed
polyplexes. The size of the ternary polyplexes increased with addition of PGA (Figure
2.2C) to a maximum and then decreased to a plateu around 150 nm. The increase in size
with addition of PGA may be due to competition between PGA and DNA for binding the
PEI, loosening the polyplexes and allowing them to swell. Alternatively, the increase in
size may be due to aggregation of polyplexes, as the PGA/PEI/DNA ratios exhibiting the
maximum size corresponds closely to the ratios leading to zeta potential near zero. TEM
revealed individual polyplexes with sizes that are consistent with the hydrodynamic
diameters determined by DLS (Figure 2.2D), which is consistent with an increase in size
due to swelling. Binary polyplexes at the PEI/DNA weight ratio 3:1, as measeured by TEM,
were ~168 nm. Ternary polyplex weight ratios at 3:1 PEI/DNA resulting in +11 mV
(1.5:3:1) and -11 mV (5.2:3:1) were 231 nm and 205 nm respectively as opposed to neutral
polyplexes at 358 nm (4:3:1). As PGA is added beyond the weights resulting in neutral
charge, polyplex size decreases. It is possible that, at this point, all free PEI is bound up in
ghost particles and additional PGA is forced to interact with PEI from the polyplex. This
decrease in size following neutral zeta potential might therefore be accounted to the loss of
PEI from the polyplex upon disruption by excess PGA.
Polyplexes exhibiting a negative zeta potential may be expected to aggregate to a
lesser extent with negatively charged serum proteins compared to polyplexes exhibiting a
positive zeta potential. Thus, aggregation of BSA with polyplexes of varying zeta potential
was quantified (Figure 2.2E). At concentrations similar to those present during
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transfections, free PEI and polyplexes with PGA/PEI/DNA weight ratios of 0:3:1 (binary
polyplexes, ζ = +16 mV), 1.5:3:1 (+11 mV), 4:3:1 (0 mV), 5.2:3:1 (-11 mV) and 5.6:3:1 (16 mV) were incubated with 2 mg/mL BSA, which is comparable to the total anionic
protein concentration in cell growth media containing 10% serum. The isoelectric point of
BSA is 4.9, making the protein negatively charged at physiological pH. After 1 h, the
mixture was centrifuged to pellet any aggregated protein and polyplexes. Increasing
amounts of PGA in the polyplexes, corresponding to decreasing zeta potential, decreased
the aggregation of BSA.
2.3.2

Transfection and Cellular Internalization of Ternary Polyplexes
The reduced aggregation of PGA/PEI/DNA with serum proteins may be expected

to enhance transfection in the presence of serum. In addition, competitive binding of PGA
and DNA may be expected to facilitate polyplex dissociation within the cell, which is
necessary for DNA transcription. The presence of sufficiently high amounts of PGA,
however, may result in exposure of the DNA to nucleases, premature decomplexation, or
loss of DNA from the polyplexes, as observed in gel electrophoresis (Figure 2.2B).
Therefore, the effect of PGA/PEI/DNA ratios on transfection efficiency in three model cell
lines was investigated.
Transfections were performed with ternary polyplexes containing a fixed amount
of DNA and varying ratios of PGA and PEI (Figure 2.3A, D, and G). At all PEI:DNA
ratios, transgene expression increased with addition of PGA to a maximum and then
decreased, and the ratio of PGA in polyplexes at the maximum increased with increasing
PEI/DNA ratios. This may be expected since greater amounts of PEI should require greater
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amounts of PGA to coat the surface and loosen the PEI interaction with DNA. In addition,
transgene expression increased with increasing PEI/DNA ratios up to 3:1 (w:w), but
decreased for ternary polyplexes with PEI:DNA 5:1 (w:w). In all three cell lines, the
maximum gene delivery efficiency was observed at PGA/PEI/DNA ratio of 1.5:3:1
(w:w:w), which exhibited a zeta potential of +11 mV. These trends are consistent with the
competing effects of PGA in facilitating polyplex dissociation described above.
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Figure 2.3: Transfection (A,D,G), cellular uptake (B,E,H), and cytotoxicity (C,F,I) of
PGA/PEI/DNA polyplexes at various PGA:PEI:DNA weight ratios in HeLa (A-C), U-87
MG (D-F), and HEK 293 (G-I) cell lines. PGA/PEI ghost particles (GHOST) were formed
at ratios corresponding to the PGA:PEI weight ratios that provided maximum transfection
efficiency (0.5:1:1, 1.5:3:1, and 2:5:1).
To determine if the differences in gene delivery efficiency were due to the amount
of DNA entering the cells, cellular internalization of fluorescently labeled PGA/PEI/DNA
polyplexes was quantified by flow cytometry (Figure 2.3B, E, and H). Addition of small
amounts of PGA to PEI/DNA at 1:1 (w:w) resulted in an increase in internalization, but
uptake decreased to levels similar to binary PEI/DNA polyplexes at higher amounts of
PGA. The effect of PGA on PEI/DNA at 2:1 (w:w) in U-87 MG cells was similar. In
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contrast, addition of PGA to PEI/DNA at 2:1 (w:w) in HeLa and HEK 293 cells and
PEI/DNA 3:1 (w:w) in all three cell lines resulted in ~2- to 3-fold decrease in
internalization with PGA/DNA ratio of 1:1 (w:w), followed by an increase and subsequent
decrease in internalization as the amount of PGA further increased. Interestingly, the
polyplex stoichiometries resulting in the maximum internalization did not correlate with
the ratios leading to the maximum transgene expression. In fact, the maximum uptake was
observed for polyplexes exhibiting nearly neutral zeta potential. This is somewhat
surprising since neutral polyplexes lack the potential for electrostatic interaction with the
cell membrane. That the ideal PGA/PEI/DNA ratio for internalization is not necessarily
ideal for gene delivery suggests that polyplex charge may govern the pathway of
internalization, which is known to affect delivery efficiency.
PEI is known to be cytotoxic in many cell lines, primarily due to the disruption of
the cell membrane by the high density of protonated amines [163]. Addition of a polyanion
to the polyplex may reduce cytotoxicity by shielding the positively charged PEI from the
cell membrane. Thus, the cytotoxicity of polyplexes with various compositions was
investigated (Figure 2.3C, F, and I). Binary and ternary polyplexes with PEI/DNA ratio of
1:1 (w:w), as well as free PEI at an equivalent concentration, exhibited minimal
cytotoxicity, regardless of the presence of PGA. Free PEI at concentrations equivalent to
that present in the polyplexes with PEI/DNA 3:1 and 5:1 (w:w), however, decreased
viability by 20-30% and ~40-60%, respectively. Addition of PGA to PEI/DNA 3:1 (w:w)
polyplexes had little effect on cytotoxicity in HeLa and U-87 MG cells but decreased
cytotoxicity in HEK 293 cells. In contrast, increasing amounts of PGA in the ternary
polyplexes at PEI/DNA weights ratio of 5:1 significantly decreased cytotoxicity in all three
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cell lines and at 3:1 PEI/DNA in HEK 293. In the presence of PGA/PEI/DNA polyplexes
at the optimal stoichiometry for gene delivery, 1.5:3:1 (w:w:w), viability of all three cell
lines was estimated to decrease by less than 20%.
Suspensions of PEI/DNA polyplexes are known to contain a significant amount of
free PEI (up to 85% of total PEI), which is thought be beneficial for transfection by
participating in endosome escape but may also play a significant role in the cytotoxicity of
PEI/DNA polyplexes [181]. In the preparation of PGA/PEI/DNA polyplexes, free PEI
likely interacts with the PGA to form ghost particles. Ghost particles prepared at PGA/PEI
weight ratios of 0.5:1, 1.5:3, and 2:5, corresponding to the ratios in ternary polyplexes
providing optimal transfection efficiency, were significantly less cytotoxic than free PEI at
an equivalent concentration. Furthermore, transfection efficiency of binary PEI/DNA
polyplexes at 1:1 (w:w) increased 15-fold in the presence of ghost particles prepared at
equivalent weights of 200 ng PGA/PEI while only a factor of 2 in the presence of 600 ng
free PEI (Figure 2.4). Thus, it appears that the presence of PGA in ternary polyplexes may
enhance transfection by facilitating polyplex dissociation and reducing aggregation, as
described above, as well as by binding free PEI, decreasing cytotoxicity.
2.3.3

Ghost Particle Effect on Transfection and Viability
To determine the effects of ghost particles and free PEI on transfection efficiency

and resulting cell viability, binary polyplexes of PEI/DNA at 1:1 (w:w) were transfected
in HeLa cells in the presence of ghost particles at PGA/PEI 1:1 (w:w) or equivalent weights
of free PEI. The presence of ghost particles had a clear positive effect on the transfection
efficiency where transgene expression was increased by a factor of 15 with the addition of
200 ng of PGA and PEI whereas free PEI increased transgene expression by a factor of 2
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in the presence of 600 ng free PEI (Figure 2.4A). Both ghost particles and free PEI induced
toxicity in the cells. Ghost particles, however, were less toxic than equivalent weights of
free PEI (Figure 2.4B). At the ghost particle weight producing maximum transgene
expression, toxicity was 13% whereas free PEI toxicity at equivalent weights was 40%.
Free PEI toxicity at its weight producing maximum transgene expression was 67% whereas
the equivalent weight of ghost particles produced 55% toxicity. Therefore, the presence of
PGA reduces the toxicity associated with free PEI. This likely occurs due to PEI amine
group electrostatic interactions with PGA carboxylic groups, reducing the potential for cell
membrane disruption. However, the reduction of membrane interactions also reduces the
capacity for endosomal buffering and escape. Therefore, the dramatic increase of transgene
expression in the presence of ghost particles compared to free PEI is surprising. It is
possible that excessive free PEI taken into endosomes with the polyplex dominates the
buffering process, preventing the polyplex from buffering its amine groups and
dissociating. The addition of PGA to form ghost particles prevents this buffering
misbalance and allows polyplex dissociation. However, at excessive weights of ghost
particles, buffering dominance is again detrimental to dissociation as indicated by
decreased gene expression after the optimum ghost particle weight.
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Figure 2.4: (A) Transfection of HeLa cells with binary PEI/DNA polyplexes at 1:1 (w:w)
in the presence of PGA/PEI ghost particles of 1:1 (w:w) or free PEI. All samples were
normalized to binary polyplex controls transfected in the absence of ghost particles or free
PEI. (B) HeLa cell viability after transfection with binary polyplexes in the presence of
ghost particles or free PEI as in A. (n=4, error bars represent standard deviation).
2.3.4

Inhibitor Toxicity and Specificity
To provide a more quantitative analysis of internalization mechanisms associated

with polyplex charge, pharmacological inhibitors were used to selectively inhibit clathrindependent endocytosis, caveolin-dependent endocytosis, or macropinocytosis. Genistein
(GST) is a potent inhibitor of tyrosine phosphorylation on caveolin and microtubule
polymerization, which makes it suitable for inhibiting the caveolin-dependent pathway
[182]. Another caveolin-dependent endocytosis inhibitor is methyl-β-cyclodextrin
(mBCD), which sequesters membrane cholesterol and disrupts lipid-rich domains that form
caveolae [183]. Chlorpromazine HCl (CPZ) is a cationic, amphipathic drug responsible for
sequestering clathrin on endosomal membranes, preventing recycle to the plasma
membrane for pit formation [184]. Amantadine HCl (AMN) is a similar drug shown to
inhibit clathrin heavy chain recycling to the cell membrane [185]. Amiloride (AML) blocks
membrane Na+/H+ channels, which serves to lower sub-membranous pH and prevent Rac1
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and Cdc42 signaling involved in macropinocytosis [186]. These inhibitors are known to
have non-specific effects, making it necessary to include appropriate controls [187, 188].
Therefore, the cytotoxicity of each inhibitor and inhibition of internalization of pathwayspecific markers was investigated in each cell line.
To determine allowable inhibitor concentrations, the cytotoxicity of the inhibitors
was evaluated in each cell line (Figure 2.5A). Inhibitors performed as expected with
decreases in viability with increasing dose. CPZ was the least cytotoxic in all three cell
lines followed by GST, AML, AMN, and mBCD. The U-87 MG cell line was the most
resilient to the inhibitors, tolerating the highest concentrations of all inhibitors. HeLa and
HEK 293 each possessed similar tolerance, though less than that of U-87 MG. For further
experiments involving transfections in the presence of inhibitors, concentrations were
selected at which >80% viability was achieved in order to maintain healthy cell function
after exposure to inhibitors (Figure 2.5A-C). To verify the inhibitory quality of the selected
concentrations, fluorescently tagged endosome markers were delivered 1 h after pathway
inhibition and compared to non-inhibited controls (Figure 2.5D-F). Transferrin is an ironbinding glycoprotein that has been shown to bind the transferrin receptor and internalize
through invaginations of clathrin-coated pits [189, 190]. Cholera toxin subunit B (CTxB)
is a pentamer that binds specifically to surface ganglioside GM1, which is distributed on
the plasma membrane and is concentrated in caveolae. Though many internalization
mechanisms are implicated in its uptake, CTxB tends to become trapped in caveosomes.
When used in low concentration for short periods, trapped CTxB can be used to identify
caveosomes [191-193]. Finally, dextran is known to internalize through macropinocytosis
[194, 195], making it a good marker of the macropinosome. Caveolin-dependent
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endocytosis inhibitors GST and mBCD both reduced uptake of CTxB by 50% or more
(p<0.03) in all three cell lines while not statistically significantly affecting uptake of
clathrin and macropinocytosis markers. CPZ and AMN reduced the uptake of Tf by
approximately 50% in HeLa and HEK 293, while uptake of Tf by U-87 MG cells in the
presence of AMN was not statistically significant (p>0.07). Unfortunately, clathrin
inhibitors exhibited some non-specificity in HeLa and HEK 293 cells as demonstrated by
the mild effect of CPZ and AMN on CTxB uptake, though the decrease was not statistically
significant. Finally, macropinocytosis inhibition by AML produced at least 50% reduction
in uptake of DEX in all three cell lines without non-specific effects on uptake of caveolin
or clathrin markers (p<0.01).
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Figure 2.5: (A-C) Cytotoxicity of GST, mBCD, CPZ, AMN, and AML in (A,D) HeLa,
(B,E) U-87 MG, and (C,F) HEK 293 cell lines. Metabolic activity was normalized to cells
in the absence of inhibitors. (D-F) GST, mBCD, CPZ, AMN, and AML effect on uptake
of markers of caveosomes (CTxB), clathrin-coated vesicles (Tf), and macropinosome
(DEX). (n=3, error bars represent standard deviation; *p<0.05, †p<0.01, ‡p<0.001
compared to control groups).
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Table 1: Endocytic inhibitors, their mechanisms of action, and concentrations producing
80% viability in HeLa, U-87 MG, and HEK 293 cell lines.

HeLa

U-87 MG

HEK 293

100 mg/L

200 mg/L

70 mg/L

10 g/L

27 g/L

20 g/L

Genistein

Caveolin Inhibitor: Inhibits
tyrosine kinase necessary for
caveolar vesicle trafficking

mBCD

Caveolin Inhibitor: Sequesters
plasma membrane cholesterol,
inhibiting lipid raft formation

Chlorpromazine

Clathrin Inhibitor: Stabilizes
intracellular clathrin and prevents
recycling to plasma membrane

15 mg/L

20 mg/L

18 mg/L

Amantadine

Clathrin Inhibitor: Stabilizes
intracellular clathrin and prevents
recycling to plasma membrane

750 mg/L

800 mg/L

650 mg/L

Amiloride

Macro-pinocytosis Inhibitor:
Blocks membrane Na+/H+
channels

500 mg/L

665 mg/L

300 mg/L

2.3.5

Effect of Polyplex Charge on Endocytic Pathway
To investigate the effect of polyplex charge on internalization pathways and

subsequent intracellular trafficking, co-localization of PGA/PEI/DNA polyplexes with
specific endosomal vesicle markers, clathrin heavy chain, caveolin-1, and dextran (which
is internalized primarily by micropinocytosis), was visualized by confocal fluorescence
microscopy. PGA/PEI/DNA 1.5:3:1 (w:w:w) with a zeta potential of +11 mV were chosen
as representative positively charged polyplexes, while 5.2:3:1 (w:w:w) exhibiting an
estimated zeta potential of -11 mV represented negatively charged polyplexes. Colocalization of PGA/PEI/DNA polyplexes of positive or negative charge was observed with
the markers of all three pathways (Figure 2.6). Mander’s coefficient represents the fraction
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of a specific fluorophore that co-localizes to another fluorophore where 0 indicates no
overlap and 1 indicates complete co-localization. Positively charged polyplexes showed
strong co-localization to caveosomes (Mander’s coefficient > 0.7) in all three cell lines.
However, there was a much less co-localization to clathrin-coated vesicles (Mander’s
coefficient < 0.35) and an even lower overlap with dextran in macropinosomes (Mander’s
coefficient < 0.1), with the exception of U-87 MG where the Mander’s coefficient was
0.33. These data suggest that positively charged polyplexes are internalized through a
combination of all three pathways with the largest portion of uptake through caveolindependent endocytosis. Negatively charged polyplexes were less dependent on caveolindependent endocytosis where Mander’s coefficients ranged from 0.42 to 0.55 in the three
cell lines. However, negatively charged polyplex co-localization to clathrin-coated vesicles
exhibited Mander’s coefficients of 0.65 to 0.71, Negatively charged polyplex colocalization to macropinosomes, similar to that of positively charged polyplexes, gave a
Mander’s coefficient of <0.15, which may be expected as macropinocytosis is a nonspecific endocytic pathway. Thus, it appears that positively and negatively charged
polyplexes were internalized by different mechanisms, with positively charged polyplexes
preferentially internalized via caveolin-dependent endocytosis and negative polyplexes via
clathrin-dependent endocytosis (Figure 2.7).
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Figure 2.6: (Top) Fluorescence confocal micrographs of HeLa, U-87 MG, and HEK 293
cells transfected with positive (1.5:3:1 w:w:w:, +11 mV) and negative (5.2:3:1 w:w:w:, 11 mV) polyplexes and immuno-stained for caveolin-1 or clathrin heavy chain, or exposed
to dextran Texas Red to label caveosomes, clathrin-coated vesicles, or macropinosomes.
Mander’s coefficients are listed for green overlap with red under each image (M2). Blue
indicates cell cytoskeleton, green indicates polyplexes, and red indicates endosomes.
(Bottom) Co-localization maps highlighting only overlap regions.

Figure 2.7: Co-localization of positively and negatively charged polyplexes to caveosomes,
clathrin-coated vesicles (CCV), and macropinosomes. Mander’s coefficients were
normalized for co-localization to each of the three pathways.
The effect of polyplex charge and internalization pathway on gene delivery was
investigated by quantifying the transfection efficiency and cellular internalization of
PGA/PEI/DNA 1.5:3:1 (+11 mV) and 5.2:3:1 (-11 mV) in the absence and presence of the
pathway-specific endocytosis inhibitors (Figure 2.8). The caveolin-dependent endocytosis
inhibitors (GST and mBCD) essentially eliminated transgene expression mediated by both
positively and negatively charged polyplexes in all three cell lines with the exception of
GST in the HEK 293 cells, in which the inhibitor had no significant effect. The presence
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of GST also produced greater than 50% inhibition of uptake of positively charged
polyplexes in all three cell lines, ~50% inhibition of uptake of negatively charged
polyplexes in U-87 MG and HEK 293 cells, and no effect on uptake of negatively charged
polyplexes in HeLa cells. Uptake of positively charged polyplexes in the presence of
mBCD increased to 250% in HeLa and HEK 293 cells and 130% in U-87 MG cells.
Negatively charged polyplex uptake in the presence of mBCD was unaffected in HeLa and
HEK 293 but increased to 160% in U-87 MG cells. The decreases in transgene expression
in the presence of both GST and mBCD indicate that caveolin-dependent endocytosis is an
effective route for transfection mediated by both positively and negatively charged
PGA/PEI/DNA polyplexes.
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Figure 2.8: Luciferase gene expression (A-C) and polyplex uptake (D-F) of positive
(1.5:3:1 w:w:w, +11 mV) and negative (5.2:3:1 w:w:w, -11 mV) polyplexes in the presence
of endocytic inhibitors of caveolin-dependent endocytosis (GST and mBCD), clathrindependent endocytosis (CPZ and AMN), or macropinocytosis (AML) in HeLa (A,D), U87 MG (B,E), and HEK 293 (C,F). All inhibited samples were normalized to a noninhibited control of equivalent polyplex charge to determine effect on gene expression or
uptake. (n=6 for gene expression, n=3 for uptake, error bars represent standard deviation;
*p<0.05, †p<0.01, ‡p<0.001 compared to control groups).
In HeLa and U-87 MG cells, inhibition of macropinocytosis by AML had similar
effects to GST in that transgene expression following transfection with both positively and
negatively charged polyplexes was severely reduced to less than 10%, while uptake was
only mildly decreased. In HEK 293 cells, however, AML had no effect on transfection
efficiency of positively charged polyplexes, but decreased transfection of negatively
charged polyplexes to approximately 45%. This suggests that macropinocytosis is
62

important in transfection by positively and negatively charged PGA/PEI/DNA polyplexes,
especially in HeLa and U-87 MG. This is not unexpected as macropinocytosis is a nonspecific endocytic pathway. Furthermore, the pathway is upregulated in cancer cells as a
rapid means to internalize nutrients, which is demonstrated by the more prominent effect
of AML on the cancer cell lines (HeLa and U-87 MG).
Transfection efficiency of negatively charged polyplexes in all cell lines was
reduced to approximately half in the presence of clathrin inhibitors CPZ and AMN.
However, transfection with positively charged polyplexes nearly doubled in the presence
of CPZ in HeLa and U-87 MG while increasing to 130% in the presence of AMN in U-87
MG. Interestingly, the opposite effect on transfection with positively charged polyplexes
was observed in HEK 293 cells as both CPZ and AMN decreased transgene expression to
~50%. Thus, it appears that clathrin-dependent endocytosis is an inefficient pathway for
positively charged polyplexes in HeLa and U-87 MG cells, but leads to transfection in HEK
293 cells. However, this was not the case for negatively charged polyplexes where
decreased transgene expression suggest clathrin-dependent endocytosis is an effective
pathway for gene delivery. Clearly, efficiency of clathrin-dependent internalization and
resulting transgene expression is not only cell line dependent, but also dependent on
polyplex charge. This may be explained by differing amounts of clathrin-dependent
endocytosis or sorting of the resulting endocytic vesicles from cell line to cell line.
2.3.6

Intracellular Trafficking
To investigate the effect of polyplex charge on endocytic trafficking, including

potential trafficking to lysosomes, and the role of acidification of endocytic vesicles on
gene delivery efficiency, transfections were performed in the presence of 10 nM
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bafilomycin, 20 µM chloroquine, or a combination of both [100]. Bafilomycin A1 (BAF)
is a V-type ATPase inhibitor that inhibits endosomal acidification [196]. Chloroquine (CQ)
is an endosomal buffering agent commonly used to enhance gene delivery mediated by
vectors lacking ionization potential through promoting endosomal escape by membrane
disruption [197]. For example, CQ has been shown to improve transgene expression
mediated by polymers such as polylysine [198], starches [199], and beta-cyclodextrincontaining polymers [200], as well as lipids such as PCEP [201] and DORIE [32]. In
addition to endosomal buffering, the aromatic rings of CQ are capable of intercalating
DNA and causing conformational changes, which inhibit enzymatic digestion of DNA
[202, 203]. CQ is known to accumulate in acidic endosomal compartments, primarily
lysosomes. Therefore, CQ is expected to affect the transfection efficiency of polyplexes
that pass through acidic late endosomes or lysosomes.
The presence of BAF and/or CQ had no effect on transfection mediated by
positively charged polyplexes in any of the three cell lines (Figure 2.9A), suggesting that
these polyplexes are do not enter acidified endosomes or lysosomes, or do not depend on
an acidic environment for endosome escape or polyplex dissociation. . These results agree
with co-localization of positively charged polyplexes with caveosomes (Figure 2.6) and
loss of transfection efficiency in the presence of caveolin-dependent endocytosis or
macropinocytosis inhibitors (Figure 2.8). Upon transfection with negatively charged
polyplexes, however, 80% and 50% decreases in transgene expression were observed in
the presence of BAF and CQ, respectively, suggesting that negative polyplexes are
trafficked through acidified vesicles and the exposure to lower pH plays a role in effective
gene delivery. In addition, negatively charged, but not positively charged, polyplexes co64

localized with Lysotracker, a fluorescent, acidotropic probe with high selectivity for acidic
organelles (Figure 2.9B). However, the decrease in transgene expression in the presence of
GST and mBCD (Figure 2.8A-C) suggests that internalization of negatively charged
polyplexes is dependent to some degree on caveolin-dependent endocytosis. Therefore, it
is likely that negatively charged polyplex internalization involves a combination of all three
endocytic mechanisms. Though caveolin-dependent endocytosis is likely the more efficient
pathway for gene delivery (as indicated by the effects of GST and mBCD), acidification of
clathrin-dependent endocytosis and macropinocytosis or lysosomal degradation of
clathrin-dependent endocytosis is not preventing transfection mediated by negatively
charged polyplexes.
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Figure 2.9: (A) HeLa, U-87 MG, and HEK 293 transfections of positive (1.5:3:1 w:w:w,
+11 mV) and negative (5.2:3:1 w:w:w, -11 mV) polyplexes in presence of ATPase inhibitor
bafilomycin A1 (BAF) and/or endosomal buffering agent chloroquine (CQ). All samples
treated with BAF and/or CQ were normalized to untreated controls. (B) Co-localization of
negative (top) and positive (bottom) polyplexes with acidified endosomes marked by
Lysotracker in HeLa cells. Green indicates polyplexes, red indicates endosomes, and blue
indicates cell cytoskeleton. (n=4, error bars represent standard deviation; *p<0.02,
**p<0.004).
These results suggest that polyplexes undergo internalization through multiple
endocytic pathways (Figure 2.10). While the conventional model of endosomal escape is
dependent on the acidification of endosomes, the present results suggest that exposure to
an acidified environment is not necessary for efficient gene delivery. Caveolin-dependent
internalization and macropinocytosis, not clathrin-dependent endocytosis, appear to lead
to successful transfection with both positively and negatively charged polyplexes. While
polyplex charge does not cause exclusive uptake through a singular pathway, it does affect
the dominant pathway involved. Positively charged particles were found predominately in
caveolin-containing endosomal compartments, while at least half of the negatively charged
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polyplexes were trafficked to acidified late endosomes or lysosomes, which result from
clathrin-dependent endocytosis. Negatively charged polyplexes were shown to have
similar amounts of uptake to positive polyplexes. However, gene expression associated
with negatively charged polyplexes was inferior to that of positively charged polyplexes
(Figure 2.3B, E, and H). Therefore, the limiting step in transfection efficiency lies not in
the process of internalization, but in the intracellular trafficking differences of the
polyplexes. Since negatively charged polyplexes were shown to traffic to acidic late
endosomes and lysosomes while positively charged polyplexes were not, this
endolysosomal pathway is likely a source of inefficiency. Therefore, negatively charged
polyplexes may benefit from surface chemistries that trigger internalization through
alternative pathways. This may be achieved by addition of targeting moieties that bind
receptors or surface markers that are known to internalize through desirable endocytic
pathways. Herein, we have shown caveolin-dependent endocytosis to be an effective means
of internalization of polyplexes due to the avoidance of acidified endosomes and
lysosomes. Therefore, design of negatively charged polyplexes to target entry through nonacidified pathways may result in higher efficacy of delivery vectors capable of in vivo gene
therapies. This has been achieved in various nanoparticles systems through the use of
mimetic peptides [204], folate [100], integrin [205], and insulin [206], all targeting
caveolin-dependent uptake. Conjugation of these factors to the surface of negatively
charged polyplexes, therefore, may improve internalization and subsequent gene
expression through controlled intracellular trafficking.
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Figure 2.10: Summary of internalization pathways associated with positive and negative
charged polyplexes. CME designates clathrin-dependent endocytosis, CAV designates
caveolin-dependent endocytosis, and MP designates macropinocytosis.
2.4

Conclusions
The rational design of polymer vectors for gene delivery requires an understanding

of the effects of various design parameters on particle function. Here, we showed that
polyplex charge plays an important role in cellular internalization and intracellular
processing. While negatively charged polyplexes internalize through clathrin-dependent
endocytosis and are trafficked to lysosomes, positively charged polyplexes tend to avoid
acidified endolysosomal compartments by internalization through caveolin-dependent
endocytosis. The avoidance of the acidified, degradative environment of lysosomes results
in increased transfection efficiency. Therefore, design of negatively charged polyplexes to
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internalize through caveolin-dependent endocytosis is expected to help compensate for
poor transfection efficiency through targeted intracellular trafficking.

Copyright © Landon Mott 2019
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CHAPTER 3. DELIVERY AND INTRACELLULAR PROCESSING OF POLYMER AND
NANOCERIA HYBRID POLYPLEXES FOR GENE AND ANTIOXIDANT THERAPY
3.1

Introduction
Gene therapy is a promising approach to treat genetic and acquired indications [207,

208], in which nucleic acids are delivered to cells by either viral [10, 209] or non-viral
[210-212] vectors. Recombinant viral vectors remain unrivaled in delivery efficiency, but
safety concerns have prevented the progression of many clinical trials. As a result, nonviral systems comprising non-toxic, non-immunogenic materials, such as cell penetrating
peptides, lipids, polymers, and inorganic materials, are of interest, but the efficiency of
these vectors is comparatively poor. Rational design of more efficient non-viral vectors
and their components, therefore, is necessary to improve their potency while ensuring
safety.
The vast majority of cancer cells exhibit an imbalance of pro-oxidants and
antioxidants, resulting in higher levels of oxidative stress in tumors compared to healthy
tissue [213, 214]. In healthy cells, highly regulated production of reactive oxygen species
(ROS) is involved in signaling pathways involving cell division, immune regulation,
inflammation, autophagy, and stress-related response [215]. However, dysregulation of
homeostasis by an elevated redox state produces DNA damage and overall poor genomic
integrity [216]. This oxidative stress results in rapid tumorigenesis and tumor progression,
causing further ROS generation and activation of pro-oncogenic signaling and survival
[215]. Mature cancer cells may even develop feedback loops to maintain the elevated ROS
levels that promote survival and high metabolic function while avoiding extreme ROS
levels that trigger apoptosis [217]. Therefore, two strategies involving ROS modulation
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have been developed for cancer treatment [218]. First, delivery of natural oxidants and
chemotherapeutics inducing ROS generation to apoptotic levels has shown success at
inducing tumor and cell death [219-221]. However, off-site targeting of healthy cells can
result in tumorigenesis and cytotoxicity. Further, advanced-stage cancers often have the
capacity to confer drug resistance in response to modulated ROS levels through
upregulated antioxidant response, rendering this technique ineffective [222]. As a second
approach, antioxidants that scavenge and neutralize ROS have long been suspected to have
anticancer properties [223, 224], though evidence of this has never been established [225].
Reduced oxidative stress is thought to minimize the chance of cancer development in
healthy cells while ROS scavenging potentially downregulates tumor growth and invasion
[226]. Therefore, treatment of early-stage cancers with antioxidants might be a successful
method to help reduce or prevent tumor progression, mobility, and aggressive growth
associated with high oxidation environments without adversely affecting healthy tissue.
This strategy has implications for stand-alone therapies or adjunct treatments that synergize
with other cancer treatments [227, 228]. Several gene therapies targeting ROS-generating
sources have been shown to be effective in reducing oxidative stress in cells [229, 230].
However, such treatments act by preventing pro-oxidant generation and are unable to
remove radicals already present. On the other hand, many radical scavengers have shortterm effects since they lose potency after radical absorption. Therefore, there exists an
opportunity to provide a combined gene and antioxidant therapy for the immediate
reduction and extended downregulation of ROS in cancers.
Cerium is a rare-earth element of the lanthanide series that, when combined with
oxygen, can be found in one of two oxidation states, Ce3+ or Ce4+. The resulting fluorite
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crystalline structure possesses a large, catalytic surface area capable of interacting with free
radicals. A characteristic property of cerium oxide nanoparticles (nanoceria) is the unique
ability to shift between oxidation states based on environmental conditions. This trait
endows nanoceria with oxygen radical scavenging capability similar to catalase or
superoxide dismutase (SOD), which maintains low levels of oxidative stress in the cellular
environment [231]. Therefore, nanoceria is a potent antioxidant that works to reduce
oxidative stress in cells through free radical scavenging [232, 233]. Though most
endogenous antioxidants are targeted for specific radicals, the catalytic activity associated
with nanoceria allows neutralization of all kinds of radical species, making it an
outstanding option for antioxidant therapies [234]. However, the oxidation state of
nanoceria is pH dependent. It acts as an antioxidant at physiological pH and shifts to a prooxidant state at more acidic pH [235, 236]. Since many cancer cells promote more acidic
extracellular environments than healthy cells [237], it has been hypothesized that nanoceria
might act as an antioxidant in the healthy cellular environment at physiological pH while
acting as a pro-oxidant in more acidic cancer cell environments, triggering cancer apoptosis
from induced oxidative insults [238]. However, this mechanism is highly controversial as
reports using the same core elements produce radically different results [239, 240]. It has
been further hypothesized that the disparities in the literature may be due to differences in
physiochemical parameters of the nanoceria such as the method of synthesis, particle size,
and stabilizer (coating) [239, 240]. Functionality and oxidative state are therefore not only
dependent on environmental factors but also on physiochemical and structural properties,
making the therapeutic effect of nanoceria (antioxidant vs. pro-oxidant) vary on a case-by-
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case basis [241]. As such, this report and others show promising results for cancer
treatment using nanoceria [235, 238, 242-246].
Here, we show that citrate-coated nanoceria (NC), DNA, and 25-kDa
polyethylenimine (PEI) can form a ternary electrostatic complex providing co-delivery of
nucleic acid and antioxidant to HeLa cells. PEI is a common benchmark for polymeric gene
delivery due to its relatively high in vitro gene delivery efficiency and has been used to
deliver NC previously [247]. To our knowledge, however, a polymer system for
simultaneous delivery of DNA and NC to cancer cells has not been previously reported.
The resulting NC/PEI/DNA polyplexes were characterized and gene delivery efficiency
quantified and compared to ternary polyplexes comprising 15-kDa poly-L-α-glutamic acid
(PGA)/PEI/DNA. The Trolox equivalent antioxidant capacity of the NC/PEI/DNA
polyplexes was evaluated as a measure of antioxidant activity, and the effect of NC on the
mechanism of cellular internalization and intracellular processing of NC/PEI/DNA
polyplexes was investigated.
3.2
3.2.1

Materials and Methods
Materials
Polymer (25-kDa polyethylenimine and 15-kDa poly-L-α-glutamic acid sodium

salt) and pharmacological endocytic inhibitors (genistein, methyl-β-cyclodextrin,
chlorpromazine hydrochloride, amantadine hydrochloride, and amiloride hydrochloride)
were purchased from Sigma-Aldrich. The luciferase reporter plasmid (pGL3) encoding
firefly luciferase was purchased from Elim BioPharm.
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3.2.2

Cell Culture
HeLa cells used in this project were purchased from ATCC along with EMEM cell

culture media. Cells were cultured according to the ATCC recommended protocol using
EMEM supplemented with 10% fetal bovine serum (FBS) at 37ºC and 5% CO2. Cells were
washed with phosphate buffered saline (GE Life Sciences, 6.7 mM PO4, 137 mM NaCl,
pH 7.2) and dissociated with Trypsin (Corning, 0.53 mM EDTA). Cell culture lysis reagent
(CCLR) was used to lyse cells at pH 7.8 composed of 25 mM Tris-Phosphate buffer, 0.7
g/L 1,2 diaminocyclohexane, 10% glycerol, 1% Triton X-100, and 1% protease inhibitor
cocktail (Millipore).
3.2.3

Standard Transfection Protocol
Solutions of DNA, PEI, PGA, or NC at 0.1 mg/mL were diluted in 5X volume PBS.

The polycation (PEI) is then rapidly mixed into the DNA dilution while vortexing to
electrostatically form a binary polyplex. After 10 min incubation at room temperature, the
anion (PGA or NC) is added to the binary solution and incubated 10 min at room
temperature. Cation and anion may be varied at a constant DNA dose of 1 µg per 1x105
cells. 96 well plates and 24 well plates are prepared at 2x104 cells and 2x105 cells per well
respectively. The resulting ternary polyplex is then added to EMEM and FBS added to 5%.
This solution was added to a 96 well plate at 50 µL or a 24 well plate at 500 µL. Wells
were aspirated and washed with PBS before addition of polyplexes. For experiments
involving endocytic inhibitors, cells were incubated with concentrations of inhibitor
producing less than 20% cell death for 1 h to disable selected endocytic pathways.
Polyplexes were then added on top of inhibitors for 3 h before aspirating and adding growth
media. Cells were then incubated until 24 h after transfection before lysing and collecting
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lysate. A BCA assay (G Biosciences) was used to determine sample total protein and a
bioluminescence Luciferase protein assay (Promega) used to evaluate reporter gene
expression on a BioTek Synergy 2 microplate reader. Relative luminescence units (RLU)
were normalized to total protein for each well. All transfections were performed in the
presence of 5% serum unless stated otherwise.
Charge ratios were calculated based on the molar quantity of carboxylic groups (O)
in 15 kDa PGA or citrate coating of NC, the molar quantity of primary amine groups (N)
in 25 kDa branched PEI, and the molar quantity of phosphodiester backbone units (P) in
DNA. P charge was calculated assuming DNA monomer weight of 330 g/mol (3.03 mol
P/mg DNA) and N charge calculated assuming PEI monomer weight of 43 g/mol (23.26
mol N/mg PEI). For PGA, O charge was calculated assuming PGA monomer weight of
129 g/mol with two CO bonds per monomer (15.5 mol O/mg PGA). For NC coated with
citrate at 75 citrate molecules (2 available CO charge centers) per NC particle, O charge
was calculated assuming each particle weight of 14,581 g/mol (10.3 mol O/mg NC).
3.2.4

Size and Zeta Potential
Nanoparticle zeta potential was determined using a Malvern zetasizer and particle

size was determined by dynamic light scattering using a Brookhaven 90Plus Particle Size
Analyzer. For size analysis, polyplexes of NC:PEI:DNA or PGA:PEI:DNA were formed
according to the standard protocol at various O/N/P ratios based on 800 ng pGL3 plasmid.
These particles were diluted to 1 mL in 0.1X PBS and added to a disposable cuvette before
analyzing size over three reads of 5 min each. For zeta potential measurements, polyplexes
were formed according to the standard protocol at various O/N/P ratios based on 2 µg pGL3
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plasmid, diluted to 750 µL in 0.1X PBS, and added to a Malvern Nano Series disposable
folded capillary cell. Zeta potential was analyzed over three reads, each consisting of 20
measurements. All samples were run in triplicate.
3.2.5

Scanning Transmission Electron Microscopy
PEI:DNA (23:1, N/P), NC:PEI:DNA (1.7:23:1 and 20:23:1 O/N/P), and

PGA:PEI:DNA (10:23:1 O/N/P) were formed by the standard protocol with the exception
that all polymer, DNA, and NC were buffered in water to avoid salt presence. All samples
were prepared on lacey carbon, 300 mesh, copper grids by dipping the grids in the polyplex
dilution for 60 sec and then drying overnight. Super-resolution scanning transmission
electron microscopy was performed on a Talos F200X. EDS mapping was performed on
selected samples to confirm the co-localization of nitrogen (from PEI amine groups),
phosphor (from DNA backbone), and cerium as a polyplex.
3.2.6

Generation of Nanoceria
Nanoceria crystallites were generated via a single step hydrothermal method [248].

The ceria nanoparticles were coated with citric acid during synthesis. Citric acid adsorbs
onto the nanoceria surface to stabilize the aqueous dispersion. The product was dialyzed
for 120 h in total, changing the dialysate every 24 h, against pH 7.4, 110 mM, iso-osmotic
citric acid to further coat the nanoceria and remove unreacted cerium salts. The product
was further dialyzed against DI water for an additional 72 h, again changing the dialysate
every 24 h, to remove free citric acid. The nanoceria dispersion was then stored in the dark
at 4°C. Dynamic light scattering and zeta potential were obtained with nanoceria dispersed
in DI water at a concentration of 0.5 mg/mL.
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3.2.7

Antioxidant Potential
Cerium oxide is a known cellular anti-oxidant. It’s ability to scavenge reactive

oxidative species (ROS) make it a promising therapeutic agent for reducing the high
oxidative state of cancer cells. This anti-oxidant potential was measured using a CellROX
Deep Red anti-oxidant kit (Thermo Fisher). HeLa cells at 2x104 cells per well were cultured
in a 96 well plate or in a multi-chambered Lab-Tek 2 Chamber Slide (ThermoFisher) and
incubated for 24 h. NC:PEI:DNA or free NC were prepared according to the standard
protocol and 100 µL added to each well. After a 3 h incubation, wells were aspirated and
washed with PBS. 24 h after transfection, cells were damaged using 200 µM menadione
(Sigma Aldrich) for 1 h in growth media. Cell exposure to this reagent results in production
of high levels of ROS within the cell. CellROX Deep Red Reagent was then added at 10
µM in each well and incubated 1 h. The reagent is not fluorescent unless reduced by ROS
into fluorescent state. Cells in microscope slides were then prepared for confocal
microscopy (see Co-Localization methods) while cells in 96 well plates were lysed. Lysate
fluorescence was then assessed on a BioTek Synergy 2 micro-plate reader equipped with
filters at 620/40 ex and 680/30 em. Auto-fluorescence of untreated/undamaged cells was
subtracted from each sample before normalizing to damaged controls. A Trolox standard
was also used as a ROS scavenger positive control at concentrations of 0, 12.5, 50, and 200
nM. Cells were exposed to Trolox standards 1 h before damaging with menadione.
3.2.8

Polyplex and Inhibitor Toxicity
Polyplex, NC, and endocytic inhibitor cytotoxicity towards HeLa cells were

determined using a Cell Titer Blue viability assay (Promega). NC:PEI:DNA,
PGA:PEI:DNA, or free NC particles were prepared in 96 well plate at varying O/N/P ratios
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according to the standard protocol. For endocytic inhibitor trials, cells were exposed to
each of the inhibitors at varying doses for 1 h and then 50 µL EMEM added for the
remaining 3 h before changing media. 24 h after transfection, well media was replaced with
100 µL growth media and supplemented with 20 µL of Cell Titer Blue reagent. Cells were
incubated for 2 h at 37ºC and 5% CO2 before 100 µL of well media was transferred to an
opaque plate and analyzed for fluorescence on a BioTek Synergy 2 micro-plate reader
equipped with filters at 530/25 ex and 590/35 em. Fluorescence was converted to cell count
using a standard curve of non-treated cells. Endocytic inhibitor concentrations were
selected that produced 80% cell viability.
3.2.9

Polyplex Transfections Optimizations
HeLa cells were seeded and incubated for 24 h in 96 well plates at 2x104 cells per

well for gene expression studies and 2x105 cells per well in 24 well plate for uptake studies.
For endocytic inhibition studies, 50 µL of each inhibitor (Genistein, Methyl-βcyclodextrin, Chlorpromazine hydrochloride, Amantadine hydrochloride, Amiloride
hydrochloride) at the desired concentration was incubated with cells for 1 h. NC:PEI:DNA
or PGA:PEI:DNA polyplexes were complexed according to the standard protocol at
various O/N/P ratios (at constant P) and incubated with cells for 3 h, either in or out of the
presence of inhibitors. After incubation, 24 well plates were prepared for uptake analysis
by flow cytometry (see Flow Cytometry methods) and 96 well plates incubate until 24 h
after transfection, at which time cells were lysed and assayed for total protein and reporter
gene expression.
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3.2.10 Flow Cytometry
Uptake of polyplexes was assessed by flow cytometry. HeLa cells were seeded in
a 24 well plate 24 h before transfection at 2x105 cells per well. Cells were transfected with
polyplexes of varying O/N/P ratios according to the standard protocol with the exception
that pGL3 plasmid was pre-incubated for 30 min with YOYO-1 iodide (Invitrogen) at a
ratio of 15 μL of 1 mM stock per 1 μg pGL3. For experiments involving endocytic
inhibition, cells were exposed to inhibitors at desired concentrations in 200 μL growth
media for 1 h before polyplex addition. After 3 h polyplex incubation, wells were aspirated
and cells washed twice with PBS then once with 0.001% sodium dodecyl sulfate in PBS to
remove surface bound particles. Cells were dissociated with 200 μL Trypsin and diluted to
a total volume of 1 mL in PBS. Cell samples were analyzed by an Attune Acoustic
Focusing Cytometer (Thermo Fisher) reading forward scatter, side scatter, and
fluorescence intensity in the YOYO-1 appropriate channel. Data was analyzed using
FlowJo analysis software by selecting viable cells through standard gating techniques and
calculating mean fluorescence.
3.2.11 Co-Localization Imaging
In order to visualize NC:PEI:DNA or PGA:PEI:DNA polyplexes within the cell,
PEI was tagged with AlexaFluor 488 fluorescent tag (Thermo Fisher) at a ratio of one dye
molecule per 50 PEI monomer units. Cells were plated at 1.5x104 cells per chamber in a
multi-chamber Lab-Tek 2 Chamber Slide (Thermo Fisher) and incubated 24 h. Polyplexes
were formed according to the standard protocol (using tagged PEI) at 100 μL and added to
the chamber well. To visualize endocytic vesicles resulting from caveolin-mediated uptake,
tagged cholera toxin subunit B (Biotium) was added at 2 μg/L 20 min after polyplex
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addition. To visualize endocytic vesicles resulting from clathrin-mediated uptake, tagged
transferrin protein (Biotium) was added to the well at 25 μg/L immediately following
polyplexes. For investigation of co-localization to the macropinosome, 70 kDa dextran
Texas Red (Invitrogen) at 0.5 mg/mL was added to the well immediately. Polyplex and
marker solutions were incubated with cells for 30 min to ensure internalized polyplexes
were localized to early-late endosomes. Cells were aspirated and washed with 0.001%
sodium dodecyl sulfate in PBS to remove surface bound particles and then washed twice
with PBS. Cells were fixed with 4% formaldehyde for 10 min, permeabilized with 0.1%
Triton X100 in PBS for 15 min, and then blocked with 1% bovine serum albumin in PBS
for 45 min. Wells were aspirated, washed thoroughly and stained for 1 h with Alexa Fluor
405 Phalloidin (Invitrogen) at 165 nM diluted in PBS. Cells were washed four times in
PBS before mounting a No.1.5H precision coverslip (Thor Labs) using Prolong Diamond
Antifade mountant (Invitrogen). Slides were imaged within 24 h using the 60X objective
of a Leica SP8 confocal microscope. Fiji was used to determine co-localization Mander
coefficients for overlap of polyplexes with endosomal markers.
3.2.12 Intracellular Trafficking
To determine if trafficking to lysosomes is occurring and to assess endosomal
acidification’s effect on gene delivery, transfections were performed in the presence of 10
nM bafilomycin A1 and/or 20 µM chloroquine. BafA1 or chloroquine was incubated with
the cells in 50 µL EMEM for 1 h before NC:PEI:DNA (0.5:5.3:1, w:w:w) or PEI:DNA
binary (5.3:1, w:w) polyplexes were added to a final volume of 100 µL. 3 h after
transfection, wells were aspirated and growth media added for 21 h. BCA and Luciferase
expression assays were performed to quantify total protein and gene expression. NC ternary
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polyplexes and binary polyplexes were also co-localized on microscope slides with
acidified andosomal compartments using Lysotracker. Cells were prepared on glass slides
and transfected with NC:PEI:DNA or PEI:DNA polyplexes for 1 h. After 30 min
incubation, Lysotracker Deep Red was added to 1.6 µM. After the remaining 30 min of
incubation, wells were washed, fixed, and permeabilized before staining with Alexa Fluor
405 Phalloidin for 1 h and mounting for imaging.
3.3
3.3.1

Results
Nanoceria Synthesis
Nanoceria was generated by a hydrothermal method in the presence of citric acid

to coat the particle surfaces. The zeta potential of the particles was -43.5 ± 1.6 mV at a
measured pH of 6.5. The nanoceria mean primary particle size was 4.1 ± 0.5 nm as
determined by TEM. The particles were determined to be hexagonal in shape, consisting
of closely packed nanoceria crystallites with sharp, distinct edges. As indicated by DLS,
the hydrodynamic size distribution is bimodal, with the first peak at a diameter of 12 nm
and the second, 29 nm (Figure 3.1A). However, greater than 90% of the nanoceria is
present in the first peak and likely represents individual particles or aggregates of a few
particles. Nanoceria has the tendency to self-associate, resulting in small agglomerates
when dispersed indicated by the small secondary peak [249]. Fourier-transform infrared
spectroscopy (FTIR) confirmed the presence of citric acid on the surface of the nanoceria
(Figure 3.1C). A broad peak ranging from 2800 to 3600 cm-1 is characteristic of a hydroxyl
group, typically present on metal oxide surfaces. The two peaks at 1375 and 1540 cm-1 are
attributed to the stretching bands of the carboxyl groups in citric acid.
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Figure 3.1: (A) Surface-area-weighted distribution of hydrodynamic diameters of
nanoceria suspended in water. (B) TEM image of polyhedral, crystalline nanoceria. (C)
FTIR spectrum of citrate-coated nanoceria. Peak at 3300 cm-1 represents a hydroxyl group.
Peaks at 1375 and 1540 cm-1 represents a carboxylic group.
3.3.2

Formation and Characterization Ternary Polyplexes
Ternary polyplexes of NC/PEI/DNA and PGA/PEI/DNA were produced

sequentially by adding a solution of PEI to a DNA solution to form binary polyplexes and
subsequently adding a suspension of NC or PGA solution (Figure 3.2A). By varying the
ratios of PEI and anion (PGA or NC) at a fixed amount of DNA, particles of various charges
and sizes were formed. TEM imaging showed polyplex diameter of 160 nm, 244 nm, and
166 nm for PEI/DNA (23:1 N/P), PGA/PEI/DNA (10:23:1 O/N/P), and NC/PEI/DNA
(1.7:23:1 O/N/P), respectively (Figure 3.2B-E). EDS mapping of NC/PEI/DNA showed
co-localization of N (from PEI amine groups and DNA), P (from DNA backbone), and Ce
(from nanoceria), indicating that imaged particles were in fact NC/PEI/DNA polyplexes
(Figure 3.2F). The binary PEI/DNA polyplexes exhibited a zeta potential of +8.87, 8.90,
and 9.51 mV at N/P 7.7, 23, and 38, respectively. Addition of NC or PGA to binary
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polyplexes resulted in decreasing surface charge (Figure 3A-B). For polyplexes at N/P 7.7,
the zeta potential plateaued at approximately -20 mV at O/N/P 200:7.7:1, whereas the zeta
potential of polyplexes at N/P 23:1 and 38:1 decreased to -18.8 mV and -22.3 mV at O/N/P
of 200:23:1 and 272:38:1, respectively. Interestingly, addition of PGA decreased the zeta
potential until a plateau around -28 mV followed by an increase in zeta potential, with the
exception of polyplexes at N/P 38:1. The binary PEI/DNA polyplexes exhibited diameters
of 232, 142, and 111 nm at N/P 7.7, 23, and 38, respectively. Regardless of N/P ratio,
addition of increasing amounts of PGA increased the particle diameter until the
PGA/PEI/DNA ratio corresponding to near neutral zeta potential was reached, beyond
which the size decreased (Figure 3.3C). Addition of NC had a smaller effect on both
polyplex size and zeta potential as much higher O/N/P ratios were required to observe
property changes. Addition of NC caused quite small particle growth (<50 nm) initially
and higher charge ratios resulted in polyplex aggregates (>1 μm) (Figure 3.2B).

83

Figure 3.2: (A) Complexation of NC with PEI and DNA to form a polyplex. (B-D)
Transmission electron microscope imaging of binary (B) PEI/DNA (23:1 N/P), (C)
PGA/PEI/DNA (10:23:1 O/N/P), and (D) NC/PEI/DNA (1.7:23:1 O/N/P) polyplexes. (E)
EDS spectrum of imaged NC/PEI/DNA polyplex. N peak indicates the presence of PEI
and DNA, P peak indicates presence of DNA, and Ce peak indicates presence of nanoceria.
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Figure 3.3: (A) NC/PEI/DNA zeta potential curves at various O/N/P ratios. (B)
PGA/PEI/DNA zeta potential curves at various O/N/P ratios. (C) NC/PEI/DNA and (D)
PGA/PEI/DNA size curves at various O/N/P ratios determined by DLS. (n=3, error bars
represent standard deviation).
3.3.3

Transfection with NC/PEI/DNA and PGA/PEI/DNA Polyplexes
HeLa cells were transfected with NC/PEI/DNA and PGA/PEI/DNA polyplexes at

various O/N/P ratios. The ratios of cation (PEI) and anion (NC or PGA) were varied while
the amount of DNA was held constant in order to determine the optimal O/N/P ratios. The
NC/PEI/DNA polyplexes exhibited maximum transgene expression at 1.7:23:1 O/N/P,
which was 80% of the maximum PGA/PEI/DNA polyplex gene delivery activity at 10:23:1
O/N/P (Figure 3.4A). However, this difference was not statistically significant (p=0.34).
Cellular internalization of PGA/PEI/DNA polyplexes was generally 10-40% higher than
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NC/PEI/DNA polyplexes (Figure 3.4B). For all PEI/DNA weights, the NC expression
optimum remained constant at an O ratio of 1.7 whereas the PGA/PEI/DNA optimums
required increasing O ratios with increasing PEI amounts. Further, the optimum transgene
expression of NC/PEI/DNA polyplexes correlated with the maximum uptake whereas the
PGA/PEI/DNA polyplexes did not.
NC was not cytotoxic at all concentrations equivalent to the amount of NC present
in polyplexes during transfection (Figure 3.4C). Binary PEI/DNA polyplexes at N/P 7.7:1
exhibited no cytotoxicity, but cell viability decreased by ~20% and 40% in the presence of
PEI/DNA polyplexes at N/P 23:1 and 38:1, respectively, due to disruption of the cell
membrane and mitochondrial wall by PEI [163]. Addition of NC had no significant effect
on cytotoxicity of NC/PEI/DNA polyplexes up to 7:23:1 and 68:38:1. Further addition of
NC decreased cytotoxicity, but at much higher amounts than in polyplexes exhibiting
optimal transfection efficiency.
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Figure 3.4: (A) Expression of luciferase reporter gene delivered by NC/PEI/DNA or
PGA/PEI/DNA polyplexes (dashed lines). (B) Uptake of NC/PEI/DNA and
PGA/PEI/DNA polyplexes at various O/N/P ratios. (C) NC/PEI/DNA polyplex toxicity
profiles for varying O/N/P ratios of NC/PEI/DNA. White bars indicate samples treated
with only NC. (n=4, error bars represent standard deviation).
3.3.4

Antioxidant Activity of NC/PEI/DNA Polyplexes
To investigate the potential antioxidant activity of NC/PEI/DNA polyplexes, HeLa

cells were exposed to menadione to generate free radicals prior to addition of NC or
polyplexes, and the antioxidant activity was determined 24 h after transfection by the
addition of CellROX Deep Red, which becomes fluorescent upon oxidation in the presence
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of ROS. The antioxidant activity was quantified by comparison to the antioxidant activity
of Trolox standards at 0-200 nM [250, 251]. NC/PEI/DNA polyplexes at the optimum gene
delivery ratio, 1.7:23:1 O/N/P, produced a 25% reduction in ROS, which corresponded to
a Trolox equivalence of 12.5 nM (Figure 3.5A). At a charge ratio of 27:23:1 O/N/P, ROS
was reduced to levels present in cells not exposed to menadione, corresponding to a 200
nM Trolox equivalence. Similar results were observed by confocal fluorescence
microscopy in which increasing ratios of NC reduced the CellROX fluorescence (Figure
3.5B-G). Free NC at weights equivalent to NC/PEI/DNA at 13:23:1 and 27:3:1 was
observed to reduce ROS levels to 90% and 83%, respectively. Delivery of NC/PEI/DNA
at a ratio of 27:23:1, therefore, increase the antioxidant effect by 480% compared to
delivery of equivalent amounts of free NC.
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Figure 3.5: (A) Anti-oxidant dose curves for Trolox standard and NC/PEI/DNA polyplexes
at 23:1 N/P. All samples were damaged with menadione except for “Cells” control. NC
indicates nanoceria incubated with cells in absence of PEI or DNA. Trolox samples were
normalized to a 0 nM Trolox control and NC/PEI/PGA were normalized to NC-free
(binary) control. Free NC samples were normalized to non-treated controls. (B) Nondamaged control HeLa cells and (C) menadione-damaged control cells. (D-E) Trolox
antioxidant activity in HeLa cells at 12.5 nM and 200 nM concentrations. (F-G)
NC/PEI/DNA antioxidant activity in HeLa cells at O/N/P ratios of 1.7:23:1 and 27:23:1.
Red represents CellRox indicating presence of ROS and blue is phalloidin cell cytoskeleton
stain. (n=3, error bars represent standard deviation).
3.3.5

Mechanism of Internalization of NC/PEI/DNA Polyplexes
To investigate the pathways through which NC/PEI/DNA polyplexes enter HeLa

cells, transfections were performed in the presence of pharmacological agents that inhibit
caveolin-mediated endocytosis through inhibition of tyrosine phosphorylation and
cholesterol

scavenging

(genistein

and

methyl-β-cyclodextrin),

clathrin-mediated

endocytosis by prevention of clathrin heavy-chain recycle to cell membrane
(chlorpromazine HCl and amantadine HCl), and macropinocytosis by inhibition of ruffle
formation upon blocking Na+/H+ channels (amiloride HCl) [182-188]. Concentrations
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were selected for each at which 80% viability was achieved in HeLa cells under standard
transfection protocol (data not shown). These concentrations were determined to be 150
mg/L, 12 g/L, 14.5 mg/L, 450 mg/L, and 140 mg/L for genistein, methyl-β-cyclodextrin,
chlorpromazine HCl, amantadine HCl, and amiloride HCl, respectively. Inhibition of
caveolin-mediated endocytosis with genistein (GST) or methyl-β-cyclodextrin (mBCD)
decreased transgene expression by ~90% compared to non-inhibited controls, while uptake
was unaffected by genistein but increased by 112% in the presence of mBCD (Figure
3.6A). Inhibition of clathrin-mediated endocytosis with chlorpromazine HCl (CPZ)
resulted in a 50% increase in both uptake and transgene expression, but amantadine HCl
(AMN) had no effect. Finally, the presence of amiloride (AML) decreased transgene
expression by 60% while uptake was unaffected. Internalization through these three
pathways was confirmed through co-localization of fluorescently labeled polyplexes with
fluorescent markers cholera toxin subunit B (CTxB), transferrin, or 70-kDa dextran (Figure
3.6B). CTxB is a surface ganglioside GM1 binding pentamer that concentrates in caveolae
when administered at low concentrations for short amounts of time [193, 252]. Transferrin
binds the transferrin receptor on the cell surface, triggering internalization through
invaginations of clathrin-coated pits [189]. Finally, dextran is known to be internalized
primarily through macropinocytosis [194]. Mander’s coefficients of 0.60, 0.87, and 0.60
were calculated for co-localization of polyplexes to caveosomes, clathrin-coated vesicles,
and macropinosomes, respectively.
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Figure 3.6: (A) Endocytic inhibitor (GST, mBCD, CPZ, AMN, and AML) effects on gene
expression and uptake of NC/PEI/DNA at optimum O/N/P ratio (1.7:23:1) in HeLa cells.
All inhibited samples were normalized to controls in the absence of inhibitors. (B) Colocalization of NC/PEI/DNA polyplexes to cholera toxin subunit B (caveosomes, CAV),
transferrin protein (clathrin-coated vesicles, CCV), and 70-kDa dextran (macropinosomes,
MP). Particles are in green, endosomal compartments in red, and cell cytoskeleton is in
blue. Images were captured with a 60x objective. (n=4, error bars represent standard
deviation; *p<0.05, †p<0.01, ‡p<0.001 compared to control groups).
3.3.6

Intracellular Trafficking
Bafilomycin A1 (BafA1), chloroquine (CQ), and Lysotracker dye were used to

investigate the trafficking of NC/PEI/DNA polyplexes to acidified vesicles and determine
the importance of acidification for efficient gene delivery [100]. BafA1 prevents the
acidification of endosomes through inhibition of V-type ATPase [196], and a decrease in
gene delivery in the presence of BafA1 suggests that acidification plays a role in endosomal
escape. Similarly, chloroquine (CQ) is lysosomotropic agent often delivered with vectors
lacking ionization potential such as polylysine to enhance transfection efficiency [197].
Changes in transfection efficiency in the presence of CQ indicates that at least a portion of
polyplexes was at some point localized to lysosomes.
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Both PEI/DNA polyplexes and the optimum NC/PEI/DNA polyplex were used to
transfect HeLa cells in the presence of BafA1and/or CQ. Transgene expression mediated
by both binary and ternary polyplexes decreased ~80% in the presence of BafA1or a
combination of BafA1and CQ and ~45% in the presence of CQ (Figure 3.7A). Localization
of polyplexes in lysosomes was confirmed by confocal fluorescence microscopy (Figure
3.7B). Mander’s coefficients for co-localization of polyplexes and Lysotracker were 0.27
and 0.41 for ternary and binary polyplexes respectively.

Figure 3.7: (A) Effects of bafilomycin A1 (BafA1, 10 nM) and chloroquine (CQ, 20 µM)
on gene expression of optimum ternary NC/PEI/DNA (1.7:23:1, O/N/P) and binary
PEI/DNA polyplexes (23:1, N/P). Samples treated with BafA1and/or CQ were normalized
to controls treated with neither. (B) Co-localization at 1 h of NC/PEI/DNA polyplexes or
(C) binary PEI/DNA polyplexes to lysosomes using Lysotracker. Polyplexes are in green,
lysosomes (Lysotracker) in red, and cell cytoskeleton in blue. (n=4, error bars represent
standard deviation; *p<0.05, †p<0.01 compared to control groups).
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3.4

Discussion
Citrate-coated NC particles are small, carry a negative charge, resist aggregation,

and possess antioxidant capacity. The carboxylate groups of the citrate coating provided
electrostatic interactions with the amine groups of PEI for the formation of hybrid ternary
polyplexes. Based on significantly decreased antioxidant effect of NC compared to
NC/PEI/DNA polyplexes at equivalent weight, the nanoceria alone does not efficiently
enter HeLa cells, likely due to their negative zeta potential (Figure 3.5). However, the NC
did avoid toxicity and aggregation at physiological pH. Nanoceria offers the unique ability
to reversibly bind or release free radicals depending on environmental and physiochemical
factors, such as pH [235, 236]. For HeLa cells (cytosol pH 7.3) [253, 254] transfected with
citrate-coated nanoceria electrostatically bound to a PEI/DNA polyplex, this report shows
strong transgene expression and antioxidant capacity in vitro. After mediating cellular
entry, the NC either dissociates from the polyplex or remains bound (Figure 3.8). In either
case, NC was shown to produce antioxidant effects through ROS scavenging (Figure 3.5).
Loading the polyplex with nanoceria corresponding to the transfection optimum had
minimal effect on particle size and zeta potential (Figure 3.3), despite TEM showing NC
throughout the polyplex (Figure 3.2). Addition of PGA at similar charge ratios had a much
stronger effect on polyplex size and charge, indicating that electrostatic interactions
between PGA and PEI are stronger than those between NC and PEI. At higher amounts of
NC, particle size increased drastically (Figure 3.3). These large particles of near-neutral
zeta potential were likely aggregates resulting from lack of charge repulsion. As such, these
large polyplexes were well outside the range of optimum transfection efficiency.
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Figure 3.8: Transfection and cellular processing of NC/PEI/DNA polyplexes for combined
gene and antioxidant therapy in cancer cells.
The pathways through which nanoparticles are internalized have been shown to
influence subsequent intracellular processing [100, 102, 103, 105, 106]. Internalization
through caveolin-mediated endocytosis involves the formation of caveolae vesicles that are
released from the membrane in a dynamin-dependent process. The resulting caveosomes
are thought to avoid extreme acidification and trafficking to lysosomal compartments [86,
170]. Internalization by clathrin-mediated endocytosis, on the other hand, involves the
formation of clathrin-coated vesicles (CCV) that bud off the membrane in a dynamindependent manner similar to caveosomes. However, these CCVs are rapidly acidified into
late endosomes of pH 5-6 and then trafficked to lysosomes for further acidification to pH
~4.5 [81, 169]. This acidic environment is expected to be detrimental to the fate of nucleic
acids. Finally, macropinocytosis is a fluid-phase pathway for the internalization of large
components at the cell surface. Arf6-induced ruffle formations internalize large volumes
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of extracellular fluid into macropinosomes up to 5 µm in size. These macropinosomes are
inherently leaky and are the internalization pathway used by several types of viruses due
to the ease of endosomal escape [255]. Though evidence of acidification exists,
macropinosomes are not believed to fuse with lysosomes in many cell types other than
macrophages [171, 172]. Internalization of NC/PEI/DNA hybrid polyplexes occurred
through a combination of caveolin-dependent endocytosis, clathrin-dependent endocytosis,
and macropinocytosis (Figure 3.6). Inhibitors of caveolin-dependent endocytosis caused a
significant decrease in NC/PEI/DNA-mediated gene delivery, suggesting that caveolin is
an efficient pathway for transfection in HeLa cells. Similar but less severe decreases in
gene delivery were observed in the presence of macropinocytosis inhibitors. In addition,
co-localization of polyplexes with macropinosomes and caveosomes was similar. This
indicates that macropinocytosis, a non-specific pathway, is also an efficient mechanism of
gene delivery, likely due to its inherently leaky nature. Inhibition of clathrin-mediated
uptake, on the other hand, increased gene expression indicating that clathrin-mediated
endocytosis does not lead to effective gene delivery. At least a portion of polyplexes were
trafficked to lysosomes as shown by the effect of chloroquine on gene delivery and the colocalization of polyplexes with Lysotracker (Figure 3.7). This was not surprising due to
high polyplex co-localization to the clathrin-mediated pathway. Bafilomycin A1 indicated
that the acidification process aids in efficient gene delivery. This acidification is believed
to be an important step in escape from the endosome through osmotic swelling [99, 177].
These results would therefore indicate that acidification, but not lysosomal trafficking, is
likely beneficial to gene expression through promotion of endosomal escape. However,
efficient delivery through caveolin-dependent mechanisms shows highly efficient
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internalization and gene expression (Figure 3.6) despite the belief that this pathway avoids
endosomal acidification. Therefore, the caveolar pathway is either subject to acidification,
despite scientific belief, or bafilomycin A1 is capable of interfering with non-acidified
pathways in currently unknown mechanisms. The latter is more likely since caveolin-1 has
been shown to co-localize with the V-type proton pumps that bafilomycin A1 inhibits
[256]. Further, bafilomycin A1 was shown to inhibit cellular organelles such as parts of the
Golgi complex, a target of the caveolin-mediated pathway [257]. Therefore, bafilomycin
A1 may affect intracellular trafficking of polyplexes through mechanisms other than
inhibition of endosomal acidification. That being said, it is still likely that at least a portion
of the decreased transgene expression can be accounted to inhibition of endosomal
buffering.
Gene therapies producing antioxidants or inhibiting the production of pro-oxidants
have been shown to be successful at producing therapeutic effects in cardiovascular disease
and amyotrophic lateral sclerosis [229, 230]. Strategies designed to deliver genes encoding
antioxidant proteins such as extracellular superoxide dismutase (EC-SOD) are effective
methods to produce and excrete SOD. A benefit to this strategy is that excreted SOD helps
to reduce oxidative stress in the surrounding extracellular space as well as in the
intracellular environment [258]. Thus, it is not necessary to deliver the genes directly to
the tumor since transfected healthy tissue will excrete excess EC-SOD, which can provide
downstream therapeutic effects to the targeted tumor. Another potential gene therapy
approach is the modulation of transcription factors that elicit concerted expression or
repression of multiple genes. This pleotropic strategy is particularly successful by
upregulating nuclear factor erythroid 2–related factor 2 (Nrf2), a transcription factor that
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regulates the expression of antioxidant proteins that mitigate oxidative stress induced by
physical injury or inflammation [259]. The complex network of genes regulated by Nrf2,
however, is not completely understood, making its therapeutic potential accompanied by
potential undesired pathological consequences. Regardless, upregulation of these
downstream genes by amplification of Nrf2 has been shown to be an effective means for
reducing oxidative stress in muscle cells and neurons [260, 261]. Combination of these
gene therapies designed to activate cellular defense mechanisms with nanoceria would
likely produce a rapid decrease in oxidative stress (from NC scavenging) followed by longterm decrease in ROS levels (from transgene expression). However, combined delivery of
antioxidant nanoceria and genes reducing oxidative stress is redundant.
An alternative strategy may be to deliver nanoceria with genes that provide
synergistic therapeutic effects. While only reporter genes were utilized here, combinations
of antioxidants with genes such as growth factors, tumor suppressors, or anti-inflammatory
targets could provide synergistic effects in cancer cells. Oxidative stress results in the
upregulation of many growth factors and inflammatory cytokines [216]. For instance,
radiotherapy induces epidermal growth factor activation in carcinoma cells, which triggers
proliferation. Gene therapies blocking this activation prevent this proliferative response to
radiation and improve radiosensitization [262]. Regarding inflammation factors, therapies
preventing nuclear factor kappa B activation are increasingly successful at reducing the
inflammatory nature of cancer cells [263]. Working together, this co-drug would
ameliorate nearly all the direct and side effects produced by high oxidative stress on the
cell. Other options are to use tumor suppressor genes to minimize further damage done to
the cellular genetics or even use genes disabling angiogenesis, thereby starving tumors of
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key nutrients. Many tumor suppressors are dependent on the type of target cancer [264].
However, there are a few genes implicated in almost all cancers such as regulators of
transcription factors p53 or PTEN. Gendicine is the first gene therapy product that utilizes
the p53 tumor suppressor while PTEN is commonly used to suppress tumor growth and
restore chemotherapeutic sensitivity [265]. Finally, a popular tumor suppressor strategy
involves the knockdown of VEGF, which regulates signaling of new vasculature around
expanding tumors. Combination of siRNA targeting VEGF mRNA with antioxidants
would produce a pacified cell that could not effectively expand or produce invasive
proteins for invading surrounding tissue. These combinations allow for the alleviation of
multiple facets of stress on the cell simultaneously, resulting in gene therapies of higher
efficacy with little additional effort in antioxidant loading.
3.5

Conclusions
Here, we showed that nanoceria is a potent antioxidant capable of scavenging free

radicals produced by cancer-generated pro-oxidants. PEI condensed DNA to form binary
polyplexes exhibiting positive charge, which were further coated with anionic nanoceria.
The gene delivery efficiency of the NC/PEI/DNA ternary polyplexes was similar to
PGA/PEI/DNA ternary systems while simultaneously providing antioxidant activity.
While nanoceria was visible on the polyplex, its presence did not significantly affect the
route of internalization or intracellular processing. Internalization occured through a
combination of pathways with clathrin-mediated endocytosis showing highest levels of colocalization to polyplexes. Caveolin-dependent endocytosis and macropinocytosis showed
half the co-localization as clathrin but were more efficient means of entry, presumably due
to the avoidance of lysosomes. While only reporter genes were delivered here, nanoceria
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paired with genes such as ROS-scavenging proteins, transcription factors, growth factors,
anti-inflammatory, tumor suppressors, or even angiogenesis inhibitors are expected to
provide potent co-therapeutic effects on cancers.

Copyright © Landon Mott 2019
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CHAPTER 4. EGFR-TARGETED RNA APTAMER POTENTIATES 3WJ
INTERNALIZATION THROUGH CLATHRIN-MEDIATED ENDOCYTOSIS AND INDUCED
MACROPINOCYTOSIS
4.1

Introduction
RNA nanotechnology is a rapidly advancing field involving the bottom-up self-

assembly of organized architectures from sequences of RNA. These structures are of the
nanometer scale and offer several advantages over DNA assemblies; base stacking,
noncanonical base pairing, elasticity, thermostability, and catalytic capacity [266]. While
useful for the fabrication of advanced materials, RNA nano-assemblies also have
promising capacity for imaging, detection, and gene therapy in biological systems [267].
Guo et al. showed that three-way junction (#WJ) motifs could be derived from the phi29
bacteriophage

and

functionalized

to

harbor

siRNA,

miRNA,

fluorophores,

chemotherapeutic small molecules, or targeting ligands on each of three functional
modules [268]. These and other phi29-derived structures were shown to remain stable in
circulation even at ultra-low concentration while undergoing “ratcheting” into tumor
vasculature [269, 270]. These structures are well suited for the transport of therapeutic
siRNA as well as RNA aptamers to promote internalization in targeted cells. Little work
has been done on studying the process of internalization and subsequent intracellular
trafficking of RNA nanoparticles, which may hold considerable effects on therapeutic
efficacy.
Aptamers are sequences of nucleic acids that form tertiary structures that recognize
specific biomarkers [271]. The onset of SELEX has rapidly increased the rate at which
DNA/RNA aptamers are being designed for specific targets [272]. For example, a potential
biomarker for targeting triple negative breast cancers, for which there is no current
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targeting strategy, is the epidermal growth factor receptor (EGFR) [273]. SELEX
technology was used to develop several RNA aptamers for high specificity and high avidity
targeting of EGFR [274-276]. The capacity to functionalize RNA scaffolds with these RNA
aptamers gives RNA nanoparticles the ability to target cancer cells overexpressing
receptors on their surface. Such targeting, combined with the capacity to harbor therapeutic
RNA, provides the opportunity for targeted gene therapies based on RNA nanotechnology.
Herein, 3WJ motifs developed by Guo et al. [268] were outfitted with imaging
fluorophores, reporter gene siRNA, and CL4 aptamer targeting EGFR [275]. siRNA
delivery was evaluated in a MDA-MB-231 cells, a triple negative breast cancer line known
to overexpress EGFR [277]. Interactions between the aptamer and EGFR were validated
using tyrosine kinase inhibitors as well as EGFR knockdown via siRNA to ensure specific
uptake through receptor-mediated endocytosis. Further, the internalization mechanism
associated with the aptamer and resulting intracellular trafficking were analyzed using
pharmacological endocytosis inhibitors and confocal fluorescence microscopy.
4.2
4.2.1

Materials and Methods
Materials
Non-targeted control 3WJ and 3WJ equipped with an EGF-targeting aptamer (3WJ-

EGFapt) were purchased from NanoBio Delivery Pharmaceutical Company, LTD.
Epidermal growth factor protein (EGF) tagged with Alexa Fluor 647 was purchased from
Invitrogen and non-tagged human epideral growth factor (hEGF) was purchased from
Sigma- Aldrich. Pharmacological endocytic inhibitors (Genistein, Methyl-β-cyclodextrin,
Chlorpromazine hydrochloride, Amantadine hydrochloride, and Amiloride hydrochloride)
were purchased from Sigma-Aldrich. EGF-targeting siRNA (siEGF) was purchased from
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Dharmacon and siRNA targeting Luciferase reporter gene (siLUC) and negative control
(siNEG) were purchased from Bioneer. All transfections were performed in Opti-MEM
reduced serum media from Thermo Fisher Scientific.
4.2.2

Cell Culture
The Renilla Luciferase gene was knocked into a standard MDA-MB-231 cell line

and provided as a gift from Guo Lab at the Ohio State University. MDA-MB-231-Luc cells
were cultured using L-15 media (ATCC) supplemented with 10% fetal bovine serum
(VWR Life Sciences) at 37ºC and 5% CO2. Trypsin comprising 0.53 mM EDTA (Corning)
was used for dissociating cells and phosphate buffered saline (GE Life Sciences, 6.7 mM
PO4, 137 mM NaCl, pH 7.2) for washing. Culture lysis buffer at pH 7.8 composed of 25
mM Tris-Phosphate buffer, 0.7 g/L 1,2 diaminocyclohexane, 10% glycerol, 1% Triton X100, and 1% protease inhibitor cocktail (Millipore) was used for lysing cells.
4.2.3

Cell Transfections
3WJ and 3WJ-EGFapt were transfected either in or out of the presence of endocytic

inhibitors into MDA-MB-231-Luc cells. Inhibitors were added to 50 µL Opti-MEM
reduced serum media to concentrations that produced 80% cell viability while retaining
inhibitory effect and incubated with 25,000 MDA-MB-231-Luc cells in a 96-well plate for
1 h at 37ºC and 5% CO2. Either 3WJ, 3WJ-EGFapt, or EGF were then added to each well
at the desired particle concentration and incubated for a further 3 h. After 3 h incubation,
well contents were replaced by growth media followed by a 21 h incubation. Cells were
lysed and total protein determined by a BCA protein quantification kit (G Biosciences) and
Luciferase protein expression quantified by a Luciferase assay (Promega). In trials
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involving delivery of siLuc, siEGF, 3WJ, or 3WJ-EGFapt mediated by a delivery agent,
particles were complexed with Lipofectamine 2000 (Invitrogen) for 20 min before adding
to cells.
4.2.4

Inhibitor Toxicity and Validation
Cell Titer Blue viability assay (Promega) was used to determine toxicity of all

inhibitors used (genistein, methyl-β-cyclodextrin, chlorpromazine hydrochloride,
amantadine hydrochloride, and amiloride hydrochloride). MDA-MB-231-Luc cells were
exposed to each inhibitor for 1 h before addition of 10 µL Opti-MEM media to simulate
addition of nanoparticles. After 3 h incubation, well contents were replaced with growth
media and incubated another 21 h. Cell Titer Blue was mixed at a ratio of 1:5 (v:v) in L15 growth media and 120 µL added to each well. After 4 h incubation, 100 µL was removed
from the well and transferred to an opaque assay plate for fluorescence analysis on a
BioTek Synergy 2 micro-plate reader equipped with filters at 530/25 ex and 590/35 em.
Fluorescence was converted to cell count using a standard curve of non-treated MDA-MD231-Luc cells. Inhibitor concentrations were selected that produced 80% viability. To
verify that uptake was occurring at the selected doses, uptake of fluorescence tagged
endocytic markers was performed. Cholera toxin subunit B (5 µg/mL) was used to mark
caveolin-based endosomes, transferrin (25 µg/mL) was used to mark clathrin-coated
vesicles, and 70-kDa dextran Texas Red (50 µg/mL) was used as a macropinosome marker.
Uptake markers were added to the cells 1 h after exposure to endocytic inhibitors.
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4.2.5

Flow Cytometry
Uptake of 3WJ, 3WJ-EGFapt, or EGF was monitored using the 647 filter of an

Attune Acoustic Focusing Cytometer (Thermo Fisher). Cells were plated in a 24-well plate
at 2x105 cells per well. 24 h later, cells were transfected by procedure outlined above. 4 h
after transfection, cells were washed twice with PBS and collected using 200 μL Trypsin.
Samples were diluted to 1 mL in PBS before analyzing by cytometry. FlowJo analysis
package was used to gate out debris and calculate mean fluorescence of each sample.
4.2.6

EGFR Inhibition
EGFR was knocked down by EGFR targeting siRNA. 50 nM Luciferase siRNA

was transfected into 300,000 cells in a 6-well plate using 4 μL Dharmafect Transfection
Reagent for 6 h. Media was replaced with growth media and cells incubated for 18 h before
being split into a new 6-well plate at 30% confluency. A further 48 h incubation was
followed by plating 25,000 cells in a 96-well plate with a 24 h incubation to allow
attachment and growth. 3WJ, 3WJ-EGFapt, or EGF were then transfected at desired
concentrations in Opti-MEM for 4 h before pure fetal bovine serum was added to bring the
well serum concentration to 10%. Cells were incubated for 20 h and then lysed for analysis
of uptake and Luciferase expression.
4.2.7

Confocal Microscopy
To visualize the presence of 3WJ, 3WJ-EGFapt, or EGF within the cell and to

determine the degree of co-localization with specific endosomal compartments, confocal
microscopy was employed. 2.5x104 MDA-MB-231-Luc cells per chamber were plated in
a multi-chamber Lab-Tek 2 Chamber Slide (Thermo Fisher) and incubated 24 h. Cells were
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then transfected with 3WJ-EGFapt for 1 h. During this time, wells investigating
macropinosomes co-localization also contain 0.5 mg/mL 70 kDa Dextran as an endosomal
marker. Wells were washed twice with PBS before fixing with 4% formaldehyde for 10
min. Cells were then permeabilized with 0.1% Triton X100 in PBS for 15 min followed by
blocking with 1% bovine serum albumin in PBS for 45 min. Following blocking, cells were
exposed to primary antibodies for caveolin-1 (CAV-1) or clathrin heavy chain (CLTC,
Invitrogen) diluted to 1:125 and 1:200 respectively in blocking solution for 2 h. After
washing, cells were then stained for 1 h with a mixture of Alexa Fluor 405 Phalloidin
(Invitrogen) at 165 nM and Alexa Fluor 594 goat anti-mouse IgG secondary antibody
(Invitrogen) diluted to 2 µg/mL. No.1.5H precision coverslip (Thor Labs) and Prolong
Diamond Antifade mountant (Invitrogen) were used to prepare the slides. Imaging was
performed on a Leica SP8 using a 60X objective within 24 h of slide preparation and Fiji
used to calculate Mander’s coefficients.
4.2.8

Intracellular Trafficking
Bafilomycin A1 (BAF) at 10 nM was used to assess the importance of acidified

endosomal environments on the therapeutic efficacy of 3WJ or 3WJ-EGFapt. Chloroquine
(CQ) at 20 µM was used to determine whether nanoparticle sorting to lysosomal
compartments occurred or not. MDA-MB-231-Luc cells were pre-incubated with either
BAF, CQ, or a combination of both for 30 min before adding 200 nM of either 3WJ or
3WJ-EGFapt. After 3 h incubation, FBS was added to the wells to 10% to stimulate healthy
cellular activity. 24 h after transfection, cells were lysed and assessed for total protein and
Luciferase expression.
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4.3
4.3.1

Results
Validation of EGFR Expression
To validate the EGFR expression levels in the MDA-MB-231-Luc cell line

compared to standard MDA-MB-231 cells, fluorescently tagged epidermal growth factor
(EGF-AF647) was incubated with both cell lines, and EGF-AF647 fluorescence in cells
lysates was quantified to determine EGF internalization. At doses commonly used for
siRNA studies (0-100 nM), there was no statistical significance between uptake for either
cell line (Figure 4.1A). At concentrations beyond 500 nM, the MDA-MB-231-Luc line
demonstrated elevated uptake compared to the standard line.
4.3.2

Transfection with 3WJ Nanoparticles
3WJ, 3WJ-EGFapt, and EGF-AF647 were incubated with MDA-MB-231-Luc cells

at varying concentrations. After 6 h, cell lysates were assayed for the presence of RNA
nanoparticles or EGF-AF647. At all concentrations, EGF was internalized most efficiently,
followed by 3WJ-EGFapt and 3WJ (Figure 4.1B). Internalization of EGF was statistically
higher (p<0.01) than either RNA nanoparticle. Further, 3WJ-EGFapt was statistically higher
than 3WJ uptake at all concentrations (p<0.05). Visualization after 15 min incubation of
cells with either 3WJ, 3WJ-EGFapt, or EGF confirmed the findings where EGF showed the
highest number of internalized particles followed by 3WJ-EGFapt and then 3WJ
nanoparticles (Figure 4.1).
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3WJ-EGFapt
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Figure 4.1: (A) Uptake of EGF at various concentrations in MDA-MB-231-Luc and MDAMB-231 cell lines. (B) 6 h uptake of 3WJ, 3WJ-EGFapt, and EGF at various concentrations
in MDA-MB-231-Luc cells. (C) Receptor-bound 3WJ, 3WJ-EGFapt, or EGF (red) 15 min
after transfection. Red represents nanoparticles or EGF. Blue represents cell cytoskeleton
stain. (n=3, error bars represent standard deviation).
MDA-MB-231-Luc cells were transfected with 3WJ and 3WJ-EGFapt to evaluate
their siRNA delivery efficiency (Figure 4.2). As a positive control, siLUC was also
transfected at equivalent concentrations mediated by Lipofectamine2000. 3WJ particles
did not produce any statistically significant knockdown at any concentration. 3WJ-EGFapt
mediated 18% knockdown at 100 nM and 35% at 500 nM. Equivalent concentrations of
both 3WJ and 3WJ-EGFapt delivered using Lipofectamine2000 produced ~70-80%
knockdown. Furthermore, the siLUC positive control produced approximately 80%
knockdown at all concentrations.
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Figure 4.2: Knockdown of luciferase expression mediated by 3WJ and 3WJ-EGFapt in
MDA-MB-231-Luc cells. All samples were normalized to non-treated controls. (n=3, error
bars represent standard deviation; *p<0.05, †p<0.01, ‡p<0.001 compared to control
groups).
4.3.3

EGFR Dimerization
Dimerization of multiple tagged EGF receptors is a pre-requisite to internalization.

Therefore, to determine whether 3WJ-EGFapt was capable of triggering dimerization of
EGFR on the MDA-MB-231-Luc surface, 3WJ-EGFapt was transfected in MDA-MB-231Luc cells in the presence of varying concentrations of free EGF (Figure 4.3). Addition of
EGF at concentrations up to 10 µM had no effect on the uptake of 3WJ-EGFapt. This result
was verified both by cytometry and by cell lysate analysis on a plate reader.
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Figure 4.3: Internalization of 3WJ-EGFapt in MDA-MB-231-Luc cells in the presence of
varying concentrations of EGF. LIPO represents a positive control of 3WJ or 3WJ-EGFapt
delivered using Lipofectamine2000 transfection agent. Data by (A) cytometry and (B) plate
reader yielded the similar results. (n=3, error bars represent standard deviation).
4.3.4

Investigation of EGFR-Specific Internalization of 3WJ Nanoparticles
In order to evaluate the importance of EGFR on internalization of 3WJ-EGFapt,

EGFR expression was knocked down by RNA interference. Upon knockdown of EGFR
expression using siEGFR, internalization of EGF and 3WJ-EGFapt was reduced to ~5560% while internalization of 3WJ was not affected (Figure 4.4A). Luciferase knockdown
by 3WJ was unaffected by siEGFR knockdown, but knockdown mediated by 3WJ-EGFapt
decreased 40% (Figure 4.4B).
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Figure 4.4: (A) Uptake and (B) luciferase expression of 3WJ and 3WJ-EGFapt following
EGFR inhibition using EGFR-targeting siRNA (siEGFR) compared to non-targeted siRNA
negative controls (siNEG) transfected with 3WJ or 3WJ-EGFapt. (n=3, error bars represent
standard deviation; *p<0.05, †p<0.01, ‡p<0.001 compared to control groups).
4.3.5

Investigation of Internalization Pathway of 3WJ Nanoparticles
To investigate the internalization of 3WJ-EGFapt through caveolin-dependent

endocytosis,

clathrin-dependent

endocytosis,

endosomal

compartments

were

immunofluorescently labeled with antibodies against caveolin-1 and clathrin heavy-chain.
In addition, macropinosomes were marked by exposing cells to 70-kDa dextran Texas Red,
which is known to be internalized by fluid-phase macropinocytosis [194, 195]. Colocalization of 3WJ-EGFapt with each marker was observed by confocal fluorescence
microscopy (Figure 4.5). Mander’s coefficient characterizes the degree of overlap between
two fluorophores, where 0 indicates no overlap and 1 indicates complete co-localization.
3WJ-EGFapt were observed to co-localize least to caveolin-containing vesicles, with a
Mander’s coefficient of 0.101. Co-localization to clathrin-coated vesicles and
macropinosomes were similar with Mander’s coefficients of 0.699 and 0.634, respectively.

110

Endosome

3WJ-EGFapt

Co-Localization

Combined

CAV

CCV

MP

Figure 4.5: Endosomal co-localization of 3WJ-EGFapt to caveosomes (CAV), clathrincoated vesicles (CCV), or macropinosomes (MP) in MDA-MB-231-Luc cells. Green
represents tagged endosomes, red represents 3WJ-EGFapt nanoparticles, and blue
represents cell cytoskeleton. Images were captured using a 60x objective.
To further elucidate the pathways associated with the uptake of 3WJ and 3WJEGFapt, pharmacological inhibitors were used to disable major endocytosis pathways.
Genistein (GST) and methyl-β-cyclodextrin (mBCD) are inhibitors of caveolin-dependent
endocytosis, chlorpromazine (CPZ) and amantadine (AMN) are inhibitors of clathrinmediated endocytosis, and amiloride (AML) is an inhibitor of macropinocytosis [182-186,
188, 278]. The specificity and cytotoxicity of each inhibitor was determined, and the
concentration producing 80% or more cell viability while maintaining inhibitory effect on
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uptake of control compounds was selected for endocytic pathway analysis (Figure 4.6AB). Concentrations of 0.01, 3.75, 0.006, 0.075, and 0.08 g/L were selected for GST, mBCD,
CPZ, AMN, and AML, respectively. At these concentrations, GST and mBCD reduced
uptake of CTxB to approximately 30% and 50%, respectively, with little effect on
internalization of Tf or dextran. CPZ and AMN reduced uptake of Tf to approximately
20% and 25%, respectively, and AML reduced uptake of DEX to 40%. Internalization of
RNA nanoparticles and EGF was unaffected by caveolin inhibitors GST and mBCD
(Figure 4.6C). However, internalization of EGF and 3WJ-EGFapt decreased to
approximately 40% and 75%, respectively, in the presence of clathrin inhibitors. The
presence of AML caused a statistically insignificant reduction in internalization of 3WJ
and EGF while decreasing uptake of 3WJ-EGFapt to 40%. GST and mBCD decreased
luciferase expression upon transfection with 3WJ to 70% and 79%, respectively, but the
effect was not statistically significant. Knockdown mediated by 3WJ-EGFapt was not
affected by GST or mBCD (Figure 4.6D). CPZ and AMN had no effect on luciferase
expression following transfection with 3WJ but luciferase expression following
transfection with 3WJ-EGFapt decreased to 65% and 42%, respectively. Finally, AML had
no statistically significant effect on luciferase expression upon transfection with either 3WJ
or 3WJ-EGFapt.
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Figure 4.6: (A) Cytotoxicity of GST (10 mg/L), mBCD (3.75 g/L), CPZ (6 mg/L), AMN
(75 mg/L), and AML (80 mg/L) in MDA-MB-231-Luc cells. Inhibited samples were
normalized to controls in the absence of inhibitors. (B) Inhibitor effect on uptake of control
compounds marking caveosomes (CTxB), clathrin-coated vesicles (transferrin, Tf), and
macropinosomes (dextran, DEX). Uptake of all inhibited samples was normalized to
controls in the absence of inhibitors. (C) Uptake and (D) Luciferase expression of 3WJ,
3WJ-EGFapt, or EGF following transfections in the presence of GST, mBCD, CPZ, AMN,
or AML. All inhibited samples were normalized to controls transfected with 3WJ or 3WJEGFapt in the absence of inhibitors. (n=3, error bars represent standard deviation; *p<0.05,
†p<0.01, ‡p<0.001 compared to control groups).
4.3.6

Intracellular Trafficking of 3WJ Nanoparticles
In order to understand the effects of endosomal acidification and lysosomal

trafficking on 3WJ-EGFapt delivery, MDA-MB-231 cells were transfected in the presence
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of 10 nM bafilomycin A1 (BAF), 20 µM chloroquine (CQ), or both [100]. BAF is a V-type
ATPase inhibitor that prevents acidification of endosomes [196] while CQ is
lysosomotropic agent commonly used to buffer lysosomes and enhance endosomal escape
and gene delivery [203]. When delivered in the absence of DNA, CQ is localized to
acidified cellular endosomes, especially lysosomes [197]. Therefore, responsiveness to
BAF indicates the importance of endosomal acidification on gene delivery, while
responsiveness to CQ indicates particle localization to late endosomes and lysosomes.
Uptake of nanoparticles was unchanged in the presence of BAF or CQ, demonstrating that
these drugs only affect intracellular trafficking and not uptake (Figure 4.7A). Upon
transfection with 3WJ in the presence of BAF and/or CQ, the change in luciferase
expression was negligible (Figure 4.7B). When transfecting with 3WJ-EGFapt, however, an
increase in luciferase expression (decrease in knockdown) was observed in the presence of
CQ but not BAF or BAF and CQ together.
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Figure 4.7: (A) Relative uptake of 3WJ or 3WJ-EGFapt in MDA-MB-231-Luc when
transfected in the presence of bafilomycin A1 (BAF) and/or chloroquine (CQ).
(B)Transfections of 3WJ or 3WJ-EGFapt in the presence of BAF and/or CQ. All inhibited
samples were normalized to controls transfected with 3WJ or 3WJ-EGFapt in the absence
of inhibitors. Further, all inhibited samples were corrected for metabolic shift associated
with BAF or CQ by normalization to BAF- or CQ-only controls. (n=3, error bars represent
standard deviation; *p<0.05, compared to control groups).
4.4

Discussion
The MDA-MB-231-Luc cell line exhibited equivalent EGFR expression levels

compared to standard MDA-MB-231 cells (Figure 4.1A). In this cell line, EGF
internalization was significantly greater than that of 3WJ or 3WJ-EGFapt. However, the
presence of the EGF aptamer did increase uptake of 3WJ-EGFapt compared to the nontargeted 3WJ nanoparticles (Figure 4.1B). This improved uptake correlated with
knockdown mediated by 3WJ-EGFapt where 500 nM 3WJ-EGFapt produced 36%
knockdown compared to no knockdown with 3WJ nanoparticles at the same concentration
(Figure 4.2). This knockdown was extremely poor compared to Lipofectamine-mediated
transfection of siLUC at concentrations of only 50 nM, which resulted in 80% knockdown.
However, when 3WJ and 3WJ-EGFapt were delivered using Lipofectamine, knockdown
was comparable to that of siLUC controls, demonstrating that 3WJ and 3WJ-EGFapt are
capable of delivering the siLUC oligonucleotide and interacting with the RNA interference
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pathway. Based on fluorescence co-localization and post-transfection low lysate
concentrations compared to Lipofectamine-mediated 3WJ and 3WJ-EGFapt (Figure 4.3), it
was inferred that low internalization was the source of poor efficacy and that something
was preventing particles from binding or activating the target receptor.
One explanation for poor internalization of the RNA nanoparticles is that, after
binding EGFR, 3WJ-EGFapt were incapable of dimerizing EGFR, a process required for
EGFR internalization [279]. However, 3WJ-EGFapt uptake was not altered in the presence
of free EGF (Figure 4.3). If 3WJ-EGFapt is incapable of triggering dimerization, then EGF
presence should bind surrounding receptors and activate dimerization with receptors
harboring 3WJ-EGFapt. The non-response to EGF indicated that dimerization with
surrounding receptors was not boosting uptake or, alternatively, 3WJ-EGFapt particles were
preventing dimerization altogether. Therefore, the CL4 aptamer affinity for EGFR was
either poor or mechanistically incapable of interacting with EGFR. To evaluate the
interaction of EGFR with EGF and 3WJ-EGFapt, siRNA against EGFR was used to
knockdown EGFR. The use of siEGFR to knockdown surface expression of EGFR resulted
in decreases in uptake of EGF and 3WJ-EGFapt but no change in uptake of non-targeted
3WJ (Figure 4.4A), confirming that internalization of EGF and 3WJ-EGFapt depends on
binding EGFR. EGFR knockdown resulted in a decrease in luciferase knockdown (increase
in expression) mediated by 3WJ-EGFapt, but not 3WJ. This indicates that the efficacy of
3WJ-EGFapt, but not 3WJ, is somewhat dependent on the presence of functional EGFR.
Therefore, internalization of at least a portion of 3WJ-EGFapt was preceded by binding
EGFR.
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Since siRNA inhibition of EGFR validated that 3WJ-EGFapt was capable of
interacting with EGFR, the next goal was to investigate the internalization pathway and
subsequent intracellular trafficking. Endocytic inhibitors and confocal fluorescence
microscopy were used to determine the degree of uptake through caveolin-mediated
endocytosis, clathrin-mediated endocytosis, and macropinocytosis. Uptake of 3WJ, 3WJEGFapt, or EGF was unaffected by inhibitors of caveolin-mediated endocytosis (Figure
4.5C), indicating internalization is not likely occurring through this pathway and confirmed
by poor fluorescence co-localization of 3WJ-EGFapt with caveosomes (Mander’s = 0.101)
(Figure 4.6). Clathrin inhibitors, however, reduced EGF and 3WJ-EGFapt uptake to 40%
and ~75%, respectively. This was a strong indicator that clathrin-mediated endocytosis was
involved in the internalization of EGF and 3WJ-EGFapt. The clathrin-dependence of EGF
internalization by EGFR has been reported previously [280]. Interestingly, the decrease in
uptake of 3WJ-EGFapt in the presence of CPZ and AMN resulted in a corresponding
increase in luciferase knockdown to approximately 60% and 40%, respectively (Figure
4.5D). The discrepancy between 3WJ-EGFapt uptake and knockdown suggest the presence
of a compensatory internalization mechanism. As such, inhibition of macropinocytosis
resulted in a decrease in 3WJ-EGFapt uptake to 40% while not affecting luciferase
expression, which is consistent with the ability of 3WJ-EGFapt to enter cells via alternative
pathways. The dependence of 3WJ-EGFapt delivery on macropinocytosis was unexpected
since these particles were shown to interact preferentially with EGFR. However, colocalization coefficients indicated equal co-localization of 3WJ-EGFapt with clathrincoated vesicles and macropinosomes (Figure 4.6). Therefore, clathrin-mediated
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endocytosis and non-specific macropinocytosis were key pathways in 3WJ-EGFapt
internalization.
Blocking the acidification of endosomal vesicles with bafilomycin A1 did not affect
luciferase expression compared to controls upon transfection with 3WJ or 3WJ-EGFapt
(Figure 4.7B), indicating that either the RNA nanoparticles are not trafficked through
acidified vesicles or acidification is not important for delivery by RNA nanoparticles. Since
endocytosis inhibitors and microscopy showed little internalization through non-acidified
pathways such as caveolin-mediated endocytosis, it is likely that the RNA nanoparticles
are resilient to acidification. This is a characteristic difference in RNA and DNA since
naked DNA is easily digested by acidifying factors and endosomal DNase. 3WJ technology
tends to be more resilient to this degradation due to –OH substitution with 2’-fluoro or 2’O-methyl. This substitution as well as its double stranded nature make it stable in serum
and resilient to endosomal RNases targeted to single-stranded RNA [281]. In the presence
of chloroquine, an endosomal buffering agent that localizes to acidic compartments and
enhances endosomal escape, 3WJ-EGFapt-mediated knockdown decreased (Figure 4.7).
Since only acidified compartments contain chloroquine, this response was evidence that
3WJ-EGFapt was sorted, at least in part, to acidified late endosomes and lysosomes. This
finding was in agreement with the hypothesis that 3WJ-EGFapt was primarily internalized
through macropinocytosis and clathrin-mediated endocytosis, both resulting in acidified
endosomes and the latter sorting to lysosomes. Further, the enhanced endosomal escape of
chloroquine was not apparent when delivered with 3WJ-EGFapt. In fact, decreases in
knockdown indicate that the presence of chloroquine was detrimental to knockdown. Due
to the intercalating effect of chloroquine, it is possible that 3WJ-EGFapt localized to late
118

endosomes or lysosomes containing chloroquine and became intercalated, hindering
interaction with the RNA interference machinery and preventing knockdown.
Macropinocytosis is the non-specific process by which membrane ruffles engulf
components in fluid-phase near the plasma membrane. The resulting macropinosome is
large (up to 5 µm), is considered inherently leaky, and undergoes acidification but does not
fuse with lysosomes [171, 172]. 3WJ and 3WJ-EGFapt particles are likely entrained by
these membrane ruffles that engulf extracellular fluid near the cell. However, binding
EGFR has been shown to activate the macropinocytic pathway in a number of cell types
[282, 283]. Indeed, EGFR stimulation was shown to improve the uptake of exosomes by
activation of the macropinocytic pathway [88]. Therefore, it is possible that the interaction
of a portion of 3WJ-EGFapt bound to EGFR were not triggering uptake through EGFRmediated internalization but were activating macropinocytosis. While this is a viable
explanation of the macropinocytic inhibitor effect on uptake, there are a few questions as
to why the CL4 aptamer on 3WJ-EGFapt is undergoing different receptor interactions than
EGF. One potential differentiation is the monovalency of the 3WJ-EGFapt. Literature shows
that multivalency (particles possessing multiple copies of a ligand) have the ability to
activate higher-order, multireceptor pathways through interaction with and stabilization of
multiple local receptors simultaneously [284]. Therefore, the monovalent nature of the
3WJ-EGFapt may not be triggering receptor dimerization, though this was explored here by
delivery with free EGF to promote dimerization. Another potential cause could be the
targeting of high vs. low affinity EGFR. Signaling cascades associated with interaction
between high and low affinity EGFR with respective ligands have been shown to be
dependent on receptor specificity. For example, non-canonical binding to low-affinity EGF
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was observed to activate a host of signal transducers and activators of transcription and
phospholipase C-gamma 1 [285]. Combination of discrete affinity receptors is an effective
means to allow the cell to respond differently to varying concentrations of ligands. It is
possible that the aptamer is an imperfect mimic that preferentially binds to non-canonical,
low affinity receptors, promoting alternative interactions such as macropinocytosis
activation. A further explanation is that CL4 binds to the receptor with such an avidity that
it disallows release within the endosomal pathway. Reports show that structurally similar
EGF and transforming growth factor-alpha (TGF-alpha) produce different effects on
endocytic sorting despite having similar binding affinities [286]. TGF-Alpha is released
much sooner than EGF due to higher required dissociation pH and subsequently allows
EGFR recycle. 3WJ-EGFapt may bind with such an affinity that dissociation is difficult at
early endosomal pH. If dissociation does not occur, the fate of the particle will be the same
as the fate of the receptor, sorting to lysosomes for degradation or recycle back to the cell
surface. If recycled to the surface, the likelihood of macropinocytosis activation is
increased.
Since clathrin inhibitors only affect internal endosome formation, they do not
prevent surface EGFR interaction with 3WJ-EGFapt. Therefore, clathrin inhibition should
result in a loss in uptake of nearly half the particles as indicated by equivalent confocal colocalization to clathrin vesicles and macropinosomes (Figure 4.6). Here, however, there
was only a mild decrease of ~25%. Therefore, a portion of 3WJ-EGFapt particles might
involve non-canonical receptor interactions that trigger ruffle formations that eventually
engulf the receptor-particle complex by macropinocytosis. Since the macropinosome is a
notoriously leaky vesicle and 3WJ-EGFapt lacks endosomal buffering capacity, the
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macropinosome may be a more efficient means of cellular entry due to ease of endosomal
escape. However, macropinocytosis inhibition reduced uptake of 3WJ-EGFapt to 40%
while leaving gene expression unchanged (Figure 4.5C-D). Upon macropinosome
inhibition,

non-canonically

bound

3WJ-EGFapt

particles

cannot

stimulate

macropinocytosis and either internalize through clathrin-mediated mechanisms or become
stripped from the cell surface during washing. Therefore, macropinocytosis inhibition
should increase gene expression above that of the controls due to internalization
mechanism shifting towards the less efficient clathrin-mediated uptake. Since this does not
occur, there is little evidence that macropinocytosis is more efficient than clathrin-mediated
endocytosis. Therefore, the sorting of 3WJ-EGFapt to late endosomes and lysosomes
associated with clathrin-mediated internalization are not necessarily prohibitive of
therapeutic effect.
4.5

Conclusions
Though EGFR interaction with the CL4 aptamer was verified by EGFR knockdown

using RNA interference, it was shown in this report that the interaction of the aptamer
produced different receptor response compared to EGF protein. The protein was
demonstrated to induce receptor-mediated endocytosis through classic clathrin-mediated
internalization while the aptamer produced a combination of uptake through clathrindependent endocytosis and macropinocytosis. Though it is not abnormal to observe
macropinocytic activation upon EGFR stimulation, it is uncertain as to why internalization
of 3WJ-EGFapt is not restricted to EGFR-mediated internalization but proceeds through
multiple pathways. The likely explanation is that the particles have affinities for traditional
and non-canonical EGFR binding such that a portion of particles proceed through clathrin121

mediated endocytosis while a portion remain receptor-bound until stimulatory signal is
strong enough to activate macropinocytosis, upon which the particle-receptor pair becomes
indirectly internalized through the natural formation of the macropinosome. Though this
pathway is likely an easier means of entry due to ease of endosomal escape, there is no
evidence that lysosomal sorting associated with clathrin-mediated endocytosis is
detrimental to efficacy. While these findings are detrimental to the rapid internalization of
3WJ-EGFapt through traditional receptor-mediated endocytosis, they do present the unique
effect that RNA has on EGFR. Therefore, structural modifications of the aptamer for the
specific use in MDA-MB-231 cells is a pre-requisite to efficient delivery.

Copyright © Landon Mott 2019
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CHAPTER 5. EVALUATION OF FOXC1 AS A THERAPEUTIC TARGET FOR BASAL-LIKE
BREAST CANCER
5.1

Introduction
Basal-like

breast

cancer

(BLBC)

is

an

aggressive

malignancy

of

basal/myoepithelial cells with poor prognosis. BLBC accounts for approximately 15% of
all breast cancer diagnoses [287, 288] and exhibits a tendency to metastasize to the brain
and lungs [289]. The cancer is often diagnosed in younger women, typically AfricanAmerican, and exhibits low patient survivability due to rapid growth rate [290] and
aggressive mobility [291]. Ninety percent of basal-like carcinomas are associated with the
triple-negative phenotype (TNP), characterized by an under expression of estrogen receptor
(ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)
[292]. Therefore, BLBC tumors cannot be treated by targeted therapies such as tamoxifen,
aromatase inhibitors, or Herceptin. BLBC treatments are limited to doxorubicin and
taxanes which exhibit poor success rates and dose-limiting side effects. Thus, there is an
urgent need for the development of a more robust treatment option for the basal-like subset
of breast cancers.
Recent studies identified the forkhead-box transcription factor C1 (FOXC1) as a
unique biomarker for BLBC [293]. Further studies solidified a link between FOXC1
expression and the activation of Pin1 and the NF-kB signaling pathway [294], both of
which are associated with the ER-negative phenotype exhibited by the majority of BLBC
[295]. Further, overexpression of FOXC1 in BLBC tumors resulted in activation of the
epithelial-to-mesenchymal transition [296] and accelerated cell proliferation accompanied
by aggressive mobility [293]. Therefore, inhibition of these activated gene pathways and
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the inhibition of FOXC1 itself are potential therapeutic approaches. Indeed, knockdown of
FOXC1 was shown to reduce proliferation and mobility as well as reverse the epithelialto-mesenchymal transition in vitro [293].
Gene therapies involving transfer of nucleic acids for inducing expression of a
therapeutic gene or inhibiting expression of a disease-associated gene product are a
promising methodology for cancer treatments. In particular, RNA interference (RNAi)
mediated by delivery of small interfering RNA (siRNA) is capable of knocking down
expression of virtually any gene. For example, cellular proliferation was suppressed in
pancreatic cancer by siRNA knockdown of NUF2 [297], cell survival was reduced by
siRNA-mediated knockdown of eIF3c in colon cancer [298], and the malignant phenotype
of prostate cancer was inhibited by siRNA-mediated knockdown of RPL19 [299].
Similarly, RNAi may be a promising approach for knockdown of FOXC1 expression in
BLBC to decrease proliferation and metastasis, in analogy with the in vitro effects
described above. Efficacy of RNAi therapies, however, is hindered by the lack of safe and
efficient methods for in vivo siRNA delivery [300].
To evaluate the potential of RNAi therapy for BLBC, we have investigated the
effects of FOXC1 inhibition in a murine mammary carcinoma cell line, 4T1, commonly
employed as a model of BLBC [301]. In particular, we have determined the effects of
siRNA-mediated knockdown of FOXC1 on proliferation, migration and invasion of 4T1
cells in vitro. In addition, a cell line lacking FOXC1 expression, 4T1-∆FOXC1, was
generated by CRISPR/Cas9 technology as a “best-case scenario” to evaluate the potential
of FOXC1 knockdown on the tumor biology, growth, and metastasis in an orthotopic model
of BLBC in mice.
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5.2
5.2.1

Materials and Methods
Materials and Cell Lines
The 4T1 murine cell line was obtained from ATCC (ATCC® CRL2539™). Cells

were cultured according to ATCC protocols in DMEM (ATCC) supplemented with 10%
premium grade fetal bovine serum (Seradigm) at 37ºC and 5% CO2. Phosphate buffered
saline from GE Life Sciences (6.7 mM PO4, 137 mM NaCl, pH 7.2) was used to wash cells
and trypsin containing 0.53 mM EDTA (Corning) was used to dissociate cells. Cells were
transfected with siRNA using a Lipofectamine RNAiMAX vehicle (Invitrogen). Cells were
lysed using Triton lysis buffer (25mM HEPES, 100mM NaCl, 1mM EDTA, 10% glycerol,
1% Triton X-100, 10mM DTT, 1mM sodium orthovanadate, 10ng/mL leupeptin, 1%
protease inhibitor, pH 7.4) FOXC1 and negative control siRNA were purchased from Santa
Cruz Biotech. Protein quantification kit (BCA assay) was obtained from GE Biosciences.
5.2.2

In vitro siRNA Transfection
Murine mammary carcinoma cells (4T1) were cultured to 80% confluence and then

plated into 6-well plates at 300,000 cells per well. The plates were incubated for 24 h in
media containing 10% fetal bovine serum. The culture media was removed and cells
washed with PBS. An siRNA dilution was formed by mixing 10 μL siRNA from a 10 μM
stock with 150 μL serum-free media. Also, a lipofectamine dilution was formed by mixing
varying volumes (0-10 μL) of Lipofectamine RNAiMAX in serum-free media to a total
volume of 150 μL. The siRNA dilution was then added to the lipofectamine dilution and
allowed to complex for 20 min. Serum-free media was then added to a volume of 3 mL to
produce the desired final siRNA concentration (8.3-50 nM). The lipoplexes were pipetted
onto the cells and incubated for 4 h. After incubation, media was removed, wells washed
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with PBS, and 3 mL of growth media added to wells. Lipoplexes were formed with either
siRNA targeting FOXC1 (Santa Cruz Biotech, sc-145221) or a negative control siRNA
(Santa Cruz Biotech, sc-37007). After a total of 48 h incubation, media was removed from
cells and each well washed with PBS. The cells were lysed with 35μL Triton lysis buffer
and total protein quantified via bicinchoninic acid assay.
5.2.3

Western Blot
FOXC1 expression was determined by Western blot. Cell lysates (diluted to 50 μg

total protein in 50 μL) were electrophoresed on SDS PAGE (10% polyacrylimide) for 2 h
at 100 V. The protein was transferred from the polyacrylamide gel to a nitrocellulose
membrane (Amersham Bio) for 2 h at 200 mAh. The membrane was stained with rabbit
anti-FOXC1 primary antibody overnight followed by 2 h of secondary HRP-linked antirabbit antibody. The membrane was washed three times with Tween 20 supplemented
(0.2%) Tris-buffered saline and then once with Tris-buffered saline (200 mM Tris-base,
1.37 M NaCl, pH 7.6) for 5 min. Wash fluid was drained from the membrane and 1 mL
SuperSignal West Pico Luminol Enhancer solution and 1 mL West Pico Stable Peroxide
solution (Thermo Scientific) were added followed by incubated in light-shielded
environment for 5 min. The membranes were then exposed in a dark room to produce
protein bands on autoradiography film which was scanned to produce digital images.
ImageJ software was used to adjust the band intensities based on a β Actin control and
normalize by negative controls to produce a numerical representation of protein
knockdown.
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5.2.4

Silencing of FOXC1 Expression in 4T1 Cells by CRISPR/Cas9
An all-in-one plasmid kit was purchased from GeneCopeia (MCP227640-CG01-3)

to facilitate the cloning of FOXC1 knockout cells using CRISPR/Cas9 [302]. The kit
included three different plasmids containing unique sgRNA targeting sequences for the
FOXC1 gene, Cas9, a mCherry reporter gene, and neomycin resistance gene. The plasmids
were amplified in E. coli DH5α and purified using Wizard Plus Midiprep DNA Purification
System (Promega). The plasmids were complexed with Lipofectamine 2000 (Invitrogen)
at 120 μL Lipofectamine 2000 / 24 μg plasmid and added to 4T1 cells in a 100-mm dish
for 5 h. Media was then replaced with 10 mL DMEM supplemented with 10% FBS and
incubated a total of 48 h. The cells were imaged by confocal microscopy to verify positive
transfection and plasmid expression by visualization of mCherry fluorescence. The cells
were cultured in the presence of 150 μg/mL neomycin in DMEM supplemented with 10%
FBS to select for transfected cells. Clones were isolated using cloning rings, dissociated
using 5 μL trypsin, and expanded. Multiple colonies were collected as potential clone lines
for each CRISPR/Cas9 plasmid as well as a cocktail of all three plasmids. Knockout of
FOXC1 was quantified in Western blots of 4T1-∆FOXC1 lysates compared to unmodified
4T1 cells as described above.
5.2.5

Cellular Proliferation
4T1 cells were cultured to 80% confluency and plated at 30,000 cells per well in a

24-well plate. The plates were incubated for 20 h, the media removed, and the cells were
washed with PBS. Cell Titer Blue live cell counting assay (Promega) was added to each
well at 1:5 (v:v) of media (100 μL in 500 μL media). Cells were incubated for 4 h at 37ºC
and then 100 μL media samples from each well moved to an opaque assay plate for
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fluorescent quantification (530ex/590em) in a BioTek Synergy 2 plate reader. This was
considered the 0 h time point (starting cell count). Cells were then (24 h post seeding)
transfected with 2 μL siFOXC1 (20 pmol, 33.3 nM) and 1.6 μL Lipofectamine RNAiMAX
in 600 μL serum-free media and incubated for 4 h as described above. Media was replaced
with growth media and cell count assessed at 0, 22, 44, 72, 96, and 124 h via Cell Titer
Blue assay. After each assay, wells were washed, media replaced, and cells returned to the
incubator.
5.2.6

Migration and Invasion
4T1 cells were plated in 6-well plates at 300,000 cells per well and incubated for

12 h. Cells in each well were transfected with siFOXC1 or control siRNA at 33.3 nM
siRNA as described above. Plates were incubated for 48 h, media was removed, and cells
were washed with PBS. Cells for invasion assays were dissociated with trypsin containing
0.53 mM EDTA and plated into Transwell inserts pre-coated with Cultrex basement
membrane extract (Corning, 8 μm pore, 24-well) at 100,000 cells per insert. Cells for
migration assays were dissociated and plated into Transwell inserts with no apical
membrane coating (Corning, 8 μm pore, 24-well) at 100,000 cells per insert. After 1 h, Cell
Titer Blue assay was used to determine the initial number of plated apical cells and the
media was replaced with serum-free DMEM. Agonist (DMEM with 10% FBS) was added
to the basal reservoir and the cells were incubated for 19 h for migration assays and 25 h
for invasion assays. Non-mobile apical cells were swabbed off the apical side of the
membrane. Basal cells were fixed with 4% formaldehyde and stained with Giemsa stain
(Sigma Aldrich) for microscope imaging. Cells were counted in five fields (top, bottom,
left, right, and center) and averaged.
128

Scratch assays were performed using ibidi μ-Dish culture inserts. 4T1 cells treated
with siFOXC1 were plated in the insert chambers and allowed to grow to confluency. The
insert was removed and the cells allowed to migrate into the 500 μm gap. Progress was
imaged at 0, 21, and 29 h. The same procedure was performed for 4T1 cells treated with
negative control siRNA.
5.2.7

Orthotopic BLBC Model
4T1 or 4T1-∆FOXC1 cells were implanted (0.5−1 x 106 cells in 20 μL volume) into

the abdominal mammary fat pad of female BALB/c mice (n=12) to generate orthotopic
breast cancer tumors. Body weight was determined and tumor size measured with calipers
twice per week. Twenty-four days after the tumor implantation the mice were sacrificed
and tumor weight as well as metastatic activity were evaluated. Tumor samples of 250 mg
were excised, cleaned, and sonicated in 2 mL Tissue Cell Lysis Buffer (Golden Bio).
Lysates were assessed for FOXC1 expression by Western blotting according to the
methods above.
5.3
5.3.1

Results
Optimization of FOXC1 Knockdown
RNA interference was used to knockdown FOXC1 expression in 4T1 cells. To

optimize knockdown, varying volumes (0-10 μL) of Lipofectamine RNAiMAX were
complexed with a fixed concentration of siFOXC1 (33.3 nM). Resulting knockdown for
each lipid/siRNA ratio was determined via Western blot. FOXC1 knockdown increased
with the lipid/siRNA ratio, as expected (Figure 5.1). Essentially complete knockdown was
observed with a lipid/siRNA ratio of 8:10 (v:v). In addition, the siRNA dose was scaled to
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determine the minimum amount that would produce 100% knockdown of FOXC1.
Knockdown was 0% at 8.325 nM siFOXC1, 64% at 16.65 nM siFOXC1, and >95% at
>33.3 nM siFOXC1 (Figure 5.2). Thus, all subsequent transfections were performed at
lipid/siRNA ratio of 8:10 (v:v) and 33.3 nM siRNA.

Figure 5.1: (A) Western blot of FOXC1 expression in 4T1 cells transfected with 0.1 nmol
siFOX or siNEG and the indicated volume of Lipofectamine RNAiMAX. (B)
Quantification of FOXC1 knockdown expressed as [1-(intensity of siFOX band)/(intensity
of siNEG band)]x100%.
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Figure 5.2: (A) Western blot of FOXC1 expression in 4T1 cells transfected with the
indicated siRNA concentration at lipid:siRNA 8:10 (v:v). (B) Quantification of FOXC1
knockdown expressed as [1-(intensity of siFOX band)/(intensity of siNEG band)]x100%.
5.3.2

Generation of 4T1-∆FOXC1 by CRISPR/Cas9
In order to assess in vitro and in vivo behavior of 4T1 cells lacking FOXC1, 4T1-

∆FOXC1 cells were generated using the CRISPR/Cas9 genome editing system. 4T1 cells
were transfected with one of three plasmids encoding Cas9 nuclease and a sgRNA
complementary to the FOXC1 gene sequence or a pool of all three plasmids. Successfully
modified colonies were verified by Western blotting for FOXC1 expression compared to
unmodified 4T1 controls. Plasmids A and C were unable to reliably knockout FOXC1
expression (Figure 5.3). However, plasmid B and the pooled plasmids produced several
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knockout clones. Clone 5 resulting from transfection of 4T1 cells with plasmid B (4T1∆FOXC1) was chosen for further studies.

Figure 5.3: Western blot of FOXC1 expression in 4T1 cells transfected with the indicated
CRISPR/Cas9 plasmid(s). (*, clones with successful FOXC1 knockout)
5.3.3

Effect of FOXC1 Knockdown on 4T1 Proliferation
To confirm the effects of FOXC1 expression on cellular growth rate, 4T1 cells were

transfected with siFOXC1 at the optimal conditions described above (33.3 nM). A 35%
reduction in cell count of siFOXC1-transfected cells compared to unmodified 4T1 cells
(p=0.0125) was observed at 4 days post-transfection (Figure 5.4A). Similarly, a 33%
reduction in cell count of siFOXC1-transfected cells compared to siNEG was observed.
Beyond 4 days, the difference between siFOXC1-treated cells and negative controls
decreased until confluency was achieved. The siNEG-treated control also exhibited a small
but statistically insignificant (p=0.155) reduction in cell growth compared to unmodified
4T1 cells perhaps due to cytotoxicity of the transfection reagent. A similar decrease in cell
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count after four days was observed in 4T1-∆FOXC1 cells compared to 4T1 cells (Figure
5.4B).

Figure 5.4: (A) Proliferation of 4T1 non-transfected controls (NTC), 4T1 cells transfected
with negative control siRNA (siNEG), and 4T1 cells transfected with FOXC1 siRNA
(siFOXC1). Cell counts were normalized by the initial cell number (n=3, ± standard
deviation). (B) Proliferation of 4T1 and 4T1-∆FOXC1 cell lines.
5.3.4

Effect of FOXC1 Knockdown on 4T1 Mobility
Migration and invasion of 4T1 cells treated with siFOXC1 as well as 4T1-∆FOXC1

cells were investigated using Boyden chamber assays. Migrating and invading cells were
counted at 19 and 25 h after seeding, respectively. Migration and invasion of siFOXC1transfected cells decreased by 39% and 33%, respectively, compared to siNEG-transfected
cells. Similarly, migration and invasion of 4T1-∆FOXC1 decreased by 33% and 36%,
respectively, compared to unmodified 4T1 cells (Figure 5.5). Thus, both transient
knockdown and complete elimination of FOXC1 expression reduced the metastatic
potential of 4T1 cells in vitro.
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Figure 5.5: Migration and invasion of 4T1 cells transfected with siFOXC1 or siNEG, and
4T1-∆FOXC1 cells in Boyden chamber assays. (n=3, ± standard deviation)
In addition, migration of FOXC1-expressing and -deficient cells was compared
using a 2D scratch assay. After 21 h, a larger gap was observed in 4T1 cells transfected
with siFOXC1 compared to the negative control (Figure 5.6B and E). By 29 h, the 500 μm
scratch in siNEG-transfected 4T1 cells had completely filled (Figure 5.6E) while a small
gap in the siFOXC1-transfected cells remained (Figure 5.6C).
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Figure 5.6: 2D migration of 4T1 cells transfected with FOXC1 siRNA (A-C) or negative
control siRNA (D-F) before transfection (A, D) and at 21 (B, E) and 29 h (C, F) posttransfection.
5.3.5

Effect of FOXC1 on 4T1 Tumor Growth and Metastasis In Vivo
4T1 or 4T1-∆FOXC1 cells were injected into the mammary fat pads of Balb/c mice

as an orthotopic model of stage IV breast cancer. The total body mass of all three groups
remained undifferentiated over all 24 days of the study (Figure 5.7A). Surprisingly, the
volume of 4T1-∆FOXC1 tumors was equivalent to 4T1 tumors up to 17 days and increased
compared to unmodified 4T1 tumors at 21 and 24 days (Figure 5.7B). Visual inspection
and mass of excised tumors confirmed these observations with 4T1-∆FOXC1 weighing
67% more than unmodified tumors, 1.45±0.25 g and 0.867±0.086 g (α=0.05) respectively
(Figure 5.7C-D).
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Figure 5.7: (A) Body weight of animals receiving 4T1 or 4T1-∆FOXC1 cells. (n=6, ±
standard deviation) (B) Tumor volume (measured by calipers) after implantation with 4T1
or 4T1-∆FOXC1 cells. (n=6, ± standard deviation) (C) Mass of 4T1 and 4T1-∆FOXC1
excised after 24 days. (n=6, ± standard deviation) (D) Excised 4T1 and 4T1-∆FOXC1
tumors after 24 days. (E) Excised organs 24 days after injection of 4T1-∆FOXC1 cells
showing tumor colonies as indicated by arrows.
After 24 days, major organs were excised and inspected for the presence of
metastases. All mice injected with 4T1 (not shown) or 4T1-∆FOXC1 (Figure 5.7E)
exhibited tumor colonies on the liver and lungs, suggesting that FOXC1 knockout did not
significantly inhibit metastasis in this model. Since knockout of FOXC1 is unable to block
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metastasis, it appears unlikely that an siRNA treatment capable of producing 80%-95%
knockdown would be efficacious in reducing tumor growth or metastasis.
To ensure that the lack of difference in 4T1 and 4T1-∆FOXC1 tumor growth was
not due to reversion of 4T1-∆FOXC1 to the wild-type phenotype following implantation,
FOXC1 expression was compared in two excised 4T1-∆FOXC1 tumors, a wild-type 4T1
tumor, and 4T1 cells grown in vitro by Western blotting. 4T1-∆FOXC1 tumor lysates
showed significantly less FOXC1 expression compared to the 4T1 cell culture control and
wild-type tumor (Figure 5.8). Thus, it appears the 4T1-∆FOXC1 tumors maintained their
FOXC1-negative phenotype throughout the duration of the experiment.

Figure 5.8: Western blots of 4T1 cell culture lysates (4T1) and excised wild-type 4T1 (WT)
and 4T1-∆FOXC1 (KO1 and KO2) tumor lysates for protein expression of FOXC1 and βActin loading control.
5.4

Discussion
The results reported here align well with the trends observed by Ray et al. [293],

confirming that downregulation of FOXC1 expression has a negative effect on
proliferation, migration, and invasion in vitro. Ray found that knockdown of FOXC1
expression produced a reduction in the proliferative efforts of 4T1 cells by approximately
50% after 3 days. Similar reduction by approximately 35% was observed for MDA-MB231 cells (human BLBC). Ray et al. also found that the migration and invasion of 4T1 cells
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were decreased ~65% with shRNA-mediated knockdown of FOXC1 protein. However, the
reduction of 4T1 proliferation was less dramatic (33%) in this project than that of
corresponding Ray studies (50%). The decrease in migration and invasion by RNAi (39%
and 33%) reported here were also less severe than that found by Ray et al. (each
approximately 65%). It is uncertain as to why the decrease in proliferation, migration, and
invasion from this project by siRNA-mediated knockdown were not as successful as those
found by Ray et al. by shRNA-mediated knockdown. Regardless, it is clear that the impact
of FOXC1 down-regulation in 4T1 and other BLBC cell lines produces a decrease in the
cellular growth rate and potential for aggressive metastasis as measured in vitro. These
results suggested that RNAi-mediated knockdown of FOXC1 expression may have
promise as a BLBC treatment strategy.
Although translation of RNAi drugs from in vitro to in vivo models is difficult due
to the many barriers faced by siRNA delivery in vivo [303, 304], successful cases have
been reported recently. Preclinical trials of Atu027 targeting the protein kinase N3 mRNA
transcript have shown significant inhibition of tumor growth and metastasis to the lymph
nodes in prostate and pancreatic mouse models [305]. As a result, Atu027 has entered phase
1 clinical trials. Similarly, CALAA-01, which targets ribonuleotide reductase, was granted
a phase 1 clinical trial. The CALAA-01 siRNA was delivered intravenously to tumor
bearing subjects using self-assembled PEGylated cyclodextrin nanoparticles tagged with
transferrin ligand. Tumor biopsies showed successful tumor targeting, intracellular
localization, and mRNA/protein knockdown [306]. These and similar trials suggest that
siRNA drugs have potential as cancer therapies.
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To initially evaluate the potential of FOXC1 knockdown while avoiding
complications due to the commonly encountered difficulties with siRNA delivery in vivo,
we constructed a 4T1 cell line deficient in FOXC1 expression using CRISPR/Cas9. Upon
injection of 4T1 or 4T1-∆FOXC1 into the mammary fat pads of Balb/c mice, we observed
no statistical difference in the growth rate of the resulting tumors or their final size after 24
days. In addition, a similar number of metastatic lesions were found in the lungs and liver
of animals with 4T1-∆FOXC1 and 4T1 tumors. The lack of effect of the absence of FOXC1
on tumor growth or metastasis was surprising, given the significant effect of FOXC1
knockdown on in vitro proliferation, migration and invasion of 4T1 cells. As the 4T1∆FOXC1 tumors, completely lacking detectable FOXC1 expression, represent a “best-case
scenario,” the results reported here suggest that an RNAi-based therapy targeting FOXC1,
and perhaps even a FOXC1 antagonist, may not show efficacy against BLBC.
5.5

Conclusions
The inhibition of FOXC1 using RNAi in vitro reduced proliferation, migration, and

invasion of 4T1 cells, confirming previously reported data by Ray et al. In addition, 4T1∆FOXC1 cells performed similarly to 4T1 cells treated with siFOXC1 in vitro. These
results, however, did not translate into an animal model. 4T1-∆FOXC1 tumors did not
exhibit reduced growth rates compared to controls despite the absence of detectable
FOXC1. FOXC1 knockout was also unable to inhibit metastasis to the lung and liver after
24 days. These results suggest knockdown of FOXC1 may not be a promising candidate
for BLBC therapy.

Copyright © Landon Mott 2019
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